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Human papilloma viruses (HPV) are non-enveloped DNA viruses that infect human skin and 
mucosa and are the causative agents of mostly benign proliferative lesions such as common 
(genital) warts (1). However, persistent infection with sexually transmitted, mucosal ‘high-risk’ 
HPV subtypes is strongly associated with the development of anogenital malignancies such as 
cervical, vulvar-, penile- and anal cancer, and also a subset of oropharyngeal cancers (1-4). The 
association is strongest for cervical cancer: illustrated by the finding that in over 99% of cervical 
cancers HPV DNA can be detected (5, 6). Notably, cervical cancer is the third most common 
cancer in women world wide, with an estimated death toll of almost 300.000 women annually, 
mostly in developing countries (7, 8). The much lower burden in the developed world is due to 
screening programs (most often Pap testing) that aim to detect early lesions, which can most 
often be cured by surgical removal of the lesion (2, 8, 9). As the immune system operates by the 
principle of non-self recognition, the involvement of a virus in the development of these types 
of malignancies provides a unique opportunity for the immune system to prevent or eradicate 
these types of malignancies. 
Preventive vaccination
Recently two vaccines have become available for the prevention of HPV induced malignancies, 
namely Cervarix® and Gardasil® (10-12). Both vaccines are directed against the two most 
prevalent high-risk subtypes, HPV16 and 18, accounting for about 50% and 20% of cervical 
cancer cases respectively (13). Gardasil is also directed against the mucosal low-risk sub types 
6 and 11, together accounting for 90% of genital warts  (14). Both vaccines are composed of 
viral like particles (VLPs) that self-assemble when the major capsid protein L1 is expressed 
in eukaryotic cells. These VLPs are highly immunogenic structures that resemble the virus 
particle, but without the genetic content of the virus and thus without the risk of inducing 
disease. The VLPs provoke a strong B cell mediated immune response against L1, resulting in 
viral capsid specific antibodies, that are believed to neutralize/shield the virions before they 
can infect, thereby providing sterile protection against infection with the corresponding 
HPV virus sub-types (11, 15). However, these vaccines have no value for the treatment of pre-
existing lesions (see below) and as a consequence these vaccines need to be administered to 
individuals before they get infected. For optimal prophylaxis, the complete population has 
to be vaccinated before the onset of sexual activity (12). So far, long-term (up to 6 years of 
follow-up) clinical trials in young (15-26 year old) women have shown nearly 100% protection 
against the development of precancerous lesions, caused by HPV16 and 18, upon vaccination 
with these preventive vaccines (16, 17). Although this efficacy is impressive, the estimated costs 
involved in the prevention of a single case of cervical cancer are extremely high: approximately 
5 million US dollar based on an incidence of 7 per 100.000 (the age standardized incidence of 
cervical cancer in Western Europe (8)) and the cost per vaccination of 360 US dollar. This is 
explained by the fact that only very few HPV infections will eventually result in the formation of 
malignancies (18, 19). It has to be noted that the prevention of precancerous lesions (that have 
a much higher incidence) as such already provides a significant clinical benefit as the treatment 
of such lesions often requires surgical intervention (16, 17).  
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1 need for theraPeutic vaccine develoPment
Beside the poor cost-effectiveness, a major drawback is that the preventive vaccines do not 
generate therapeutic effects against pre-existing lesions (20, 21), as also mentioned above. This 
is explained by the fact that upon infection the virus is maintained inside cells where antibodies 
can not reach it because they cannot pass the cell membrane. Moreover, expression of the viral 
capsid protein L1, that is recognized by these antibodies, is lost upon malignant transformation 
(22, 23). Therefore, a different approach is needed in order to generate an immune response 
that can eradicate existing lesions. The type of immune response required to eradicate 
pathogen-infected cells is called a cytotoxic T cell response. Cytotoxic T cells can kill pathogen 
infected cells upon recognition of virus-derived peptides presented at the cell surface on MHC 
class I molecules. (24). As it is well established that the viral proteins E6 and E7 of the high-risk 
sub-types play an essential role in the transformation process (25, 26), and are expressed in 
all HPV transformed cells, they are excellent targets for therapeutic vaccine development (21, 
27). Importantly, the spontaneous clearance of HPV induced (pre-)malignancies is associated 
with T cell mediated immune responses against these proteins (28-30). Over the past two 
decades, numerous therapeutic vaccine candidates, targeting mostly HPV16 E6 and E7, have 
been developed in preclinical models (15, 21, 27, 31). Disappointingly clinical success has been 
rather limited with response rates usually not exceeding the rate of spontaneous regression 
(15).  One recent study in patients suffering from grade 3 vulvar intraepithelial neoplasia (VIN 3) 
vaccinated with a vaccine consisting of E6 and E7 based long-peptides in incomplete Freunds 
adjuvant, showed a durable and complete regression in 47% of patients (32, 33). Also another 
recent study in which protein based vaccine (TA-CIN), that had no clinical effect as such (34), 
was combined with local immune modulation using Imiquimod (a TLR-7 agonist) in VIN 2/3 
patients showed complete regression in 63% of patients (35). These two recent successes 
demonstrate the true value of therapeutic vaccination. 
dna vaccination
The therapeutic vaccines developed so far consist of broadly three categories: protein or 
peptide based vaccines, viral vectored vaccines or DNA vaccines (15). Among these strategies 
we consider DNA vaccination particularly attractive as outlined below. Uptake of the DNA by 
cells at the vaccination site will lead to local intracellular production of the antigen, thereby 
mimicking natural viral infection. As a consequence the immune system will be primed to 
produce predominantly cytotoxic T cells (36, 37). In contrast, injection of the proteins as such 
would in contrast predominantly result in the production of antibodies, which are considered 
useless, as E6 and E7 are intracellular proteins. An important advantage over vectored vaccines 
is that DNA vaccines can be administered repeatedly without the risk of inducing vector specific 
immunity (37). Other advantages of DNA vaccination are the fact that DNA can be relatively 
easily produced at large scale, the fact that DNA is stable at room temperature, the good safety 
profile of the DNA vaccination platform compared to for example live vector vaccines, and 
finally DNA can be easily manipulated in order to affect the properties of the encoded protein 
(37) (see also chapter 2 of this thesis for a detailed review on DNA vaccination in general). 
Over the past years many candidate DNA vaccines targeting E6 and E7 have been developed 
in rodent models (reviewed in (38, 39) and several clinical trials have been performed, or 
are currently ongoing (15, 38, 40, 41). Although vaccine specific immune responses could be 
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1detected in some cases, the clinical outcome of these trials so far has been rather disappointing (15). Therefore, there is a strong need for optimization of E6 and E7 directed DNA vaccines. 
aim of the thesis and outline
The aim of this thesis was to develop highly immunogenic and safe candidate DNA vaccines 
for the treatment of HPV16 induced malignancies. Furthermore, we wanted to obtain insight 
in the mechanisms that contribute to the enhanced immunogenicity of so called ‘DNA fusion 
vaccines’. The content of the individual chapters is summarized below. 
chapter 2 is provides a detailed review on DNA vaccination in general and DNA tattoo 
vaccination in particular. Among the subjects discussed in this review are: the advantages 
of DNA vaccination compared to conventional vaccine platforms, the mechanisms of T cell 
priming upon DNA vaccination, the origin of the “danger-signal” in DNA vaccine preparations 
and the value of DNA tattooing, a technique developed in our lab, compared to other DNA 
delivery methods. 
chapter 3 describes the development of highly effective and safe HPV16 E7 and E6 directed 
DNA vaccine candidates. As E6 and E7 are known oncogenes, we selected so called “gene-
shuffled” versions of E6 and E7 in order to avoid cellular transformation at the vaccination 
site in case genomic integration might occur. The gene-shuffling results in the production of 
a completely rearranged protein that can be expected to have lost its oncogenic potential, 
while individual T cell epitopes are not altered. We found that these shuffled versions of E6 and 
E7 are no longer immunogenic upon DNA tattoo vaccination. Therefore, we had to develop a 
strategy to overcome the loss in immunogenicity. We constructed genetic fusions with Tetanus 
Toxin fragment C (TTFC), a bacterial protein that had been shown previously to improve the 
immunogenicity of C-terminally coupled antigenic peptides in DNA vaccination, and evaluated 
the effect of this fusion on the immunogenicity of the shuffled versions of E6 and E7.  
chapter 4 describes the preclinical safety studies performed to demonstrate that the 
vaccine candidates, TTFC-E6SH and TTFC-E7SH developed as described in chapter 2, indeed 
lost the oncogenic potential that is associated with E6 and E7 wild-type genes. For this 
purpose we selected two different model systems. In the first model system we made use of 
murine fibroblasts (NIH 3T3 cells) that were transfected with either our vaccine candidates, or 
wild-type E6 and E7 containing plasmids. Next we introduced a model system based on the viral 
transduction of primary human foreskin keratinocytes (HFKs). The latter model system can be 
regarded as more relevant as it comprises the use of the natural target cell of vaccination (the 
human keratinocyte). In addition, since we used retroviral vectors and grew the cells under 
selective pressure, we mimicked the worst-case scenario of stable integration of our vaccine 
candidates in the genome of keratinocytes, thereby increasing the likelihood of detecting 
residual oncogenic activity. 
chapter 5 describes the rational design of DNA vaccines encoding modified HPV16 E6 and 
E7. This chapter can be regarded as a follow up study of chapter 3. The exact mechanisms by 
which fusion with so called “carrier-proteins” (such as TTFC) enhances the immunogenicity of 
HPV16 E6 and E7 are not entirely clear. Often the biological function of such carrier-proteins is 
considered to play an important role. We hypothesized that rather more general mechanisms, 
such as provision of CD4+ T cell help, improvement of antigen stability or alteration of the 
subcellular localisation of the antigen, can explain the immune-potentiating effect observed 
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1 after fusion with such carrier-proteins. To test this hypothesis we developed modular DNA vaccines in which the presence of different components could be systemically altered.
chapter 6 focuses on the improvement of the delivery of dermal DNA vaccines by 
formulating the DNA into nano-particles. It is estimated that only 1 out of 5x 106 to 5x 109 DNA 
copies is taken up after DNA tattoo vaccination. Therefore, if it would be possible to only 
slightly increase the efficiency of DNA uptake this could hypothetically result in an enormous 
increase in the amount of produced antigen. This can be expected to strongly improve the 
immunogenicity of DNA vaccination, as the amount of antigen expressed is considered to be a 
limiting factor. However, we found that complexation of DNA with cationic polymers, a method 
that strongly improves DNA uptake in vitro, completely blocks DNA tattoo mediated gene 
expression in intact human skin or in mice in vivo. We hypothesised that the positive charge 
of the resulting nanoparticles might lead to immobilization of the DNA in the extracellular 
matrix by charge interactions. Therefore we shielded the cationic charge of such particles 
by the addition of charge neutral PEG chains to the particles and evaluated the effect of this 
modification on the immunogenicity of the DNA-nanoparticles. 
Finally chapter 7 contains a summarizing discussion and provides suggestions for future 
research. 
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1. an introduction on two decades of dna  
vaccination
It is now two decades ago since it was first demonstrated that injection of naked plasmid 
DNA into mouse muscle results in expression of the encoded protein (1). Soon thereafter it 
was demonstrated that both cellular and humoral immune responses can be elicited against 
DNA vaccine-encoded proteins, when applied intradermally using a ‘gene gun’ (2) or upon 
intramuscular (IM) injection (3;4). Furthermore, these DNA vaccination-induced immune 
responses were shown to confer protection in various preclinical disease models, including 
models of viral, bacterial, and parasitic diseases and various tumor models (reviewed in ref (5) 
and (6)). Based on these encouraging preclinical data and a number of perceived advantages 
of DNA-based vaccines (see below), a series of clinical trials was initiated during the late 1990s 
that evaluated the efficacy of DNA vaccines in the induction of immune responses against 
pathogen- (HIV, malaria, hepatitis B) and cancer-associated antigens (7-9). While these trials 
provided overwhelming evidence for the overall safety of DNA vaccines (7;8), immunogenicity 
of this first generation DNA vaccines was at best modest. 
Following the observation of low immunogenicity of DNA vaccines in the early human 
trials, the field has taken two directions. 1). It has been argued that while DNA vaccines may not 
induce high-level immune responses as a single modality, these vaccines would nevertheless 
be valuable to provide low-level priming. Such low-level immune responses can then 
subsequently be amplified by administration of a virus-based vaccine (10;11). Such DNA-prime 
viral vector-boost regimens can reduce the issue of vector-specific immune responses that are 
a common problem in viral vector-based vaccines. 2). As a second and more ambitious goal, a 
large effort has been made to develop (what we here will loosely call) “second generation DNA 
vaccines” that should be able to induce robust immune responses without a requirement for 
booster vaccination by virus-based vaccines. In these vaccines, optimization has either focused 
on i) improvement of the expression vectors, ii) improvement of the vaccine formulation, iii) 
enhancement of the immunogenicity of the vaccine-encoded antigen, or iv) the provision of 
molecular adjuvants in order to boost immunogenicity. A selected set of examples of such 
abstract 
Over the past two decades, DNA vaccination has been developed as a method for the 
induction of immune responses. However, in spite of high expectations based on their 
efficacy in preclinical models, immunogenicity of first generation DNA vaccines in 
clinical trials was shown to be poor, and no DNA vaccines have yet been licensed for 
human use. In recent years significant progress has been made in the development of 
second generation DNA vaccines and DNA vaccine delivery methods. Here we review the 
key characteristics of DNA vaccines as compared to other vaccine platforms and recent 
insights into the prerequisites for induction of immune responses by DNA vaccines will 
be discussed. We illustrate the development of second generation DNA vaccines with the 
description of DNA tattooing as a novel DNA delivery method. This technique has shown 
great promise both in a small animal model and in non-human primates and is currently 




optimizations will be provided. Furthermore a large effort has been made to develop novel 
physical delivery methods that aim to increase DNA vaccine efficiency, of which intradermal 
(ID) DNA tattooing forms an example.
Is it plausible that DNA vaccines will become available for human use in the foreseeable 
future? The licensing of 3 different DNA vaccines in the field of veterinary medicine (against West 
Nile virus in horses, against infectious haematopoietic necrosis virus in salmon and for treatment 
of melanoma in dogs) (12), and a recent report showing DNA vaccination-mediated protection 
of human subjects against influenza challenge (13), both illustrate the therapeutic potential of 
DNA vaccines as single modalities. Because of this, there is presently renewed optimism that DNA 
vaccines may within the next years be approved for applications in humans (11;14).
2. advantages of dna vaccination comPared to 
conventional vaccine Platforms
DNA vaccines have a number of attractive properties that contribute to the strong interest in 
their development. Among these properties are the ease and speed of vaccine production, 
the ability to induce both cellular and humoral immunity and the favorable safety profile 
as compared to other gene-based vaccine platforms that are able to induce strong cellular 
immunity. These aspects are discussed in more detail below. 
2.1 Ease and Speed of Production
Plasmid DNA is relatively easy to produce in small to large quantities in a generic way, with 
little if any need for adaptation of the production process for different individual plasmids. 
This is in sharp contrast to in particular protein-based vaccines, for which the production 
process needs to be specifically designed for each new vaccine. Moreover, since DNA vaccine-
encoded proteins are synthesized by the host cells upon delivery, difficulties associated with 
recombinant protein-based vaccine production, such as protein folding and post translational 
modifications (e.g. glycosylation) are circumvented (32;40). Another important advantage of 
DNA vaccines is the excellent stability of DNA as compared to other vaccine modalities, thereby 
likely circumventing the need for a ‘cold chain’ for vaccine distribution.
2.2 Ability to Induce Cellular Immunity
While direct experimental evidence is limited, there is some reason to assume that DNA vaccines 
are more suitable for the induction of CD8+ (‘cytotoxic’) T cell immunity than recombinant 
peptide or protein vaccines (6;41-43). Due to the fact that by definition, vaccination-induced 
antigen expression takes place by host cells, there is ample opportunity for the transfected 
cells to present peptide fragments of the antigen in MHC-class I molecules at the cell surface. 
In contrast, in many other vaccine formats such as protein, peptide, or inactivated pathogen-
based vaccines, antigen is offered within the extracellular space. As extracellular antigens are 
mainly presented via MHC-class II molecules, induction of CD4+ (‘helper’) T cell and antibody 
responses can be expected to predominate (43). This discussion is somewhat complicated by 
the observation that induction of T cell responses upon DNA vaccination occurs at least in part 
by cross-priming rather than direct interaction between naive CD8+ T cells and transfected skin 
or muscle cells (see below). However, as cross-priming is also more efficient for cell-associated 
than for soluble antigens (44), the advantage of vaccine formats that induce intracellular 
antigen expression remains.
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2.3 Lack of Vector-Specific Immune Responses
While the presumed advantage of DNA vaccines in the induction of CD8+ T cell responses is 
shared with live attenuated viral vaccines or viral vector based vaccines, the latter modalities 
bear greater risks in terms of production and safety (45;46). Furthermore, viral vector-based 
vaccines such as recombinant adenovirus or vaccinia virus can suffer from pre-existing 
immunity towards the vector or can induce vector-directed immunogenicity, thereby 
preventing repeated administration of these vectors (47). In the case of DNA vaccines the 
only immunogenic structure produced is the antigen itself, thereby allowing repeated 
administration.
2.4 Favorable Safety Profile
For the large scale use of new vaccine formats in the general population their safety profile 
obviously needs to be well-established (48;49). Because of their non-infectious and non-
replicating nature, DNA vaccines are considered more safe than live attenuated viruses or 
recombinant viral vectors. Furthermore, DNA vaccines have proven to be well tolerated and 
non-toxic in both preclinical- and clinical studies (9;14;50-52). However a few safety issues 
unique to plasmid DNA vaccines may potentially hamper their widespread use. 
The main safety concern associated with DNA vaccines is the risk of genomic integration 
into the host genome. Genomic integration could potentially lead to activation of oncogenes, 
inactivation of tumor suppressor genes, or, when integrated into the chromosomal DNA of germ 
line cells, to vertical transmission. Several studies have examined the frequency of integration 
upon DNA vaccination. Collectively, these studies indicate that integration can occur but 
with a frequency that is manifold (around 3 orders of magnitude, depending on the system) 
lower than the spontaneous gene-inactivating mutation frequency of the genome. (50;53;54). 
Vertical transmission due to genomic integration in germ line cells has been observed after 
direct injection of DNA into the gonads (55). However, genomic integration into germ-line 
cells has not been observed after DNA vaccination at sites distant from the gonads (52;56). In 
conclusion, because of the low frequency of genomic integrations at the vaccination site and 
the absence of integrations in germ-line cells, the risks associated with genomic integration 
upon DNA vaccination are at present considered negligible. An important exception to this is 
formed by DNA vaccines that encode proteins with known or suspected transforming activity 
(e.g. the HPV E6 and E7 oncoproteins). Proteins with transforming activity are attractive targets 
for vaccination as they can serve as unique tumor associated antigens. However, for such DNA 
vaccines, the survival advantage of cells that express the encoded proteins could conceivably 
lead to outgrowth of those (extremely) few cells in which genomic integration has occurred 
(57). Because of this concern, the use of engineering strategies that abolish the transforming 
properties of the vaccine-encoded antigen should be considered essential. 
A second potential safety concern in the use of DNA-based vaccines is the induction 
of anti-DNA antibodies and the subsequent development of auto-immune disease. This 
concern is increased by the fact that the bacterial derived DNA contains unmethylated 
phosphodiester-linked cytosine and guanine (CpG) motifs in the plasmid backbone that have 
an immunostimulatory activity via triggering of Toll-like receptor 9 (TLR9) (58), see also below. 
Anti-DNA antibodies are considered a hallmark of certain autoimmune diseases such as systemic 
lupus erythematosus (SLE), as most (but not all) patients manifest this characteristic of disease 
(5;59). Although induction of anti-DNA antibodies has been observed in some animal models 




associated with the development of systemic autoimmune diseases, either in healthy animals 
or in animals that are at risk for the development of autoimmune disease (reviewed in reference 
(50;60)). Furthermore, in human DNA vaccination trials no statistically significant increase in 
the presence of antinuclear antibodies and anti-DNA antibodies amongst vaccinees has been 
detected (50). 
In conclusion, all preclinical and clinical studies that have aimed to evaluate potential safety 
concerns of DNA vaccines have not provided any compelling evidence for substantial risks 
associated with the use of DNA vaccines. Because of this, we currently see no major obstacles for 
the application of DNA vaccines for therapeutic purposes, or for prophylaxis against high-risk 
disease. It is noted however that the potential toxicities of DNA vaccines would primarily concern 
long-term effects that may be difficult to address in the studies discussed above. Because of this, 
it would seem prudent to await the long-term outcome of clinical trials for high-risk indications 
before widespread application of DNA vaccination for low-risk disease is considered.
3. mechanism of t cell Priming uPon dna 
vaccination 
At first glance, the general mechanism by which plasmid DNA vaccines induce immunity seems 
straightforward. Upon administration the plasmid DNA is taken up by host cells, leading to 
production of the antigen by these cells and to the release of ‘danger’ signals as dictated by the 
danger model. However, there is still substantial uncertainty about the antigen-presentation 
pathway that leads to the display of antigen-derived epitopes to naive T cells and also by which 
molecular mechanisms ‘danger’ is perceived upon DNA vaccination. Importantly, a better 
understanding of both of these factors is likely to result in more efficient DNA vaccine formats.
3.1 Direct- Versus Cross-Priming
Through the use of bone marrow chimeras it has been demonstrated that the induction of 
cellular and humoral immune responses upon DNA vaccination is absolutely dependent on 
antigen presentation by bone marrow derived professional antigen-presenting cells (APCs) (61). 
On the other hand, for various routes of administration it has been demonstrated that antigen 
expression upon DNA vaccination primarily results in antigen expression in non-immune cells 
in peripheral tissues, such as myocytes in the muscle and keratinocytes in the skin (62;63). An 
important question therefore is whether immune activation primarily occurs by the action of a 
small number of APCs that have become directly transfected, or whether antigen produced by 
the much larger number of non-immune cells serves as a source of antigen that is handed over 
to APCs that subsequently present the antigen (a process termed cross-presentation in the case 
of CD8+ T cell activation). This issue is of more than academic interest as it has previously been 
demonstrated that the efficiency with which antigens are cross-presented can vary markedly 
depending on the context in which an epitope is provided (see also below) (64;65).
Most DNA vaccination studies performed to address this question have used gene gun or 
IM needle injection as a delivery platform. From these studies there is clear evidence that both 
direct presentation of antigen by transfected APCs (63;66-68) and cross-presentation of antigen 
acquired from non-immune cells (1;69;70) can occur in vivo after DNA vaccination. The design 
of most of these studies however does not allow a conclusion on the relative contribution of 
these two processes to CD8+ T cell activation in vivo. An exception to this is formed by a study in 
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which a DNA vaccine encoding the influenza A nucleoprotein (NP) under control of either the 
keratinocyte-specific K14 promoter or the APC-specific CD11b promoter was applied via gene 
gun (69). This study revealed that keratinocyte-directed transgene expression induced both 
higher cellular and humoral immune responses than APC-directed transgene expression, thus 
providing strong evidence for a dominant role for cross-presentation in CD8+ T cell priming 
upon gene gun immunization. These data are in apparent contrast to a second study that – again 
using gene gun application – provided evidence for a dominant role for directly transfected 
APCs in CD8+ T cell activation (63). In this study, co-transfection, but not co-immunization of 
plasmids encoding co-stimulatory molecules was shown to restore the immunogenicity of 
an otherwise non-immunogenic nuclear protein (NP) variant. This observation seems most 
consistent with antigen presentation by directly transfected APCs, as cross-presentation would 
not be expected to result in cell surface expression of the vaccine-encoded costimulatory 
molecules on the APC.  It is noted however, that the NP variant used in the latter study may 
form a poor substrate for cross-presentation, as the mutations within this antigen may prevent 
proper folding and thereby reduce antigen accumulation within the donor cell or by other 
means disrupt the transfer of antigen from the antigen-producing cells to specialized APCs 
(see below) (36). 
Taken together, to date no definitive answer exists regarding the exact mechanism of T 
cell priming upon DNA vaccination (71;72), and it is plausible that the mechanism of immune 
induction will differ between different methods of immunization (68;73), between target 
tissues (e.g. skin versus muscle) (68), and between different DNA vaccine designs.
3.2 Influencing Antigen Properties
Several strategies have been developed in which an antigen of interest is genetically fused to 
a ‘carrier’ protein. Carrier proteins that have been shown to (sometimes strongly) increase 
the immunogenicity of the fused antigen include tetanus toxin fragment C (TTFC), heat shock 
protein 70 (HSP 70), MHC class II invariant chain (Ii), calreticulin (CRT), herpes simplex virus 
viral protein 22 (HSV VP 22) and E. coli b-glucuronidase (Table 1). The exact mechanism(s) by 
which these carrier proteins enhance the immunogenicity of the fused antigen remain largely 
unclear and may vary between different carrier molecules. However, based on our current 
understanding of DNA vaccines, two broad categories are likely to play dominant roles. 
Provision of CD4+ T cell help: There is abundant evidence that CD8+ T cell responses induced 
by DNA vaccination are dependent on CD4+ T cell help (74). However, CD4+ T cell responses are 
likely to be weak or lacking when using DNA vaccines that either encode self proteins or single 
CD8+ T cell epitopes. In such cases, the provision of CD4+ T cell help via carrier encoded helper 
epitopes is likely to be an important factor in the immune-enhancing effect of foreign carrier 
molecules, like TTFC and E. coli β-glucoronidase (23;27). 
Enhancement of antigen presentation: There is strong evidence that improvement of antigen 
stability enhances DNA vaccine immunogenicity. First, many of the above mentioned fusions 
result in increased steady state antigen levels (26;27;29). Second, formal evidence for the notion 
that the stability of DNA vaccine-encoded antigens in the transfected cell contributes to vaccine 
immunogenicity has been provided using a set of engineered luciferase variants with a variable 
in vivo half-life (75). For this set of variants, immunogenicity was directly correlated to antigen 
stability. Also the observation that covalent linkage of an epitope towards a carrier protein, but not 
the simultaneous expression of the epitope and the carrier using a bicistronic vector, improves 




immunogenicity by increasing antigen half life (76). At present, the most straightforward 
explanation for the observed effect of antigen stability on vaccine immunogenicity is that it 
would enhance cross-presentation, although a direct analysis of epitope density on APCs would 
be required to provide formal evidence for this model. Genetic fusion to carrier proteins may also 
influence antigen presentation through other mechanisms. For VP-22 it has been proposed that 
it enhances antigen spreading to neighbouring cells (29). For HSP-70 it has been proposed that 
it increases uptake of the antigen by APCs via a HSP specific receptor (77). Finally, some carrier 
molecules such as Ii (26) and calreticulin (25) alter the subcellular localization of an antigen and 
might thereby improve the immunogenicity of the DNA encoded antigen. This is in line with the 
finding that the sole addition of signals influencing subcellular localization (such as ER targeting 
signals) to DNA vaccine-encoded antigens can improve their immunogenicity (29;78-80). Also 
in this case, enhanced immunogenicity may be due to increased cross-presentation, but again, 
formal evidence is lacking. Clearly, improved insight into the mechanisms by which different 
carrier influence vaccine immunogenicity will enable more rational DNA vaccine optimization 
and should be an important area of future research.
4. origin of the “danger signal” in dna vaccines
Although the addition of various adjuvants (Table 1) can enhance their immunogenicity, DNA 
vaccines are also able to induce strong immune responses in animal models without the addition 
of adjuvants that provide inflammatory signals. As the induction of adaptive immune responses 
requires not only the presence of antigen, but also the presence of signals that induce APC 
activation (something often referred to as the danger model) (73;81;82), this implies that either 
DNA vaccines themselves or the DNA vaccination procedure provides elements that result in 
a sense of danger.
4.1 Danger in ‘Naked’ DNA
For many years it has been assumed that unmethylated CpG motifs were the primary source 
of danger in DNA vaccine preparations. Unmethylated CpG motifs form one of the so called 
‘pathogen-associated molecular patterns’ (PAMP) that are recognized by pattern recognition 
receptors (PRR), in the case of CpG the TLR9. TLR9 is expressed in the endocytic pathway, 
providing endocytosing cells with the ability to detect CpG motifs within ingested material. 
Triggering of TLR9 initiates a cascade of signaling events that leads to NF-kB and activator 
protein 1 (AP-1) activation, and the subsequent induction of a pro-inflammatory response 
characterized by the release of cytokines and chemokines, e.g. type I interferons (IFNs), 
interleukin (IL)-6, IL-12 and tumor necrosis factor (TNF)-a (83). In early work, the inclusion 
of additional CpG motifs within the plasmid backbone was shown to improve DNA vaccine 
efficiency after ID vaccination in a murine melanoma model (39). As TLR9 is differentially 
expressed between mice (all dendritic cell subsets) and men (only plasmacytoid dendritic cells) 
(84), it has been suggested that a reduced ability to initiate a CpG-dependent danger response 
could explain the poor track record of DNA vaccines in humans. However, several studies have 
shown that both the induction of cellular as well as humoral immune responses is unaffected in 
TLR9-deficient mice (85;86). Assuming that TLR9 forms the sole receptor for CpG, these data 
suggest that danger in DNA vaccination must (also) be sensed by other means. 
Recently, evidence has been provided indicating that double stranded DNA (dsDNA) in the B 
form (right-handed helical structure) functions as an intrinsic adjuvant in DNA vaccines (reviewed 
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in (83) and (87)). Two dsDNA sensors have been identified thus far, namely DAI (DNA-dependent 
activator of IFN-regulatory factors) and AIM 2 (absent in melanoma-2). Contrary to TLR9, these 
dsDNA sensors are expressed within the cytosol, providing transfected cells with the ability to 
detect incoming DNA. DAI-induced immune activation is mediated through the activation of 
IFN regulatory factor 3 (IRF3) and NF-kB and results in the production of type I IFNs (88). AIM 2 
has recently been described as the cytosolic DNA sensor that is responsible for activation of the 
Table 1. Selection of methods to enhance DNA vaccine potency.
type of optimization method Proposed mode of action* ref.
improvement of the vector
gene optimization
stabilization of RNA; more 
efficient translation of RNA
(15;16)







improvement of vaccine 
formulation
formulation of naked DNA 
into nano/micro particles




improvement of antigen 
immunogenicity 






targeting of antigen for 







E. coli β-glucoronidase 
fusion
changed subcellular 
localization of antigen, 
provision of CD4+ help
(27)




enhancement of immune 
activation by addition of 
adjuvants
co-delivery  of pro-
inflamatory cytokines 
(GM-CSF, IL-2, IL-12)
recruitment, expansion and 
activation of APCs 
(30-32) 
co-delivery of chemokines 
(CCL-21, CCL27, CCL-28, 
CCL-5)
attraction of immune cells 
to the site of vaccination
(33-35)
co-delivery of co-











activation of APCs (38;39)
* For most of these methods, evidence that the increase in vaccine immunogenicity is indeed due 
to the proposed mechanism is at best circumstantial. Furthermore, only for selected strategies 




inflammasome, thereby resulting in the production of active IL-1β, IL-18 and IL-33 (89). However, 
as optimal DNA vaccine immunogenicity requires type I IFNs (90) and AIM2 is not required for 
type I IFN production, it is considered to have a secondary role in the DNA-induced adjuvant 
response (83). An important study by Ishii et al. has demonstrated a pivotal role for TANK-binding 
kinase 1 (TBK-1), a non-canonical IkB kinase, in mediating the adjuvant effect of DNA vaccines. In 
the presence of dsDNA, TBK-1 activates IRF3 and IRF7, leading to the production of type I IFNs. 
Notably, TBK-1 deficient mice were unable to generate antigen-specific humoral and cellular 
immune responses upon vaccination with a DNA vaccine delivered by IM injection followed by 
electroporation (90). In constrast, DNA vaccine-induced immune responses were not affected by 
DAI deficiency and from this observation it was concluded that TBK-1 but not DAI is essential to the 
DNA vaccine mediated adjuvant response. Recently evidence was provided for the involvement of 
another signaling component named stimulator of IFN genes (STING) in TBK-1 mediated dsDNA 
sensing (91). STING assembles with TBK-1 after dsDNA stimulation (92) and TBK-1 trafficking is 
blocked in the absence of STING (91). Morever STING is essential for intracellular DNA-mediated 
type I IFN production and STING deficient mice showed an almost complete inhibition of both 
humoral and cellular immune responses upon DNA vaccination. Notably, despite the increasing 
knowledge on the signaling route that controls cellular responses upon cytosolic DNA encounter, 
the critical element recognizing dsDNA in this pathway still needs to be identified. Our current 
knowledge on intracellular DNA sensors is summarized in Table 2. 
4.2 Administration-Induced Danger
While recognition of the introduced DNA forms one route through which DNA vaccination 
results in a danger response, the physical damage induced by the administration procedure 
itself is likely to be a second factor. Sensing of physical damage seems likely to be of particular 
importance for ID delivered DNA vaccines, as the skin has an important barrier function in host 
defense and is densely populated with immune cells. Therefore, administration procedure-
induced local skin injury is likely to result in an inflammatory response that can boost vaccine 
immunogenicity (93). This notion is supported by a recent report demonstrating that epidermal 
injury during poxvirus immunization is crucial for the generation of protective T-cell mediated 
immunity (94). Furthermore, delivery-induced damage has also been suggested to play a role 
following electroporation mediated IM delivery (95;96) and even following simple IM injection 
in mice, as the injection volume used (usually about 50 µl) exceeds the fluid capacity of the 
muscle resulting in local tissue damage (41;62). 














CpG motifs TLR9 MyD88




AIM2 Inflammasome IL-1β, IL-18, IL-33 little (89)
DAI TBK-1/IRF3 Type 1 IFN little (88)
unknown TBK-1/STING/IRF3 Type 1 IFN high (90;91)
26
dna VaccInatIon and dna tattooInG 
2
What are the molecular mediators of the inflammatory response that is induced by physical 
damage? First, cell death that occurs during vaccination may lead to the release of intracellular 
molecules (with HMGB-1 as a prototype) that can be recognized by neighboring cells, or can 
result in the formation of uric acid crystals. This class of endogenous indicators of danger, 
sometimes referred to as alarmins (reviewed in references (81;97)) is likely to grow further in 
coming years, and it seems plausible that the role of individual alarmins as indicators of danger 
will depend on the strategy used for DNA vaccine delivery. In the case of ID DNA vaccine 
delivery, the vaccination-induced damage may also result in a danger response through an 
indirect mechanism. Specifically, the disruption of the skin barrier will create opportunities for 
pathogens/skin-resident microorganisms to locally invade the epidermal or dermal layer. As a 
consequence, immune activation can be expected to occur via the sensing of one of the many 
identified PAMPs, such as LPS, peptidoglycans, flagellin etc (98). 
While there is increasing interest in the role of adjuvant signals provided by the DNA itself, 
little attention has thus far been given to the contribution of the DNA vaccination procedure 
induced damage to vaccine immunogenicity. Furthermore, our understanding of the 
contribution of different danger signals (be they either DNA- or damage-induced) to different 
types of adaptive immune responses (humoral, Th1, Th2, Th17, cytotoxic) is still limited.
5. oPtimizing dna vaccination by intradermal 
tattooing 
Given the poor performance of DNA vaccines (mostly IM delivered) in non-human primates 
and early clinical trials we set out to develop an improved strategy for DNA vaccine delivery. 
First, we postulated that a strategy in which DNA vaccines are introduced into the skin by a 
multitude of needle injections rather than a single injection would be superior. This method, 
in which DNA is delivered to the epidermal skin layer by many thousands of injections using 
a permanent make-up or tattoo device has been named DNA tattooing (99). Secondly, by 
measuring DNA vaccination-induced antigen expression in vivo using a firefly luciferase-
encoding DNA, the kinetics of antigen expression could be followed. Notably, despite the fact 
that antigen expression after ID tattoo was approximately 10-100 fold lower and of much shorter 
duration than after IM injection, presentation of the vaccine-encoded epitope to CD8+ T cells 
was shown to be markedly better. Based on the observation that DNA tattoo-induced antigen 
expression was restricted to approximately 96 hours, a vaccination schedule was developed in 
which DNA is applied three times with 2 days intervals. Using this short-interval ID DNA delivery 
schedule, robust CD8+ T-cell responses that can readily be measured directly ex vivo could be 
induced within two weeks. In contrast, IM vaccination with this short interval regimen did not 
lead to detectable T-cell responses. Furthermore, in comparison to IM DNA vaccination, DNA 
tattooing was shown to mediate substantially better protection in mouse models of influenza A 
infection and HPV16-associated cancer. A likely explanation for the higher immunogenicity of 
DNA tattoo vaccination is that skin is a better equipped for the induction of immune responses. 
In contrast to muscle, skin is rich in APCs (100) and is the body’s first line of defense against 
many pathogens (93). Also, since the tattoo procedure inflicts thousands of skin perforations 
it is likely to result in the release of many more danger signals than simple IM or ID injection, 
thereby serving as a potent adjuvant (see below). 
Interestingly, ID tattoo vaccination has also been applied to other vaccine modalities. For 




(SC) injection (101). Also adenoviral vectors have been administered via ID tattoo in a side-
by-side comparison with SC injection. In contrast to the results obtained with DNA vaccines, 
delivery of adenovirus via ID tattoo immunization did not provide any obvious advantage over 
delivery via ID injection (102). A possible explanation for this lack of superiority of ID tattoo 
vaccination is that the uptake of the adenovirus into host cells is much more efficient obviating 
the need for a more sophisticated delivery procedure and/or that viral particles themselves 
serve as a strong adjuvant, thereby making the tattoo procedure redundant. 
6. mechanism of immune induction uPon dna 
tattooing
6.1 Antigen Expression and Priming
How does ID DNA tattooing induce CD8+ T cell responses? Upon ID DNA tattoo vaccination, 
antigen expression is largely confined to cells within the epidermal layer, as revealed by 
beta-Gal staining (99). Furthermore, by flow cytometric analysis of single cell suspensions of 
tattooed ex vivo human skin (see below for more details on this model) it was shown that the 
vast majority of transfected cells consists of keratinocytes. Sporadic transfection of Langerhans 
cells (LCs) in the epidermis could also be observed (approximately 1% of transfected cells, more 
or less proportional to their frequency in human skin cell preparations) (103). Notably, the 
fact that only few antigen-expressing LCs could be recovered from human skin could not be 
explained by rapid migration of these cells after DNA administration. Does the fact that antigen 
expression upon DNA tattoo is largely restricted to keratinocytes indicate a dominant role 
for this cell type in the induction of immune responses? When vaccination-induced antigen 
expression is restricted to keratinocytes by the use of the K14 promoter, CD8+ T cell responses 
could still be induced by this strategy for DNA vaccination in a murine model (75). As there is no 
evidence for migration of keratinocytes to the skin-draining lymph nodes, nor for naïve T cell 
priming at the site of vaccination, these data strongly suggest that the induction of a vaccine-
specific CD8+ T cell response upon DNA tattooing is at least partially due to cross-priming. A 
schematic representation of the different possibilities that lead to CD8+ T cell priming upon 
DNA tattooing is provided in figure 1
6.2 Provision of Danger Signals
As discussed above, recognition of danger signals upon DNA vaccination may either involve 
the direct recognition of the introduced DNA, or the detection of physical damage caused by 
DNA introduction. Thus far, only the role of TLR9 in sensing unmethylated CpG motifs upon 
DNA tattoo has been evaluated. Consistent with data from studies that have evaluated the role 
of TLR9 in other DNA vaccination modalities, the magnitude of CD8+ T cell responses induced 
by DNA tattoo in wild type and in TLR9-/- mice were identical, demonstrating that – at least 
in mice – TLR9 mediated signaling is not essential  for the induction of immune responses 
by DNA tattoo vaccination (99). Evidence for or against a role for different cytosolic dsDNA 
sensing systems in DNA tattoo vaccination induced immunity is at present lacking. However, 
as this DNA vaccination strategy relies on the generation of thousands of skin perforations, 
a contribution of vaccination-induced skin damage to the immunogenicity of DNA tattooing 
therefore seems plausible. Support for the notion that inflammatory signals inflicted by tissue 
damage contribute to the immunogenicity of DNA tattoo is provided by a study in which we 
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measured serum IL-6 levels upon tattoo application of either DNA or water-for-injections 
(WFI). Notably, systemic IL-6 levels were increased to the same extent in both groups of mice 
and exceeded those seen upon intraperitoneal delivery of 100 IU of LPS (a known inducer of 
IL-6 (104)). These data suggest that administration-induced danger signals form a major factor 
in the immunogenicity of DNA tattoo (105). A schematic representation of the different routes 
by which danger can be sensed upon DNA tattooing is provided in figure 2. 
7. dna tattoo versus other dna delivery 
techniques
To date, a large number of different delivery methods for DNA vaccines have been developed. 
In the following section a selection of these methods is discussed and their pros and cons 
relative to DNA tattooing are evaluated.
7.1 Intramuscular Injection
IM injection is one of the first routes of administration used for the delivery of naked plasmid 














Figure 1. Possible routes for the priming of CD8+ cytotoxic T cells upon ID DNA tattoo 
vaccination. Upon DNA tattooing keratinocytes are transfected and produce antigen that is acquired 
by professional APCs, leading to cross-presentation to CD8+ cytotoxic T cells. As an alternative, 
APCs can become directly transfected, leading to direct priming of CD8+ cytotoxic T cells. Based on 




use. Although the method has proven effective in small animal models, the results obtained 
in studies in non-human primates and clinical trials have been disappointing even when doses 
up to 5 mg plasmid were used (11;106;107). This translational block has been referred to as the 
“simian barrier” (107) and is possibly explained by the impossibility to scale-up the injection 
volume used in mice (50 µl) to non-human primates and humans. Based on the difference in 
body weight (20 gr versus 80 kg) an injection volume of about 200 ml would be needed for 
a linear scale-up. Inability to perform such scale-up  may be a particularly important factor 
as it has been suggested that the tissue damage inflicted by injection of a large volume of 
DNA relative to the volume of the injection site contributes to the immunogenicity of IM DNA 
vaccination in mice (41;62).
As described above we have performed an extensive comparison of the efficiency of ID 
tattoo vaccination and classical IM DNA vaccination in murine models. These data demonstrated 
that DNA tattoo outperformed IM DNA vaccination both with respect to the speed of CD8+ T 
cell induction and with respect to the magnitude of this immune response. The superiority 
of DNA tattoo in mice has since then been confirmed in a study by Pokorna et al., in which 
previously described strategies to enhance the potency of IM DNA vaccination (cardiotoxin 
pretreatment or GM-CSF DNA co-delivery) were also included. In this study, ID DNA tattooing 
keratinocyte
Damage sensingDNA sensing
release of type 1 INFs and 
other inflamatory cytokines 
and chemokines
release of alarmins and 
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skin barrier
Figure 2. Routes by which danger can be sensed upon intradermal DNA tattoo vaccination. 
Danger can be sensed via detection of dsDNA by cytosolic DNA sensors and signaling via TBK-1/
STING, or via detection of CpG motifs by endosomal TLR9 (although the latter route is not critical). On 
the other hand, the tattoo procedure can induce damage to the skin leading to the release of PAMPs 
and alarmins. The thus released mediators can activate skin resident APCs and attract/activate other 
immune cells. The fact that tattooing without any DNA already results in strong immune activation 
as measured by serum IL-6 levels (see text) suggests that damage induced danger signals may play 
a dominant role. 
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elicited significantly higher L1 specific humoral and cellular immune responses as compared to 
all IM conditions evaluated, even if the number of IM injections exceeded the number of tattoo 
administrations (108). 
Having demonstrated the superiority of DNA tattoo in small animal models we set out to 
determine if the translational block described for IM delivery would also apply to DNA tattoo. 
To this end we performed a study in rhesus macaques, in which we delivered an HIV clade C 
DNA vaccine via ID DNA tattooing and compared the results with a prior study using exactly 
the same vaccine and vaccine dose but delivered by IM injection. This study demonstrated a 
10- to 100-fold increase in the magnitude of vaccine-specific T cell responses in peripheral 
blood from rhesus macaques vaccinated by DNA tattoo, as compared to T cell responses 
in animals immunized via the IM route. Furthermore an increase in the fraction of animals 
responding to the immunogens was also observed. In conclusion, DNA tattoo outperforms 
IM DNA vaccination in both small and large animal models, warranting its further testing in 
humans (109).
7.2 Particle-mediated epidermal delivery
Particle-mediated epidermal delivery (PMED) comprises the bombardment of the skin with 
gold particles coated with DNA and is often referred to as ‘gene gun’ vaccination. Gene gun-
mediated gene transfer is the first method that was successfully used for DNA vaccination in 
murine models (2). The method, which was originally developed for the transfection of cells in 
vitro, has been extensively studied in human subjects. Within these studies, both cellular and 
humoral vaccine-specific responses have been demonstrated and – even though a side by side 
comparison has to our knowledge not been performed in clinical trials – the method is generally 
considered more efficient than IM injection (106;110). A comparison of the efficiency of gene 
gun and ID tattoo vaccination (using the same short interval administration schedule) has 
demonstrated that the two methods are equipotent in CD8+ T cell activation in a murine model. 
The doses of DNA required to induce immune responses by gene gun administration are 
surprisingly low, about 1 mg/dose, being approximately 100-1000 fold lower than that used 
for IM injection, and this holds true for both murine and larger animal models (106;110). 
Moreover, also in human clinical trials, immune responses have been detected with doses 
below 10 mg (110). A possible explanation for this high efficiency is that gene gun is believed 
to directly deliver the DNA into the intracellular environment, in contrast to any other DNA 
delivery method (106).  However, as the capacity of the current delivery devices is also low (1-2 
µg of DNA per ‘shot’) the scaling of gun vaccination from mice to human application may still 
form an issue (40;110). Specifically, taking into account the difference in body surface (0.0075 
vs 1.85 m2), approximately 250 vaccinations would be required to achieve the same dose per 
body surface. A second drawback is that the costs per immunization may be substantial (in 
particular when such scaling is performed), because of the need for formulating the DNA onto 
gold particles (40).
7.3 Electroporation-Mediated Gene Transfer 
Electroporation (EP) is successfully used as a strategy for the transfection of cells in vitro (111). 
EP uses short electrical pulses to destabilize cell membranes. While the precise mechanism 
is unclear, EP is thought to promote cellular uptake of DNA through permeabilizing cell 
membranes and driving DNA entry via an electrophoretic process (112).  As it is believed that 




explained by the low transfection efficiency upon needle mediated delivery of naked DNA 
(113;114), EP has been extensively evaluated for its potential to increase in vivo transfection. 
Several devices for EP-assisted DNA vaccination have been developed and EP has been shown 
to result in an increase in antigen expression and vaccine immunogenicity in murine models 
when combined with either IM (62;115) or ID DNA injection (116;117). In a direct comparison, the 
combination of IM injection and EP was shown to be more efficient than gene gun-mediated 
DNA administration (118). EP mediated DNA vaccination has also been shown to increase antigen 
expression levels and vaccine immunogenicity in large animals (113;119). Based on these highly 
promising preclinical data EP is now also being evaluated in clinical trials (reviewed in ref (111)). 
A slight complication of this technique is that there are many variables such as pulse 
duration, pulse strength and the number of pulses that need to be optimized. It has been 
demonstrated that EP settings that result in high expression levels are not necessarily those 
that induce the highest immune responses (116). Furthermore, the optimal settings may also 
differ depending on the array used and the targeted tissue (120;121). 
A safety concern that has been associated with the improved transfection efficiency upon 
EP is a possible increase of the number of chromosomal integrations (50;60). In one study by 
Wang et al. it was observed that EP markedly increased the amount of plasmid associated with 
high molecular weight (i.e. genomic) DNA. Furthermore, using a newly developed PCR method, 
four independent integration events were detected in electroporated muscle, providing direct 
proof for genomic integration upon DNA vaccination (54). However, other studies have shown 
no increase in the amount of plasmid DNA associated with high-molecular-weight DNA after 
EP in combination with IM delivery (122). More importantly, it seems plausible that the risk of 
genomic integration will scale proportionally with any improvement in DNA vaccine delivery 
strategies and this risk is therefore unlikely to be unique to EP.
7.4 Jet Injection
Jet injection is a needle free technique in which fluid is injected under high pressure and this 
technique is suitable for both IM and ID administration. Jet injectors have successfully been used 
for immunizing humans with live attenuated vaccines against measles and smallpox, as well as 
inactivated life vaccines against cholera, hepatitis B, influenza and polio (123). Advantages of the 
method are that it avoids the use of sharps and its compatibility with existing vaccine formulations 
that have been developed for needle-based administration. Disadvantages of the method include 
higher levels of pain and more frequent side reactions than observed with needle-based vaccine 
delivery (123). In a report by Trimble et al., CD8+ T cell responses and antitumor effects generated 
by a DNA vaccine administered ID via gene gun or Biojector® (a jet injector suitable for ID delivery) 
and IM via needle injection were directly compared in a murine model (124). In this comparison, 
gene gun vaccination formed the most potent method of immunization. Furthermore, in 
non-human primates IM jet injection with the Biojector® or Mini-JectTM was not more efficient 
than simple IM injection with respect to the induction of both cellular and humoral immune 
responses (125). Based on these data it can be concluded that jet injection does not significantly 
improve the immunogenicity of IM administered DNA vaccines.
7.5 Microneedle-Assisted Gene Transfer
Microneedles are small needles with a size between 200 and 400 µm that have been designed 
to deliver drugs to the epidermal layer of the skin, without stimulating the pain receptors that 
populate the underlying dermis (126). Microneedles have been shown to be useful for the 
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delivery of protein-based vaccines in clinical trials as delivery of the seasonal influenza vaccine 
via microneedles has been shown to be more effective than simple IM delivery (127;128). A 
recent study by Zhou et al. demonstrated that microneedle-based delivery of a hepatitis B virus 
DNA vaccine in mice resulted in higher levels of humoral and cellular immune responses when 
compared to IM injection with the same DNA construct (129). However, protein expression 
levels upon DNA application with microneedles are also reported to be unpredictable and 
difficult to control, and because of this, further optimization is likely to be required for the 
future development of this strategy into a robust DNA vaccination platform (126). 
7.6 Concluding Remarks on the Different DNA Vaccine Delivery Methods
Compared to the above-mentioned administration techniques (summarized in Table 3), DNA 
tattoo stands out by its simplicity. There is no need for formulation of the DNA as is the case 
for PMED. As compared to jet injection, EP and PMED, the required equipment is relatively 
simple and cheap. More importantly, linear scale up from mice to man can simply be done 
by vaccination of larger skin areas. This notion is supported by the promising results of DNA 
tattoo in non-human primates (109). Furthermore, as the tattoo procedure causes substantial 
damage to the skin requirement for the inclusion of adjuvants may not be needed, making 
clinical translation relatively straightforward. By the same token, it is noted however that the 
invasiveness of the method and also the requirement for repeated administration are likely to 
limit the current DNA tattoo strategy to high-risk diseases. 
table 3: Advantages and limitations of different DNA delivery methods.
gene transfer 
method advantages limitations ref.
IM injection
Ease of the method, low 
costs of equipment
Poor track record in larger 
animals and human subjects
(1;107;109;130)
PMED (‘gene gun’)
High potency in relation to 
dose, extensive preclinical 
and clinical experience
Complex gold particle-based  
formulation/high cost of the 




Extensive preclinical and 
clinical experience, can 
be combined with other 
delivery methods
High cost of the equipment, (54;111)
Jet injection
Needle-free method, 
ability to work with existing 
formulations, and success 
with many forms of vaccines
High cost of the device, 
higher levels of pain than with 
needles
No evidence for superior 






acceptability, possibility for 
self administration
Limited experience in DNA 




Linear scale up from mice 
to men possible, relatively 
cheap/portable instrument
Invasiveness of the method 





8. clinical translation of intradermal dna 
tattooing
8.1 Ex Vivo Human Skin Model
On the basis of the promising preclinical data both in mice and in non-human primates an effort 
has been made to translate DNA tattoo vaccination into clinical application. However, before 
initiation of studies in humans it was important to determine the optimal settings for DNA tattoo 
in human skin, in particular because the physiology of human skin has obvious differences 
compared to that of furred murine and non-human primate skin (132). To address this issue we 
have analyzed the parameters that result in optimal expression of vaccine-encoded antigens 
applied to human skin by DNA tattoo (103). For this purpose, we have developed an ex vivo 
human skin, in which DNA vaccines encoding reporter proteins are applied via ID tattoo. These 
studies revealed that gene expression upon ID DNA tattoo of human skin is almost exclusively 
restricted to the epidermal layer. Furthermore, consistent with the data obtained in mice, the 
vast majority of transfected cells consisted of keratinocytes. In order to optimize variables that 
we considered likely to influence the efficiency of DNA vaccination we have tattooed a total 
of 428 skin areas with luciferase-encoding DNA, thereby examining the effect of variations in 
1) DNA concentration, 2) the duration of tattooing, 3) needle depth and 4) the type of tattoo 
machine. From these experiments, analyzed in a linear mixed effects model, it was concluded 
that DNA concentration is the most important factor influencing antigen expression in human 
skin. Furthermore, it was shown that also tattoo time and tattoo depth had significant effects 
on antigen expression. These data have been instrumental for the design of the first clinical trial 
of DNA tattoo and we speculate that this in vitro model will also be of value for the preclinical 
optimization of other DNA vaccine delivery strategies. 
8.2 Ongoing and Planned Clinical Trials
Currently a first phase I clinical trial is ongoing to evaluate the safety and tolerability of ID DNA 
tattoo for the treatment of HLA-A2 positive advanced stage melanoma patients. Melanoma 
forms an interesting target for therapeutic vaccination as there is evidence to suggest that 
cellular immune responses contribute to the spontaneous regressions that are sporadically 
observed (133). Furthermore, a large number of melanoma-associated antigens (such as 
MART-1, tyrosinase and gp100) has been identified and a substantial number of cytotoxic T cell 
epitopes from these antigens have been mapped. The DNA vaccine that is being used within 
this first trial encodes a modified (affinity-enhanced) MART-1 epitope fused to tetanus toxin 
fragment C. The plasmid DNA for this trial was manufactured in our in-house GMP production 
facility (134), illustrating that clinical translation of DNA vaccines is relatively straightforward 
as compared to most other vaccine formats. Thus far, the tattoo procedure is well tolerated 
and no obvious toxicity has been observed. MART-1 specific T cell immunity will be assayed 
in peripheral blood samples and on skin biopsies from the vaccination site, using both MHC-
tetramer staining and IFN-g ELISPOT. Furthermore, serum anti-tetanus toxin antibody titers will 
be measured in order to monitor the induction of humoral immune responses by the vaccine. 
In the near future we will also initiate a phase I clinical trial to evaluate DNA tattoo for the 
treatment of HPV-16 positive penile- and cervical cancer. HPV-induced malignancies form an 
excellent target for immunotherapy as the transformed cells express viral proteins, thereby 
enabling recognition of malignant cells without the danger of targeting healthy cells (135). For 
this trial we have developed two DNA vaccines directed against the HPV16 E6 and E7 oncogenes 
and clinical grade production of these plasmids is currently ongoing. 
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9. oPinion on usefulness of intradermal dna 
vaccination, large-scale use of dna tattoo, 
and future PersPectives
As mentioned above, disadvantages of DNA tattoo are the invasiveness of the method, the 
fact that the tattoo procedure is more time consuming than simple injection and that multiple 
administrations are required in order to induce high-level immune responses. Because of this 
we consider the method currently well suitable for the development of therapeutic vaccines for 
high risk diseases, but not for (prophylactic) mass vaccination. However, when tattoo time can 
be shortened and/ or the number of administrations can be reduced, for example by improving 
transfection efficiency and construct immunogenicity, the method may become more suitable 
for large-scale application. One of the strategies to further improve the efficiency of DNA 
tattoo vaccination that is currently under evaluation is briefly discussed below. 
Thus far, most of our studies have focused on the use of naked DNA. However, from studies 
in the ex vivo human skin model it has been calculated that the transfection efficiency of naked 
DNA upon tattooing is extremely low: estimated between 1 out of 1x10-6 to 1x10-9 copies applied 
(103). Therefore, there is ample room for improving the transfection efficiency of DNA vaccines 
applied by DNA tattoo. In a recent study we have evaluated the use of cationic nanoparticles as 
synthetic delivery vehicles for DNA vaccines (19). Interestingly, these studies revealed that the 
positive charge of such particles that dramatically enhances transfection efficiency in cell culture 
systems essentially prevents transfection in human skin. Only when the cationic surface charge 
of these particles was shielded with polyethylene glycol (PEG), transfection in human skin was 
apparent. Delivery of a model vaccine using these PEGylated nanoparticles resulted in an increase 
in transfection efficiency as compared to naked DNA both in ex vivo human skin and in mice (in 
the latter about 2-5 fold depending on the type of nanoparticle). Unfortunately, for this first 
variant DNA formulation that we have analyzed, no significant increase in immunogenicity was 
observed in spite of these higher expression levels. These data do however illustrate the value of 
the combined use of these two models for preclinical DNA vaccine delivery optimization. First, 
the human skin model allows one to rapidly identify vaccine formulations that yield substantial 
antigen expression (going from the reasonable assumption that in the absence of substantial 
antigen expression immunogenicity will be poor). Second, those selected formulations that yield 
substantial antigen expression in human skin can subsequently be analyzed for immunogenicity 
within the murine model. As an example, skin electroporation-mediated DNA delivery has 
shown great promise in both small and large animal models (117), and the combined use of DNA 
tattoo and electroporation may well be evaluated by combining these two models.
10. conclusion
DNA tattoo has progressed from the first preclinical evaluation to clinical testing in a period 
of approximately 5 years, and based on its preclinical track record ID DNA tattoo can be 
considered a promising strategy for DNA vaccination. At present the two main priorities will 
be to evaluate the current strategy for DNA tattoo in clinical trials, while at the same time 
developing optimized strategies in preclinical models that can be evaluated in follow-up trials. 
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OF HIGHLY EFFECTIVE AND SAFE 
DNA VACCINES DIRECTED 




To allow vaccination irrespective of HLA type, DNA vaccines encoding full-length 
antigens are required. However, here we demonstrate that the immunogenicity of 
DNA vaccines encoding the full-length human papilloma virus (HPV) type 16 E7 and E6 
proteins is highly reduced compared to a vaccine encoding only the immunodominant 
epitope. Furthermore, the low remaining immunogenicity is essentially lost for both E7 
and E6 when a non-oncogenic ‘gene-shuffled’ variant is utilized. To address these issues 
we tested whether alterations in transgene design can restore the immunogenicity 
of full-length and gene-shuffled DNA vaccines. Remarkably, genetic fusion of E7 with 
tetanus toxin fragment C resulted in a dramatic increase in immunogenicity both for the 
full-length and the gene-shuffled version of E7. Moreover the TTFC fusion vaccines were 
more immunogenic than a vaccine encoding a fusion of E7 and mycobacterial heat shock 
protein-70, that has recently been tested in a clinical trial. Interestingly, vaccination 
with these TTFC fusion vaccines also resulted in extremely persistent T cell responses. 
The E7-specific CD8+ T cells induced by TTFC fusion vaccines were functional in terms 
of IFN-g production, formation of immunological memory, in vivo cytolytic activity and 
tumor eradication. Finally, we show that genetic fusion with TTFC also improves the 
immunogenicity of a gene-shuffled E6 DNA vaccine. These data demonstrate that genetic 
fusion with tetanus toxin fragment C can dramatically improve the immunogenicity of 
full-length and gene-shuffled DNA vaccines. The DNA fusion vaccines developed here 
will be evaluated for the treatment of HPV positive carcinomas in future studies. 
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introduction
Persistent infection with “high risk” HPV genotypes, is strongly associated with the 
development of anogenital cancers (1,2). Of the “high risk” genotypes, HPV16 alone is known 
to be responsible for about half of the cervical cancer cases worldwide (3). Because persistent 
expression of the oncogenic HPV proteins E6 and E7 is required for carcinogenesis, these 
viral antigens are ideal targets for immunotherapeutic interventions. Since E6 and E7 are 
solely expressed intracellularly, such therapeutic interventions should induce cellular immune 
responses in order to control existing HPV induced lesions (3,4). 
DNA vaccination forms an attractive approach for the induction of cellular immune responses 
as the DNA encoded antigens are by definition produced intracellularly.  Furthermore DNA 
vaccines are safe, easy to produce, stable and do not suffer from the drawback of preexisting 
immunity or induction of anti-vector immunity (5,6). In murine models, numerous DNA 
vaccines directed against either HPV16 E6 or E7 have been tested with promising results (7-13). 
However, to date the clinical translation of these approaches has met little success (14,15). 
Recently we developed a novel DNA vaccination strategy named DNA tattoo vaccination that 
can potentially overcome this translational block. This strategy was shown to lead to the rapid 
induction of cellular immunity as compared to conventional methods of DNA vaccination in 
mice (16). Furthermore, DNA tattooing outperformed classical intramuscular DNA vaccination 
by 10-100-fold when tested in non-human primates (17). Currently, DNA tattoo vaccination is 
being evaluated in a phase I clinical trial for the treatment of melanoma, using a DNA vaccine 
that was produced in house in a GMP compliant plasmid production facility (18). 
In this study we describe the preclinical development of DNA vaccines directed against 
HPV16 E6 and E7, aiming for optimal safety and immunogenicity. In earlier work we have 
established that DNA vaccines that encode single defined antigen-derived T cell epitopes 
are highly immunogenic (19). However, the extensive polymorphism of HLA alleles precludes 
the broader application of such epitope-directed DNA vaccines, and we therefore set out to 
develop effective DNA vaccines that encompass the full epitope-encoding potential of the 
HPV16 E6 and E7 proteins. Furthermore, as HPV16 E6 and E7 are oncogenes through their 
ability to induce degradation of the tumor suppressors p53 and pRb respectively (20,21), the 
transforming potential of these genes needs to be eliminated before application in humans. 
Two strategies have previously been put forward to disrupt the oncogenic potential of E6 and 
E7 in DNA vaccines. Firstly, point mutations in the pRb binding site for E7 and in the p53 binding 
site for E6 can prevent degradation of these targets and thus prevent cellular transformation 
(11,22). Secondly, a more drastic approach – termed gene-shuffling –  has been developed 
recently to prevent the risk of cellular transformation by HPV16 E7 (9,23). In this approach, the 
gene sequence of E7 was taken apart at exactly those positions that are critical for the known 
transforming properties of the protein, and the resulting fragments were reassembled in a 
‘shuffled’ order. To avoid the loss of putative CD8+ T cell epitopes at the junctions, sequences 
encoding the 9 amino acids at either side of the different junctions in the natural protein were 
added as an ‘appendix’. Since the 3-dimensional structure of the resulting protein product will 
be markedly different from that of the parental protein, it is plausible that for thus shuffled 
proteins not only the binding to known cellular targets, but also interaction with other potential 
targets (20,21,24,25) is prevented. Consequently, gene shuffling can be considered a preferred 
approach from a safety perspective.
Here we demonstrate that the immunogenicity of DNA vaccines that encode the full-




immunodominant epitope is present. Furthermore, this low remaining immunogenicity 
is essentially lost when the preferred shuffled E6 and E7 vaccine formats are utilized. We 
subsequently demonstrate how DNA vaccines with a superior capacity for CD8+ T cell priming 
can be generated through the genetic fusion of either full-length or gene-shuffled HPV genes 
with domain 1 of Tetanus toxin fragment C (TTFC). Collectively, these experiments define the 




C57BL/6 mice (6-10 weeks) were obtained from the experimental animal department of The 
Netherlands Cancer Institute (Amsterdam, The Netherlands). All experiments were performed 
in accordance with institutional and national guidelines and were approved by the Experimental 
Animal Committee of The Netherlands Cancer Institute and in accordance with institutional 
and national guidelines. 
DNA vaccines
DNA vaccines based on HPV16 E6 and E7 genes were generated by the introduction of target 
genes or gene fragments into pVAX 1 (Invitrogen, Carlsbad, CA, USA). The generation of 
GFP-E7
49-57 
has been described elsewhere (26). GFP-E6
48-57
 encodes the immunodominant 
H-2Kb–restricted epitope EVYDFAFRDL as a genetic fusion with GFP and was constructed in 
an analogous manner as GFP-E7 
49-57
, in between the BamHI and Not I sites of pVAX. E7WT, 
E7GGG (11), E6WT and E6GG (22) were obtained from GeneArt (Hilden, Germany), with codon 
optimization for expression in human cells, and were all cloned between the HindIII and XbaI 
sites of pVAX. The generation of E7SH has been described elsewhere (23), and E6SH was 
constructed in a similar fashion. In brief, E6 was cut at positions corresponding to aa 31/32, aa 
64/65, aa 104/105 and aa 137/138, the resulting five segments were reassembled in the order 
ADCBE, and the original junctions destroyed by the dissection were added as an “appendix”. 
The design of E6SH is shown in Suppl. Fig. 1. For this study, both E6SH and E7SH were cloned 
between HindIII and XbaI sites of pVAX. The TTFC fusions, TTFC-E7WT, TTFC-E7GGG, TTFC-E7SH 
and TTFC-E6SH were generated by C terminal fusion of the gene of interest to Tetanus Toxin 
Fragment C domain 1 (TTFC) through PCR. All PCR products were cloned into the HindIII and 
XbaI sites of pVAX. pNGVL4a-sig/E7(detox)HSP70 (15) was a kind gift from T.C. Wu. Sequences 
were confirmed by sequence analysis. Plasmids were expressed and amplified in E. Coli DH5α 
and were purified using an endotoxin free DNA purification kit (Qiagen, Hilden, Germany). 
DNA vaccines for intradermal tattoo application were dissolved in water for injections (Aqua B. 
Braun, Melsungen, Germany). 
Tattoo vaccination
Intradermal DNA tattoo vaccination was performed at day 0, 3 and 6, as described previously 
with minor modifications (16). One day prior to the first DNA tattoo, the hair on the hind 
leg was removed using depilating cream (Veet®, Reckitt Benckiser, Hull, U.K.). On the day of 
vaccination, mice were anesthetized and 10 µl of a 2 µg/µl DNA solution in water was applied 
to the hairless skin of the hind leg. The DNA vaccine was applied with a Permanent Make Up 
(PMU) tattoo machine (kindly provided by MT Derm GmbH, Berlin, Germany), using a sterile 
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disposable 9-needle bar with a needle depth of 1 mm and oscillating at a frequency of 100 Hz 
for 30 seconds.
Detection of HPV-specific T cells in peripheral blood
Peripheral blood cells were obtained via tail bleeding, and erythrocytes were removed by 




, 0.1mM EDTA (pH 7.4)) on 
ice. The cells were subsequently stained in FACS buffer (1× PBS, 0.5% BSA and 0.02% sodium 
azide) with allophycocyanin (APC)-conjugated anti-CD8a mAb (BD Pharmingen, San Jose, USA) 
plus phycoerythrin (PE)-conjugated H-2Db E7
49–57
 or H-2Kb E6
48-57 
tetramers for 15 min at 20 °C. 
Subsequently, cells were washed two times in FACS buffer before analysis. Live cells were selected 
based on PI exclusion. MHC tetramers were produced by UV-induced peptide exchange, as 
described previously (27).
IFN-g assays were performed using the BD Cytofix/Cytoperm kit (Becton Dickinson 
Sciences, Franklin Lakes, NJ, USA) according to the manufacturer’s protocol. Peripheral 
blood cells were stimulated for 4 h at a 1µg E7
49-57 
peptide (RAHYNIVTF) concentration and 
subsequently stained using PE-conjugated anti-INF-g mAb (BD Pharmingen, San Diego, CA, 
USA), and APC-conjugated anti-CD8a mAb (BD Pharmingen,). All samples were analysed on 
a FACScalibur (Becton Dickinson), using Flow-Jo software (Three Star, Ashland, USA) for data 
analysis.  
In vivo cytotoxicity assay
The capacity to kill peptide loaded target cells in vivo was assayed as described previously (28). 
Briefly, splenocytes from naive mice were labeled with either 0.1 µM CFSE (low) or 1 µM CFSE (high). 
The cells labeled with 1 µM CFSE were subsequently pulsed with 10 µM RAHYNIVTF peptide for 1 
h at 37°C, and the cells labeled with 0.1 µM CFSE were pulsed with a control (influenza A-derived 
ASNENMDAM) peptide. After peptide loading, cells were washed three times and subsequently 
injected into mice in a 1:1 ratio for a total of 2 * 106 cells per mouse. After 20 h, spleen cells were 




 cells was determined by flow cytometry. The percentage 
antigen-specific cytotoxicity was determined as follows: 100 - ([% CFSE
high
 in vaccinated/ % CFSE
low
 
in vaccinated) / (% CFSE
high
 in naive / % CFSE
low
 in naive)] * 100).
TC-1 tumor challenge 
C57BL/6 mice were injected subcutaneously with 1*105 TC-1 tumor cells that express both HPV16 
E6 and E7 (29). DNA tattoo vaccination was subsequently performed on day 3, 6 and 9 after 
tumor challenge. Tumor growth was monitored 1-3 times per week using caliper measurements 
in two dimensions. The volume of the tumors was calculated as follows: volume = (width2 x 
length)/2 (30) Mice were sacrificed when the tumor diameter reached 15 mm or when the 
tumor volume exceeded 1000mm3. 
Statistical analysis
Statistical analysis was performed using a student’s t-test. A p-value <0.05 was considered to 






Immunogenicity of HPV16 E7 and E6 DNA vaccines is highly dependent 
on transgene design
We first compared the immunogenicity of the immunodominant HPV16 E7
49-57
 epitope when 
either present within the full-length E7 gene, or as a C-terminal fusion of the single epitope with 
GFP (see fig. 1 A, B, C). Consistent with earlier results (16,19), ex vivo MHC tetramer staining of 
peripheral blood of mice that had received a DNA vaccine encoding GFP-E7
49-57
 demonstrated 
that this epitope-directed vaccine was highly immunogenic (peak T cell response of 4.97% 
+/- 2.15). In contrast, immune responses against the same epitope remained low in mice that 
were vaccinated with the E7WT encoding vaccine (0.83% +/- 1.14, p<0.01 versus GFP-E7
49-57
). The 
immunogenicity of the full-length E7 was not altered by the introduction of point mutations, as 
immunogenicity of E7GGG was equally low (0.63% +/- 0.66, p<0.01 versus GFP-E7
49-57
). However, 
the immune responses elicited by a DNA vaccine in which the same epitope was present in the 
‘shuffled’ version of the E7 gene (E7SH) were not significantly different from the background 
responses detected in mock-vaccinated animals (p= 0.57). Similar to what was observed for E7, 
immune responses induced by a shuffled HPV E6 DNA vaccine (E6SH) were close to background, 
and substantially lower than those induced by E6WT, E6GG, and in particular GFP-E6
48-57  
DNA 
vaccines (5,8 fold lower, p< 0.05) (figure 1D). Taken together, these results demonstrate that the 
context in which a defined HPV16 E7 or E6 CD8+ T cell epitope is delivered strongly influences 
its immunogenicity. Importantly, the poor performance of the full-length or shuffled versions 
necessitated the optimization of the DNA vaccine design before moving to clinical evaluation. 
Fusion of full length E7 with Tetanus toxin fragment C domain 1 results 
in a dramatic increase in CD8+ T cell responses
As CD8+ T cell responses to the gene shuffled DNA vaccines were essentially undetectable, we 
first focused on improving the immunogenicity of the wild-type and point-mutated versions, 
choosing HPV16 E7 as a model vaccine. Prior work by Stevenson et al. has demonstrated that 
fusion of antigenic peptides with the C-terminus of domain 1 of Tetanus toxin fragment C 
domain 1 (hereafter referred to as TTFC) enhances CD8+ T cell responses against these peptides 
(31). To evaluate whether this strategy would also be successful for the full length E7 protein, we 
generated DNA vaccines consisting of C-terminal fusions of E7WT and E7GGG with TTFC (Fig. 
2A). Vaccination of mice with TTFC-E7WT and TTFC-E7GGG resulted in E7
49-57 
specific CD8+ T cell 
responses that were markedly increased relative to those induced by E7WT, with mean peak 
CD8+ T cell frequencies of 17.6% +/-9.83 and 16.6% +/-9.85 respectively (fig. 2B). Importantly, the 
responses induced by the TTFC-fusion vaccines were also markedly higher than those induced 
by sig/E7(detox)HSP (mean peak CD8+ T cell frequencies of 5,79% +/-3.15) that has recently 
been tested in a clinical trial (15). Surprisingly, fusion to TTFC did not only increase the peak 
height of the CTL response, but also caused a marked change in response kinetics. Specifically, 
whereas classical vaccine-induced cellular immune responses (as induced by all other vaccine 
formats tested) are characterized by a rapid contraction after the peak of the T cell response, 
tattoo vaccination with TTFC-E7 DNA vaccines induced CD8+ T cell responses that remained 
near constant for about 3 weeks after the peak of the CD8+ T cell response was reached (Fig. 
2b). Furthermore, also in the months following vaccination, marked DNA vaccine-induced T 
cell responses remained detectable directly ex vivo. 
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Functional characterization of TTFC E7 induced long-term persisting cells 
Since the kinetics of the E7 specific CD8+ T cell responses induced by TTFC-E7 vaccines were so 
markedly different from classical vaccine-induced CD8+ T cell responses, we investigated the 
functional properties of these cells. Firstly, the ability of CD8+ T cells to produce IFN-g upon E7
49-57
 
peptide stimulation was tested by intracellular cytokine staining of peripheral blood samples 
taken from DNA tattoo vaccinated mice (fig. 3). Four weeks after vaccination, the production 
of IFN-g could be detected in 4.4% +/- 3.03 and 3.6% +/-1.14 of CD8+ T cells of TTFC-E7WT and 
TTFC-E7GGG vaccinated mice, respectively. In contrast, essentially no IFN-g production above 
background could be observed in samples taken from E7WT and E7GGG vaccinated mice. 
Secondly, the ability of the vaccination-induced T cell pool to respond to secondary antigen 
encounter was evaluated by a single homologous booster vaccination 3 months after priming 
(Fig. 3C). Peak secondary T cell responses were comparable in size to the primary response 
for both TTFC-E7WT and TTFC-E7GGG. In contrast, in E7WT and E7GGG vaccinated mice, 
secondary T cell responses were markedly reduced relative to the primary response. As a 
result, the differences between E7WT and TTFC-E7WT (7.7 fold; p< 0.05) and E7GGG and TTFC-
E7GGG (12.2 fold; p< 0.001) were even more pronounced during the secondary response. As 
a third and final test for T cell functionality of the long-term persisting HPV E7-specific CD8+ 



















































































Figure 1. Transgene design and immunogenicity of HPV16 E7 and E6 encoding DNA vaccines. 
C57BL/6 mice (n=5 per group) were immunized by DNA tattoo vaccination on day 0, 3 and 6, and 
peripheral blood was analyzed for antigen-specific CD8+ T cells by MHC tetramer staining. A) 
Schematic representation of the E7 directed DNA vaccines. GFP-E7
49-57
 encodes the immunodominant 
H-2 Db–restricted epitope of HPV16 E7
49-57 
as a C-terminal fusion with eGFP. E7GGG encodes an E7 
variant with 3 point mutations in the pRb binding domain: D21G, C24G and E26G (11). E7SH encodes 
a ‘gene-shuffled’ variant of E7 (23). HPV E6 directed DNA vaccines with corresponding names were 
constructed in an identical fashion (not shown). B) Representative dot plots of MHC tetramer 
stainings at the peak of the response for the different E7 directed constructs C) Plot depicting the 
mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells for the indicated groups over time. D) 
Plot depicting the mean percentage +/- S.D. of H-2Kb E6
48-57





T cells, the ability to kill peptide loaded target cells was tested in an in vivo cytolytic assay 6 
weeks after priming with either TTFC-E7GGG or E7GGG (Fig. 4). In TTFC-E7GGG vaccinated 
mice, 59,1 +/-13.7% specific lysis of target cells was observed compared to only 15,9 +/-4.3% in 
E7GGG vaccinated mice (p=0.0013). Taken together, these results demonstrate that DNA tattoo 
vaccination of mice with TTFC-E7 fusion vaccines induces superior T cell reactivity compared to 
E7 vaccines as revealed by both antigen-specific T cell numbers and their function.
TTFC fusion also enhances the immunogenicity of the E7SH and E6SH 
DNA vaccines
Because of the perceived greater safety of shuffled HPV16 E6 and E7 genes as compared to 
point mutated HPV16 E6/E7 genes, we evaluated whether the immunogenicity of the very 
weakly immunogenic shuffled DNA vaccines could also be enhanced by TTCF fusion. As shown 
in figure 5A, the use of TTFC-E7SH resulted in a strong E7-specific CD8+ T cell response with an 
11.7 fold (p< 0.01) difference at the peak of the response compared to E7SH. Moreover, both 
the magnitude and persistence of the primary and secondary CD8+ T cell response induced 
by TTFC-E7SH was comparable to that induced by vaccination with TTFC-E7WT. Evaluation of 
Oosterhuis et al_figure 2
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Figure 2. TTFC fusion enhances DNA vaccine immunogenicity. C57BL/6 mice (n=5 per group) were 
immunized by DNA tattoo vaccination on day 0, 3 and 6, and peripheral blood was analyzed for 
antigen-specific CD8+ T cells by MHC tetramer staining A) Schematic representation of E7 variants 
that were expressed as C-terminal fusions with Tetanus Toxin Fragment C domain 1 (TTFC) (31). B) 
Plot depicting the mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells for the indicated 
groups over time. 
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the magnitude of CD8+ T cell responses induced by TTFC-E6SH relative to those induced by 
E6SH (fig 5B) revealed a modest but non-significant increase in primary T cell responses (3.0 
fold p=0.27). The delayed contraction of the vaccination-induced immune response, observed 
for TTFC-E7 fusions, was not seen for TTFC-E6SH. However, following homologous boost 
vaccination, E6-specific CD8+ T cell responses in TTFC-E6SH vaccinated mice were markedly 


















































































Figure 3. Long-term persisting E7
49-57
-specific CD8+ T cells are functional in terms of interferon-g 
production and secondary expansion. Interferon-g production of peripheral blood CD8+ cells from 
indicated groups of the experiment displayed in fig. 2 was assayed 4 weeks after start of vaccination. 
A) Representative dot plots of IFN-g staining of the indicated groups. B) Bar diagram showing the 
mean percentage +/- S.D. of interferon-g positive CD8+ T cells after 4h stimulation with the E7
49-57 
peptide. C) Secondary T cell responses of TTFC-E7WT or TTFC-E7GGG vaccinated mice. Mice from 
the experiment displayed in fig. 2 were boosted with a single homologous DNA tattoo vaccination 
at the indicated time point. Peripheral blood was analyzed for antigen-specific CD8+ T cells by 
MHC tetramer staining. The mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells for the 




Taken together these results demonstrate that TTFC fusion enhances the immunogenicity of 
both E7SH and E6SH DNA vaccines. 
Comparing the anti-tumor effect of E7SH and TTFC-E7SH DNA vaccines
To evaluate whether the difference in immunogenicity resulting from the TTFC fusion translated 
into a measurable difference in the ability of vaccine-induced T cells to eradicate HPV16 E6/
E7 transformed tumors, mice were inoculated subcutaneously with 1*105 TC-1 tumor cells. At 
day three post tumor cell injection, at which point most of the animals carry palpable tumors, 
tattoo vaccination with E7SH, TTFC-E7SH, or a control DNA vaccine was initiated. In the animals 
treated with empty vector, E7-specific T cell responses remained below the level of detection 
indicating that the TC-1 tumor itself is not immunogenic (Fig. 6A). Also in animals treated with 
the E7SH DNA vaccine, E7-specific T cell responses remained close to background, and tumor 
outgrowth and survival was indistinguishable between the two groups. In contrast, in animals 
treated with the TTFC-E7SH fusion vaccine, a robust E7-specific T cell response emerged 
(26.7 +/- 20.6%). This T cell response was accompanied by tumor regression and resulted in 
a prolonged survival for all mice (Fig. 6B, 6C). In spite of the high frequencies of E7 specific 
CD8+ T cells in TTFC-E7SH vaccinated mice, tumors did eventually recur in 60% of the mice, 
Figure 4. Cytolytic activity of long-term persisting E7
49-57
-specific CD8+ T cells. C57BL/6 mice 
(n=5 per group) were immunized by DNA tattoo vaccination on day 0, 3 and 6, and peripheral 
blood was analyzed for antigen-specific CD8+ T cells by MHC tetramer staining. A) Plot depicting 
the percentage +/-S.D. of H-2Db E7
49-57
-specific CD8+ T cells over time. The arrow indicates the time 
point at which mice were injected with peptide loaded target cells. B) Representative histograms 
displaying the ratio of target cells pulsed with specific peptide (CFSE high) or irrelevant peptide 
(CFSE low) 20h after injection. C) Plot depicting the percentage of specific kill of E7
49-57
-pulsed target 
cells. Displayed are the individual values and the mean of each group. 
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indicating that the TC-1 tumors can grow out in the face of an ongoing high-level E7-specific 
T cell response. This immune evasion by TC-1 tumors has been described previously, and has 
been attributed to both mutation of the immunodominant epitope and increased expression 
of vascular cell adhesion molecule-1 (VCAM-1) on the tumor cells (32,33). In summary, the 
increased immunogenicity of the shuffled E7 DNA vaccine obtained by TTFC fusion resulted 
in a highly reduced tumor outgrowth and a significant increase in median survival (p<0.002; 
Log-rank test).
discussion
The aim of this study was to design safe and highly immunogenic DNA vaccines that encode 
the full-length HPV16 E6 and E7 oncogenes. E6 and E7 encoding genetic vaccines thus far used 
in clinical trials contain point mutations that avoid binding of the encoded proteins to p53 and 
pRB, respectively (7,34). However, it is well recognized that both HPV16 E6 and E7 also interact 
with other cellular targets than p53 and pRB, and that these interactions may play an additional 
Oosterhuis et al_figure 5





















































Figure 5. TTFC fusion enhances the immunogenicity of E7SH and E6SH. C57BL/6 mice (n=5 per 
group) were immunized by DNA tattoo vaccination on day 0, 3 and 6, and boosted with a single 
homologous tattoo vaccination at the indicated time point. Peripheral blood was analyzed for 
antigen-specific CD8+ T cells by MHC tetramer staining. A) Plot depicting the mean percentage 
+/- S.D. of H-2Db E7
49-57
 specific CD8+ T cells for the indicated groups is displayed over time. B) Plot 
depicting the mean percentage +/- S.D. of H-2Kb E6
48-57





role in cellular transformation (1,20,21,24,25,35). Because of this concern, the use of E6 and E7 
vaccine formats in which the potential of E6 and E7 to interact with cellular targets is altered in 
a more drastic manner appears preferable. Therefore, we aimed to develop DNA vaccines that 
encode gene-shuffled variants of E6 and E7. Prior studies have already demonstrated the loss of 
oncogenic potential of the shuffled variant of E7 in in vitro assays (9,23). Likewise, shuffled E6 
shows a complete lack of transforming potential (Öhlschlager et al., unpublished observations).
While shuffled E6 and E7 genes therefore appear suitable for use in genetic vaccines from 
a safety perspective, we here observed that the immunogenicity of E7SH and E6SH upon 
DNA tattoo is strongly reduced as compared to both the unmodified and the point mutated 
variants of E6 and E7. How can the low immunogenicity of E6SH and E7SH be explained? A 
possible explanation for the reduced immunogenicity of these shuffled gene products is 
that these proteins are misfolded and hence rapidly degraded. Prior work has demonstrated 
that cross presentation of MHC class I-restricted epitopes is biased towards epitopes that 
accumulate in the antigen-producing cell (36,37), and induction of CD8+ T cell responses upon 
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Figure 6. Tumor regression by 
vaccination with the TTFC-E7SH 
fusion vaccine. C57BL/6 mice (n=5-7 
per group) were injected with 1*105 TC-1 
tumor cells on day 0. Subsequently, 
mice were immunized by DNA tattoo 
vaccination on day 3, 6 and 9 after 
tumor challenge with the indicated 
vaccines. Tumor sizes were determined 
by caliper measurements 2-3 times 
weekly. Peripheral blood was analyzed 
for antigen-specific CD8+ T cells 
by MHC tetramer staining. A) Plot 
depicting the mean percentage +/- S.D. 
of H-2Db E7
49-57
-specific CD8+ T cells for 
the indicated groups over time. B) Plot 
depicting the mean tumor size +/- S.D. 
(mm3) for the indicated groups over 
time. C) Plot depicting the percentage 
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In further support of this, we have previously demonstrated that in vivo antigen stability and 
immunogenicity of DNA vaccine encoded antigens that are introduced via intradermal DNA 
tattooing are correlated, and that the destabilization of a model vaccine via an approach very 
similar to gene shuffling also resulted in the loss of vaccine immunogenicity (38). As a second 
potential explanation, the gene shuffling procedure could conceivably disrupt CD4+ T cell 
epitopes present within the parental protein. However, as a deleterious effect of gene shuffling 
is observed for both E6 and E7, and as the regions that encompass the sites at which the parental 
protein is taken apart are rescued in the ‘appendix’, this explanation seems less likely. It has to be 
noted that the immunogenicity of (non-fused) E7SH and E7WT were comparable in a previous 
report (23). Potentially, differences in the route of administration (intramuscular injection 
versus intradermal tattoo), or number of administrations (single injection versus 3 DNA tattoo 
applications) could influence the immunogenicity of shuffled DNA vaccines. Regardless of this, 
from the current analyses it is apparent that for the planned clinical application, i.e. intradermal 
DNA tattoo, gene shuffling is highly detrimental to the immunogenicity of both HPV E6 and E7. 
We and others have previously demonstrated that DNA vaccines can be improved by fusing 
genes encoding an antigen or an epitope of interest to that of a carrier protein (7,8,12,19). Here 
we demonstrate for both E6SH and E7SH that their immunogenicity can be fully remedied by 
genetic linkage to TTFC, priorly developed as a fusion partner in DNA vaccines by the group 
of Stevenson (6,39). In these studies, the optimal configuration for the induction of CD8+ T 
cell immunity consisted of a C-terminal fusion of a minimal epitope with domain 1 of FrC (here 
referred to as TTFC for simplicity) (6,31,40).  Here we show for the first time that the beneficial 
effects of TTFC fusion do also apply to full-length gene products, thereby allowing antigen 
presentation via multiple HLA class I alleles. What is the mechanism by which fusion with a carrier 
molecule enhances DNA vaccine immunogenicity? In the case of TTFC a likely explanation is that 
fusion of genes of interest to TTFC promotes the induction of CD8+ T cell responses through the 
provision of CD4+ T cell help via one of the TTFC encoded “promiscuous” CD4+ helper epitopes 
(6,39). Support for this notion comes from prior work demonstrating that a carrier protein 
needs to be of non-self origin in order to improve DNA vaccine immunogenicity and that CD8+ 
T cell responses towards a carrier-epitope fusion encoding DNA vaccine are dependent on 
MHC-II mediated antigen presentation (19). In line with this MHC-II -/- mice were not able to 
mount measurable CD8+ T cell responses after vaccination with either TTFC-E6SH or TTFC E7SH 
(Suppl. Fig. 3). However, it is plausible that the presence of helper T cell epitopes is not the only 
relevant factor, as -as discussed above- antigen stability correlates with the immunogenicity of 
DNA vaccines. To assess whether TTFC fusion may increase the accumulation of E7(SH) protein, 
we transfected HEK293 cells with either E7WT or E7SH, or with TTFC-E7WT or TTFC-E7SH and 
detected E7 protein expression by western blot analysis 24 hrs after transfection. As shown in 
Suppl. Fig. 2, E7 accumulation was substantially higher in the TTFC E7(SH) transfected cells, 
indicating that the stability of E7 is indeed improved by this fusion. 
A remarkable observation in our study is the delayed contraction of the CD8+ T cell 
responses upon DNA tattoo vaccination with all TTFC-E7 fusion vaccines tested. Conventional 
CD8+ T cell responses rapidly contract after the peak of the response has been reached, and 
levels of CD8+ T cells that remain after contraction are generally around 5% of peak levels (41,42). 
In all our previous studies, immune responses induced by DNA tattoo showed similar kinetics, 
with contraction being close to complete about 1 week after the peak of the response (16,38). 
In contrast, upon tattooing TTFC-E7 encoding DNA vaccines, we consistently observed that 




remaining frequencies after 4 weeks were still around 20% of the initial peak height (Fig. 3). At 
present we do not know the cause of this delayed contraction, but the data available suggest a 
combination of epitope-intrinsic and epitope-extrinsic factors is required. Specifically, the fact 
that delayed contraction is observed for TTFC-E7 but not for TTFC-E6 DNA vaccines indicates 
that epitope identity does play a role. On the other hand, the fact that delayed contraction is 
observed for TTFC-E7 but not for GFP-E7
49-57
 DNA vaccines shows that the identity of the carrier 
also forms a crucial component. Clearly, understanding the molecular basis underlying both 
the increase in peak height and the improved persistence of CD8+ T cell responses induced by 
these fusion vaccines, would be highly useful for future DNA vaccine development, and will be 
the focus of our future work. 
In conclusion, we have constructed DNA vaccines targeting full length HPV16 E6 and E7 with 
good immunogenicity and safety profiles, by successfully combining strategies to “detoxify” 
and improve DNA vaccine encoded antigens. The resulting vaccine format outperformed a 
vaccine encoding sig/E7(detox)HSP that was recently tested in humans (15), providing a strong 
rationale for clinical evaluation of our vaccine format. We are currently planning to evaluate 
a combination of TTFC-E7SH and TTFC-E6SH encoding constructs, applied via DNA tattoo 
vaccination, for treatment of HPV16 positive carcinomas in a phase 1 clinical trial.  
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Supporting information figure 1. Schematic representation of E6SH. HPV 16 E6 was 
taken apart at the amino acids positions indicated in the figure, thereby dissecting the C-
X-X-C- motifs crucial for interaction with p53 (Crook et al, Cell, 1991). The resulting 
domains were reassembled in the indicated order, resulting in the E6SH core sequence. 
To avoid the loss of putative CD8+ T cell epitopes at the junctions, sequences encoding 
12-18 amino acids at either side of the different junctions in the natural protein were 
added as an ‘appendix’. 
 
Supplementary figure 1. Schematic representation of E6SH. HPV16 E6 was taken apart at the 
amino acids positions indicated in the figure, thereby dissecting the C-X-X-C- motifs crucial for 
interaction with p53 (Cr ok e  al, Cell, 199 ). The resulting domains were reassembled in the indicated 
order, resulting in the E6SH core sequence. To avoid the loss of putative CD8+ T cell epitopes at 
the junctions, sequences encoding 12-18 amino acids at either side of the different junctions in the 






























Supporting information figure 2. TTFC E6SH and TTFC E7SH specific CD8+ T cell 
responses are dependent on MHC-II-restricted antigen presentation. WT C57BL/6 mice 
(n=5 per group) or MHC-II-/- mice (n=4 per group) were immunized by DNA tattoo 
vaccination on day 0, 3 and 6, and peripheral blood was analyzed for antigen-specific 
CD8+ T cells by MHC-I tetramer staining. A) Plot depicting the percentage +/-S.D. of H-
2Db E749-57-specific CD8+ T cells of the TTFC-E7SH vaccinated mice over time. B) Plot 
depicting the percentage +/-S.D. of H-2Kb E648-57-specific CD8+ T cells of the TTFC-
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Supplementary figure 2. 
TTFC-E6SH and TTFC-E7SH 
specific CD8+ T cell responses 
are dependent on MHC-II-
restricted antigen presenta-
tion. WT C57BL/6 mice (n=5 per 
group) or MHC-II-/- mice (n=4 
per group) were immunized by 
DNA tattoo vaccination on day 0, 
3 and 6, and peripheral blood was 
analyzed for antigen-specific 
CD8+ T cells by MHC-I tetramer 
staining. A) Plot depicting the 
percentage +/-S.D. of H-2Db 
E7
49-57
-specific CD8+ T cells of 
the TTFC-E7SH vaccinated mice 
over time. B) Plot depicting the 
percentage +/-S.D. of H-2Kb 
E6
48-57
-specific CD8+ T cells of the 
































Supporting information figure 3. TTFC fusion results in enhanced accumulation of 
both E7WT and E7SH in vitro. HEK 293 cells were transfected with a mixture of 1µg 
GFP encoding DNA and 4 µg of DNA encoding either E7WT or E7SH, or their 
respective TTFC fusions. Cells were harvested 24 hours after transfection and both HPV 
16 E7 and GFP were detected by western blot analysis, using a mouse monoclonal 
antibody against E7 and a rabbit monoclonal antibody against GFP, respectively. Note 
that E7SH has a slightly higher MW than E7WT (11kDa) due to the addition of the 
appendix, and that the addition of TTFC Dom 1 (∼30 kDa) results in a protein product of 
the expected size. 
Supplementary figure 3. TTFC fusion results in enhanced 
accumulation of both E7WT and E7SH in vitro. HEK 293 cells 
were transfected with a mixture of 1µg GFP encoding DNA and 4 
µg of DNA encoding either E7WT or E7SH, or their respective TTFC 
fusions. Cells were harvested 24 hours after transfection and both 
HPV16 E7 and GFP were detected by western blot analysis, using a 
mouse monoclonal antibody against E7 and a rabbit monoclonal 
antibody against GFP, respectively. Note that E7SH has a slightly 
higher MW than E7WT (11kDa) due to the addition of the appendix, 
and that the addition of TTFC Dom 1 (~30 kDa) results in a protein 






PRECLINICAL SAFETY EVALUATION 
OF DNA VACCINES ENCODING 
MODIFIED HPV16 E6 AND E7 4
chapter 4
abstract
Persistent infection with high-risk human papillomaviruses (hrHPV) can result in the 
formation of anogenital cancers. As hrHPV proteins E6 and E7 are required for cancer 
initiation and maintenance, they are ideal targets for immunotherapeutic interventions. 
Previously, we have described the development of DNA vaccines for the induction of 
HPV16 E6 and E7 specific T cell immunity. These vaccines consist of ‘gene-shuffled’ 
(SH) versions of HPV16 E6 and E7 that were fused to Tetanus Toxin Fragment C domain 
1 (TTFC) and were named TTFC-E6SH and TTFC-E7SH. Gene-shuffling was performed 
to avoid the risk of inducing malignant transformation at the vaccination site. Here, we 
describe the preclinical safety evaluation of these candidate vaccines by analysis of their 
transforming capacity in vitro using established murine fibroblasts (NIH 3T3 cells) and 
primary human foreskin keratinocytes (HFKs). We demonstrate that neither ectopic 
expression of TTFC-E6SH and TTFC-E7SH alone or in combination enabled NIH 3T3 cells 
to form colonies in soft agar. In contrast, expression of HPV16 E6WT and E7WT alone 
or in combination resulted in effective transformation. Similarly, retroviral transduction 
of HFKs from three independent donors with both TTFC-E6SH and TTFC-E7SH alone or 
in combination did not show any signs of immortalization. In contrast, the combined 
expression of E6WT and E7WT induced immortalization in HFKs from all donors. 
Based on these results we consider it justified to proceed to clinical evaluation of DNA 
vaccines encoding TTFC-E6SH and TTFC-E7SH in patients with HPV16 associated (pre)
malignancies. 
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introduction
It has been well established that persistent infection with high-risk human papillomavirus 
(hrHPV) is causally related to the development of cervical cancer, as well as a subset of other 
anogenital and head and neck cancers (1-5). Continuous expression of the viral oncogenes 
E6 and E7 is required for the induction and maintenance of a malignant phenotype (6). The 
most well studied cellular targets of E6 and E7 are the tumour suppressor proteins p53 and pRb, 
respectively. HPV16 E6 binds to p53 via the cellular ubiquitin-protein ligase E6AP, resulting in 
rapid ubiquitin-dependent proteolytic degradation of p53 (7, 8), thereby interfering with the 
regulatory function of p53. High-risk HPV E7 interacts with pRb (9) and its family members, 
p107 and p130 (10, 11), resulting in their inactivation and thereby interfering with their control 
on the G1/S cell cycle transition. The continuous presence of viral proteins in hrHPV-induced 
malignancies provides a strong rationale for the immunotherapeutic treatment of these 
diseases (12, 13), as the recognition of these tumour specific antigens would enable the immune 
system to eradicate the malignant cells without the risk of inducing autoimmunity. 
For safety reasons the oncogenic potential of E6 and E7 should be abolished before their 
use as an antigen in human application. This is particularly important when they are applied as 
DNA vaccines as low-level integration of introduced plasmid DNA into the host genome may 
theoretically occur upon DNA vaccination (14, 15). Most commonly, detoxification is achieved 
by the introduction of point mutations that have been shown to prevent the interaction of E6 
and E7 with p53 and pRb, respectively (16-20). A more drastic approach to detoxify E6 and E7 
is termed ‘gene-shuffling’ (21, 22). This method is based on the rearrangement of the primary 
gene sequences in such a way that the known ligand binding domains are disrupted. The 
original sequence junctions that are destroyed by the gene-shuffling are added as an appendix 
to prevent loss of possible T-cell epitopes (see Supplementary figure 1). It has already been 
demonstrated that a gene-shuffled version of E7 (E7SH) has lost its transforming potential, 
as determined by the inability of E7SH transduced murine fibroblasts to form colonies in 
soft agar (21, 23). We have previously reported on the construction and evaluation of the 
immunogenicity of plasmid DNA vaccines encoding gene-shuffled versions of HPV-16 E6 and 
E7 that are genetically fused to Tetanus Toxin Fragment C domain 1 (TTFC): TTFC-E6SH and 
TTFC-E7SH (22) (see also Supplementary figure 1). The fusion with TTFC was shown to be 
critical to overcome the observed loss in immunogenicity resulting from the gene-shuffling 
procedure. When applied via DNA tattooing (24), TTFC-E6SH and TTFC-E7SH encoding DNA 
vaccines induced strong E6 and E7 specific T-cell immunity in mice. Because of these promising 
pre-clinical data, we are now planning to evaluate these vaccines in patients suffering from 
HPV16 induced malignancies. In the present study we aimed to confirm that these candidate 
vaccines indeed have no oncogenic potential, before moving to clinical application. To this end 
two different assay systems were used as outlined below.
First we compared the ability of TTFC-E6SH and TTFC-E7SH with HPV16 E6 and E7 wild-type 
to induce colony formation in an established rodent fibroblast cell line (NIH 3T3 cells) in soft 
agar. Secondly, we wanted to demonstrate the loss of transforming potential in a physiologically 
more relevant cell type. As we are planning to administer our candidate vaccines via intradermal 
DNA tattooing, keratinocytes will be primarily transfected upon vaccination (25). Hence, 
we consider primary human keratinocytes the most relevant cell type to examine the safety 
of our candidate vaccines. Primary human keratinocytes like established rodent cell lines 




Immortalization of keratinocytes has been considered a point of no return in terms of malignant 
transformation by hrHPV types (4). HPV-mediated immortalization has been recognized as 
a two-step process, involving the bypass of two replicative lifespan barriers, senescence and 
crisis, also referred to as M1 and M2, respectively. It has been well established that the host cell 
alterations leading to the immortalization of cultured primary human keratinocytes, including 
the inactivation of p53 and pRb and the activation of telomerase, closely reflect those observed 
in cervical carcinogenesis in vivo (4). To demonstrate the safety of our candidate vaccines in 
this system, primary human foreskin keratinocytes (HFKs) from 3 independent donors were 
transduced with retroviral constructs encoding the DNA vaccine candidates and grown under 
selection. Transduction with retroviral constructs was chosen in order to mimic the ‘worst-
case scenario’ of chromosomal integration. Therefore, these studies will provide an answer 
to the question what would happen if our candidate DNA vaccines would stably integrate 
into the host cell genome, leading to constitutive expression at the vaccination site. The 
transduced keratinocytes were monitored for their ability to overcome replicative senescence, 
degradation of p53 and pRb, and the upregulation of hTERT as a marker for telomerase activity 
and immortalization. In the current study the results obtained in both assay systems are 
presented and the implications for the application of the candidate vaccines are discussed. 
materials and methods
DNA and Viruses 
pVAX-TTFC-E6SH and pVAX- TTFC-E7SH fusion vaccines were developed in a previous study 
(22). These vaccines consist of ‘gene-shuffled versions of HPV16 E6 and E7 (E6SH and E7SH) 
that are C-terminally fused with Tetanus Toxin fragment C  (see also Supplementary figure 1 
for a schematic representation) and are inserted into pVAX1 (Invitrogen Life Technologies, 
Breda, The Netherlands) via 5´HindIII/3´XbaI. Plasmids were expressed and amplified in E. 
Coli DH5alpha and were purified using an endotoxin free DNA purification kit (Qiagen, Hilden, 
Germany). Retroviral vectors were constructed by the insertion of these candidate vaccines 
in the LZRS backbone (29, 30). To allow for co-selection, TTFC-E6SH and TTFC-E7SH were 
inserted in LZRS containing different selection markers, resulting in LZRS-TTFC-E6SH-MS-
IRES-blasticidin and LZRS-TTFC-E7SH-MS-IRES-neomycin, respectively. LZRS-E6WT-MS-IRES-
blasticidin and LZRS-E7WT-MS-IRES-neomycin were constructed as positive controls. Empty 
vectors (selection marker only) were used as negative controls. Helper virus–free recombinant 
retroviruses were produced after transfection of the retroviral constructs into the 293T-based 
Phoenix amphotropic packaging cell line and selection on the selectable marker puromycin, as 
described before (29). 
Soft agar transformation assays
NIH 3T3 cells were co-transfected with the CD4 expression vector (pMACS-hCD4, Miltenyi) 
together with either empty vector pTHamp (31), HPV16 E6WT or HPV16 E7WT or HPV16 E6WT 
+ HPV16 E7WT (inserted via 5´HindIII/3´XbaI cloning sites into pTHamp), or TTFC-E6SH or 
TTFC-E7SH, using Effectene transfection reagent (Qiagen) according to the manufacturer’s 
instructions. Correct transgene expression from the different plasmids was verified by RT-PCR 
(Supplementary Figure 2). The cells were analyzed by flow cytometry on a FACScan™ flow 
cytometer (BD Biosciences) one day after transfection and 5000 CD4 positive cells were seeded 
(suspended in the same medium used for the base layer) onto a precast base layer consisting of 
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5 ml DMEM/10% FCS with 1% soft agar in 50 mm petri dishes. Soft agar cultures were incubated 
at 37°C / 5% CO2 adding 0.25 ml complete DMEM / 10% FCS once per week. After four weeks 
all colonies (> 8 cells) located within a 9 cm2 field of the soft agar plate were counted. The 
percentage of transformed cells was calculated by dividing the number of colonies by the 
number of cells seeded in the field.
Primary human foreskin keratinocyte cultures
HFKs were isolated from neonatal foreskin as previously described (28). In short, epidermal 
neonatal foreskin cleared of fibrous tissue, fat and dermis upon dispase treatment was 
incubated with trypsin and filtered to obtain a cell suspension. Cells were seeded on 
collagen-coated plates and cultured in serum-free keratinocyte growth medium (Invitrogen), 
supplemented with bovine pituitary extract (50 µg/ml), epidermal growth factor (5  ng/ml), 
penicillin (100U/ml), streptomycin (100 µg/ml), and L-glutamine (2 mM). After initial passaging 
keratinocytes isolated from three independent donors were transduced with amphotrophic 
retrovirus expressing HPV16 oncogenes or the candidate vaccines using 3µg/ml polybrene and 
after 48hours selected using 2µg/ml blasticidin (Invitrogen) and 80µg/ml neomycin (G418, 
Invitrogen). The different cell cultures were split 1:5 at subconfluency and splitting dates were 
noted to generate culture characteristics to compare the different created cell lines. Cells were 
harvested every few passages for stocks, RNA and protein. Transgene expression was verified 
using RT-PCR (Supplementary Figure 3).
Beta-galactosidase staining
Beta-galactosidase staining (adapted from (32)) was used to assess expression of this senescence 
associated marker. Cells were washed, fixed and incubated at 37°C for 16 hours (no CO2) with 
5-bromo-4-chloro-3-indoyl b-D-galactopyranoside (X-gal) which yields a blue compound 
when cleaved by beta-galactosidase. By using a citric acid and sodium phosphate buffer at pH6, 
senescent associated beta-galastosidase is distinguished from acidic enzymatic activity. 
Western blot
Whole cell extracts were prepared by lysing cells for 15min on ice in a buffer containing 150mM 
NaCl, 50mM Hepes, 5mM EDTA and 0.1% NP40 supplemented with protease and phosphatase 
inhibitors. Protein concentration was determined using the BCA protein assay (Pierce 
Biotechenology Inc, Rockford, IL, USA). Typically 20µg of protein lysates were separated by 
SPS-PAGE and electrophoretically transferred to nitrocellulose membranes. Membranes were 
blocked with 3% dry milk in PBS containing 0.05% Tween20. Antibodies against pRb (clone 1F8, 
Novocastra, Leica Microsystems, Milton Keynes, UK), p53 (clone D07, Dako, Glostrup, Denmark), 
and loading control beta-actin (Cell Signalling Technology, Beverly, MA, USA) were used 
according to manufacturer’s instructions. Membranes were incubated with the appropriate 
horseradish peroxidise-conjugated secondary antibodies and the levels of corresponding 
proteins were visualized using SuperSignal West Dura Extended Duration Substrate (Pierce 
Biotechenology Inc). 
Quantitative RT-PCR  
mRNA from cell cultures was isolated using RNA-B reagent (Tel-Test, Friendswood, TX, 
USA). Isolated RNA was DNase treated (Promega, Madison, WI, USA) and used for cDNA 




was performed as described previously (33) using the following primers hTERT-forward 
5’-CACGCGAAAACCTTCCTCA-‘3, hTERT-reverse 5’-CAAGTTCACCACGCAGCC-‘3 and the probe 
FAM-5’-CTCAGGGACACCTCGGACCAGGGT-3’-TAMRA. For quantification purposes a standard 
curve was used of serial dilutions of cell line (SIHa) cDNA synthesized with specific reverse primers. 
To correct for RNA quality and input, we performed RT-PCR for the housekeeping gene snRNP 
U1A using the following primers snRNP forward 5’- TCCTCACCAACCTGCCAGA-‘3 and reverse 
5’-TGAAGCCAGGGAACTGATTGA-‘3 with probe 5’-AGACCAACGAGCTCATGCTGTCCATG-‘3.
results
Transformation of established rodent cells
Murine NIH 3T3 cells have been extensively used to study the transforming potential of HPV 
types. Both HPV16 E7 wilde-type (E7WT) and E6WT are known to independently induce 
transformation in NIH 3T3 cells, as can be shown by anchorage independent growth in soft agar 
(27). Because of the relative simplicity and short duration, we first used this assay to test the 
transforming potential of the TTFC-E6SH and TTFC-E7SH encoding candidate vaccines. To this 
purpose NIH 3T3 fibroblasts were transiently transfected with either TTFC-E6SH or TTFC-E7SH 
alone or in combination. The empty vector pTHamp was used as a negative control, and HPV16 
E6WT and E7WT were used either alone or in combination as positive controls. All vectors were 
co-transfected with an expression construct for human CD4, which allowed the purification of 
cells that had been successfully transfected. Selection of transfected cells has been shown to be 
important to increase the sensitivity of the assay (unpublished observation). As shown in Figure 
1, neither transfection with TTFC-E6SH nor with TTFC-E7SH alone or in combination enabled 
NIH 3T3 cells to form colonies. Expression of HPV16 E6WT or E7WT on the other hand, as well 
as the combination of E6WT and E7WT, resulted in colony formation indicating transformation. 
In addition, when transfection of TTFC-E6SH or TTFC-E7SH was combined with their wild-type 
counterparts the number of colonies was not increased compared to cells transfected with 
E6WT or E7WT alone. Importantly in all cases mRNA expression in the transfected cells was 
proven by RT-PCR (Supplementary figure 2). Therefore we conclude that our candidate DNA 
vaccines did not display transforming potential in this assay. 
Retroviral transduction and culture of primary human keratinocytes 
The transforming potential of shuffled E6 and E7 constructs was further analyzed using HFKs from 
three independent donors. This cell type is a well established system to analyse the oncogenic 
potential of HPV types and oncogenes (26, 27). HFKs were transduced with combinations of 
retroviruses (LZRS) containing the different constructs listed in Figure 2A. In the HFKs from the 
first donor we tested all combinations listed, in HFKs from the additional two donors we only 
tested the most critical conditions. The combination of the shuffled vaccine candidates with 
LZRS empty vector (TTFC-E6SH/LZRS, TTFC-E7SH/LZRS) best represents the situation in the 
planned clinical trial, as we will apply the vaccines on distinct areas on the skin. To maximize 
the chance of detecting residual oncogenic activity, we also tested the combination of both 
shuffled vaccine candidates (TTFC-E6SH/TTFC-E7SH), or the combinations with their wild-type 
counterparts (TTFC-E6SH/E7WTand TTFC-E7SH/E6WT). We considered this important as E6 
and E7 are known to cooperatively transform epithelial cells (34). As a positive control for 
immortalization we introduced the wild-type oncogenes together (E6WT/E7WT). Finally double 
empty vector transductions (LZRS/LZRS) served as negative controls next to untransduced 
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HFKs. After initial passaging, transgene expression was confirmed by RT-PCR using specific 
reverse primers for the shuffled sequences (Supplementary figure 3). Upon culturing, cells 
were harvested at different time-points for further analysis. 
Primary keratinocyte cell culture characteristics
Untransduced HFKs (from donor 1-3) ceased to proliferate after 37-53 population doublings 
(PDs) (Figure 2 and Table 1). In the HFKs from the first donor, double empty vector combinations 
(LZRS/LZRS) as well as cells transduced with TTFC-E6SH alone (TTFC-E6SH/LZRS) and 
TTFC-E7SH alone (TTFC-E7SH/LZRS) and the cells transduced with both vaccine candidates 
(TTFC-E6SH/TTFC-E7SH) showed a similar growth pattern. Whereas the transductants carrying 
the candidate vaccines ceased dividing at around the same number of PDs as untransduced 
cells (20-46 PD), only LZRS/LZRS transduced cells showed an increase in PDs (82PD). Also 
HFKs of donor 2 and 3 transduced with the combination TTFC-E6SH/TTFC-E7SH had a similar, 
though slightly increased, lifespan as their parental cells. All cell cultures containing the above 
combinations contained larger flattened cells at later passages, comparable to the untreated 
donor cells, which corresponded to senescence associated beta-galactosidase staining (SA-
beta-gal) (see Figure 3 and Table 1). 
In HFKs from all three donors, cells containing either E6WT or E7WT constructs combined with 
its shuffled counterpart (E6WT/TTFC-E7SH, E7WT/TTFC-E6SH), proliferated longer, ranging from 
81 to 104 PDs after which they ceased to divide and eventually died. These cells also displayed a 
senescent morphology upon reaching their final number of cell divisions. One exception, namely 
the E7WT/TTFC-E6SH combination in HFKs from donor 1, continued to grow at a low rate and 
was still in culture at the time of writing at 177 population doublings, most probably due to the 
expression of HPV16 E7WT (see discussion). Finally, the combined introduction of the wild-type 
genes (E6WT/E7WT) induced the most pronounced increase in the lifespan of HFKs from all 
donors and in all cases the cells were still in culture at 160 to 323 PDs at the time of writing. 
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Figure 1. Colony formation of NIH 3T3 cells in soft agar. NIH 3T3 cells were co-transfected with the 
indicated constructs and a CD4 expressing vector to enable selection of transfected cells. A total of 
5000 CD4 positive cells were plated, and after 4 weeks all colonies (>8 cells) located within a 9 cm2 field 
of the soft agar plate were counted. The number of transformed cells is expressed as a percentage 
of total number of cells seeded in the field. A) Photographs showing transformed NIH 3T3 cells and 
the normal appearance, the arrow highlights a single focus. B) Bar diagram summarizing the results 
of three independent experiments for the TTFC-E6SH containing combinations and controls. C) Bar 





In summary these growth characteristics indicate that introduction of the candidate 
vaccines either alone or in combination did not induce an extended growth potential in primary 
keratinocytes. The only conditions in which an extended or even infinite lifespan was observed 
were those conditions where one of the wild-type genes was present. 
Protein degradation p53 and pRb in primary keratinocytes
Previous studies have demonstrated that the bypass of the first barrier in the finite lifespan of 
keratinocytes, referred to as M1 or senescence, upon HPV E6 and E7 expression results from 
inactivation of p53 (9, 35) and pRb (36). Osen et al. already demonstrated that gene-shuffling 
of E7 resulted in loss of its ability to induce degradation of pRb (23). To demonstrate that the 
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LZRS LZRS  n.d. n.d.
TTFC-E6SH LZRS  n.d. n.d.
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Figure 2. Growth characteristics of HFKs from three independent donors transduced with 
the candidate vaccines and controls. A) Overview of the construct combinations used for the 
transduction of the HFKs from the different donors. B) Plot depicting the growth characteristics of 
the HFKs from donor 1 after transduction with the indicated combinations. C) Growth characteristics 
of HFKs from donor 2. D) Growth characteristics from of HFKs from donor 3. The cross symbol in the 
legend indicates that the culture stopped growing and the cells died. 
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Figure 3. Senescence associated beta-
galactosidase activity. Representative 
pictures after staining for senescence-
associated beta-galactosidase activity of 
the HFKs from donor 1 after transduction 
with the various construct combinations. 
Pictures were taken around passage 10 
corresponding to about 40 PDs. Similar 
results were obtained in HFKs from 
donor 2 and 3 (data not shown).
their inability to target pRb and p53, we examined the status of p53 and pRb protein expression 
in HFKs transduced with the various combinations. Both p53 and pRb remained detectable at 
the protein level in donor cells transduced with either TTFC-E7SH alone (TTFC-E7SH/LZRS), 
TTFC-E6SH alone (TTFC-E6SH/LZRS) or in combination (TTFC-E7SH/TTFC-E6SH) (Figure 4A/B 
and Table 1). As expected, cells containing E6WT (E6WT/E7WT and E6WT/TTFC-E7SH) showed 
a strongly reduced p53 expression, and E7WT containing cells (E6WT/E7WT and E7WT/TTFC-
E7SH) showed reduced pRb levels compared to conditions in which the mutated variant was 
present. Cells containing E6WT/E7WT seemed less efficient in targeting p53 for degradation 
compared to E6WT/TTFC-E7SH containing cells, which might be explained by the fact that 
intact E7WT indirectly leads to an increase in p53 expression whereas TTFC-E7SH would not 
be expected to increase p53 levels. The finding that pRb was hardly detectable in untreated 
donor cells most likely resulted from the fact that cells were already near senescence at the 
time of protein isolation. Importantly, pRb is clearly detectable in cells expressing TTFC-E7SH 
(E6WT/TTFC-E7SH and TTFC-E6SH/TTFC-E7SH) in contrast to cells expressing E7WT (E6WT/
E7WT and E7WT/TTFC-E6SH).  Taken together, these data show that both vaccine candidates 





hTERT expression in primary keratinocytes 
In primary keratinocytes, bypass of the second barrier towards immortalization (M2/crisis) has 
been associated with re-activation of telomerase, resulting at least in part from the upregulation 
of its catalytic subunit hTERT (4). In HFKs expressing E6WT either in combination with E7WT or 
E7SH displayed an upregulation of hTERT mRNA expression (Figure 5 and Table 1), consistent 
with the fact that HPV16 E6 can activate telomerase (37). The observed increase in hTERT 
mRNA upon co-expression of E6WT and E7WT is in line with previous findings (38). Importantly 
messenger RNA levels of hTERT were undetectable in all passages of HFKs containing 
shuffled oncogene constructs without wild-type constructs. Unexpectedly cells from donor 
1 transduced with E7WT/TTFC-E6SH, which reached >177 PD’s, also displayed strongly elevated 
hTERT mRNA levels, consistent with the culture characteristics. At present it remains unclear 
whether the increase in hTERT mRNA expression and concomitant continued growth results 
from the expression of E7WT, TTFC-E6SH or otherwise, such as genetic host cell alterations 
resulting from retroviral integration or prolonged culturing. However, based on the fact that in 
conditions where the wild-type E6 and E7 genes are absent no hTERT could be detected it can 
be concluded that the shuffled candidate vaccines alone or in combination consistently failed 
to induce this key characteristic of immortalization in primary keratinocytes.








































































































Figure 4. Expression levels of p53 and pRb. 
Expression of p53 and pRb was determined by 
Western blotting in HFKs from all donors after 
transduction with the indicated constructs and 
controls. Cellular lysates were prepared around 
passage 10 corresponding to about 40 PDs in 
donor 1 and about 60 PDs in donor 2 and 3. A) 
Expression levels of p53 and pRb for in HFKs from 
donor 1, actin was used as a control for equal 
loading. B) The same data for donor 2 and 3.  
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discussion
The current study describes a comprehensive analysis using two cell culture systems which 
determines whether our candidate DNA vaccines TTFC-E6SH and TTFC-E7SH, intended for use 
in a phase I clinical trial, have lost the ability to induce cellular transformation that is associated 
with the wild-type HPV16 E6 and E7 proteins. In summary, both the assays performed in NIH 
3T3 cells and the assays performed in three independent donors of HFKs demonstrate that our 
Henken et al, figure 5






















































































































































Figure 5. hTERT expression levels.  hTERT expression levels were determined by RT-PCR in all HFKs 
from all donors after transduction with the indicated constructs. RNA was isolated at the latest 
passages that the cells were still in culture. Displayed are the hTERT mRNA levels relative to mRNA 
levels of the reference gene snRNP U1A. 
Table 1.  Summary of the results obtained in the different HFK donors.
construct combination
Population- 
doublings   sa-beta-gal
p53     
expression
prb 
expression htert  mrna
donor 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
- - 37 41 53 + + + + + + ± - ± - - -
LZRS LZRS 82 n.d. n.d. + n.d. n.d. + n.d. n.d. + n.d. n.d. - n.d. n.d.
TTFC-E6SH LZRS 43 n.d. n.d. + n.d. n.d. + n.d. n.d. + n.d. n.d. - n.d. n.d.
TTFC-E7SH LZRS 46 n.d. n.d. + n.d. n.d. + n.d. n.d. + n.d. n.d. - n.d. n.d.
TTFC-E6SH TTFC-E7SH 20 51 73 + + + + + + + + ± - - -
E6WT TTFC-E7SH 81 85 98 + + + - - - + ± ± + + +
E7WT TTFC-E6SH >177 111 104 + + + ++ ++ ++ ± - - ++ - -
E6WT E7WT >323 >191 >160 - - - ± ± ± ± - ± + + +




candidate vaccines have lost their transforming and immortalizing potential, respectively. As 
outlined below we believe that the results we obtained in these assay systems justify clinical 
evaluation of these candidate vaccines.
Both NIH 3T3 cells and HFKs have been extensively used to study the transforming potential 
of HPV types (27). The ability of hrHPV types to induce carcinogenesis in humans is reflected 
by their ability to either transform NIH 3T3 (39) cells or immortalize HFKs (40), whereas HPV 
types that do not induce carcinogenesis in humans do not induce transformation in either cell 
type (27, 41). Subtle differences exist between the effects of E6 and E7 in NIH 3T3 cells and 
HFKs. For example, NIH 3T3 cells can be transformed by expression of either E6 or E7 alone, 
albeit E7 is more efficient (42, 43). Immortalization of HFKs, however is generally considered to 
require the expression of both E6 and E7 (34, 44, 45). Also E6 or E7 transformed NIH 3T3 cells 
are tumorigenic in nude mice (39), whereas E6 and E7 immortalized HFKs are not tumorigenic 
(46). These differences are likely to be explained by the general finding that established rodent 
cell lines are more easily transformed than primary human cells (47). We therefore argue that 
by examination of transforming potential in both assay systems we increased the likelihood 
of detecting residual transforming activity of the candidate vaccines. Moreover, the value of 
these in vitro systems over in vivo toxicity studies in vaccinated animals is that in vitro the cells 
are selected to express the vaccine candidates, thereby mimicking the worst-case scenario 
of stable expression. In case of our assays on HFKs we used integrating retroviral vectors and 
cultured the cells under selection in order to prevent loss of expression, thereby maximizing 
the chance of immortalization. In this respect it should also be noted that the event of stable 
integration upon DNA vaccination is estimated to be three orders of magnitude below the 
spontaneous mutation frequency (15) and therefore is negligibly low. 
As mentioned above the combination of E6 and E7 is considered most effective in inducing 
cellular transformation, therefore we are planning to apply the E6SH and E7SH encoding 
vaccines on separate locations on the body in order to further minimize the risk for cellular 
transformation. In this respect the conditions where cells were transfected or transduced 
with TTFC-E6SH or TTFC-E7SH alone are the most relevant for our risk assessment. In none 
of these conditions we observed any signs of cellular transformation neither in NIH 3T3 cells 
nor in HFKs. The small increase in PDs that is observed in the case of TTFC-E6SH or TTFC-E7SH 
transduced HFKs compared to the untransduced control, is not more pronounced than the 
increase observed for the LZRS/LZRS combination (Figure 2  and Table 1) and is most likely due 
to the nature of the viral construct used and/or the effect of retroviral integration per se. In 
HFKs we also combined TTFC-E6SH and TTFC-E7SH arguing that if any residual transforming 
activity would still be present this would be more readily detected when the two constructs 
are introduced together. Also for this combination no signs of transformation could be 
detected and the number of PDs was in the same range as the untransduced controls. Finally, 
to increase the sensitivity of our assays even more we chose to also include combinations of 
one of the shuffled genes with its wild-type counterpart. In NIH 3T3 cells these wild-type/
shuffled combinations did not show any increase in the percentage of transformed cells 
compared to usage of the wild-type sequence alone. In HFKs the combination of a wild-type 
and a shuffled gene resulted in an increase in the number of PDs in all cases compared to non-
transduced cells. In some combinations also increased expression of hTERT could be observed 
(Figure 5 and Table 1), which can most likely be attributed to  the wild-type gene introduced. 
Of note, immortalization of HFKs by E7 alone has been observed before when expressed from 
a retroviral vector (48). Importantly the Western-blot data show that in case of the wild-type/
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shuffled combinations only the targets of the wild-type sequence are degraded, and the targets 
of the shuffled sequences are in all cases still present (Figure 4 and Table 1), thus suggesting 
that any sign of cellular immortalization for the wild-type/shuffled combinations is caused by 
the wild-type protein only. Nonetheless, we cannot completely rule out the remote possibility 
that the shuffled genes do still possess some residual transforming potential when combined 
with its wild-type counterpart. However, since we will DNA vaccinate normal skin and not the 
anogenital region or oropharynx, we consider the chance of the presence of hrHPV E6 or E7 
genes negligible. Hence, we do consider it justified to proceed to clinical evaluation based on 
these results. 
For several reasons we consider the assays in HFKs paramount in the preclinical safety 
evaluation of our candidate vaccines. An obvious reason is that human genital keratinocytes are 
the natural host cells of HPV16 infections in humans and HFKs more closely reflect the target 
cells of our vaccination procedure (skin keratinocytes) than NIH 3T3 cells. Furthermore, the 
HFK assays used allowed us to study the individual steps leading to immortalization separately, 
whereas the colony formation assay in NIH 3T3 cells only provides a simple yes or no answer. It 
is well established that the steps that lead to immortalization of HFKs closely reflect the steps 
that lead to HPV induced carcinogenesis in humans (4). Finally, because HFKs from different 
donors were used, different genetic backgrounds of the target cells are taken into account, 
whereas the NIH 3T3 cells comprise a single non-human genetic background. We therefore 
consider the colony formation assay in NIH 3T3 cells suitable for a ‘quick scan’ on transforming 
potential of modified E6 and E7 but not sufficient for a preclinical safety evaluation. Our study 
demonstrates that it is feasible to use HFKs for this purpose. This may be relevant for the safety 
evaluation of other vaccine candidates targeting E6 and/or E7 as many vaccination methods 
target the skin.
In conclusion, we show that our candidate DNA vaccines, TTFC-E6SH and TTFC-E7SH do 
no longer posses the transforming activity that is associated with HPV16 E6WT and E7WT. As 
a consequence the risk of inducing a squamous cell carcinoma (or precursor thereof) at the 
vaccination site is negligible. Therefore we consider our candidate DNA vaccines safe for use 
in a phase 1/2a clinical trial in patients suffering from recurrent HPV16 associated malignancies. 
At the same time we demonstrate that it is feasible to use primary human keratinocytes to 
evaluate the safety of HPV16 E6 and E7 directed vaccine candidates, thereby setting a new 
standard for future safety studies in this field. 
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Supplementary figure 1. Schematic representation of the gene shuffling procedure and the 
construction of the TTFC-fusion vaccines. A) HPV16 E6 WT was taken apart at the amino acids 
positions indicated in the figure, thereby dissecting the C-X-X-C- motifs crucial for interaction 
with p53 (Crook et al., Cell 1991). The resulting domains were reassembled in the indicated order, 
resulting in the E6SH core sequence. To avoid loss of putative T cell epitopes at the junctions an 
appendix was added encoding sequences encoding the 14-18 amino acids surrounding the original 
junctions. In order to generate TTFC-E6SH, the E6SH sequence was fused towards the C terminus 
of tetanus toxin fragment C domain 1 (TTFC). B) The HPV16 E7 WT gene was dissected at the amino 
acid positions indicated in the figure corresponding to the pRb binding site (nt 72/37) and between 
the two C-X-X-C motifs (nt177/178 and nt 276/277). Similar to E6SH the 9 amino acids surrounding the 
original junctions were added as an appendix. TTFC-E7SH was generated by fusion of E7SH to the C 
terminus of TTFC. To minimize the potential risk of “back-to-wilde-type recombination” the codons 
of the core elements were optimized for expression in humans, but not the codons of the appendix. 
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 Henken et al, Supplementary figure 2
Gene Sequence 5'-3'
E6WT AAT GTT TCA GGA CCC ACA GGA
TCA CTC ATA TCT GTA ATA ACA
E7WT GAT TTG CAA CCA GAG ACA ACT
CCT TAA CAC ACG GGG TAG ACA
TTFC-E6SH ATG GCC GTG ATG ACG ATG TCG
TTC CAG GAC CCC CAG GAG CGG
TTFC-E7SH CTG GAC CTG CAG CCC GAG ACC
CTC GGG CTG GCC CGG GTG ATG
Supplementary figure 2. Verification of correct transgene expression in NIH 3T3 cells. A) 
Transgene expression upon transfection was verified using different primer combinations resulting 










































































































































































































































































 Henken et al, Supplementary figure 3
Gene Sequence 5'-3'   bp Ann T 
E6WT AGGTGTACGACTTCGCCTTC 109 59 
  CGGTACTCGCTGATCTTGCT   60 
E7WT CTACGAGCAGCTGAACGACA 111 60 
  CACTTGCAGCAAAAGGTCAC   59 
TTFC-E6SH GCCTAGAAAACTGCCACAGC 112 60 
  GTGCCTCTGCTTTTCCTCAG   60 
TTFC-E7SH TGCCAACCAGAGACAACTGA 111 60 
  GCACAACCGAAGCGTAGAGT   60 
 
Supplementary Figure 3. Verification of correct transgene expression in HFKs. A) Representative 
RT-PCR results for donor 1, using different primer combination to verify transgene expression. In all 
cases the combinations of constructs were correctly introduced and mRNA could be detected. A 
cross reaction was however observed between E7wt and E7sh, for which a qRT-PCR was added. B) 
qRT-PCR results, used to  discriminate between E7wt and E7sh, confirmed E7wt expression in E7wt 
cells only. C) Sequences of the used primers.
80
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suPPlementary materials and methods
RT-PCR on NIH 3T3 cells
Upon transfection with the indicated constructs RNA was isolated according using the 
Nucleospin® Total RNA Isolation Kit. For every transgene a 200bp fragment was amplified 
with gene-specific primers (see supplementary figure 2B for the primer sequences) using the 
QIAGEN® OneStep RT-PCR Kit. RT-PCR was performed in a total volume of 50µl, containing 10 
µl 5x PCR buffer, 2 µl dNTPs and 2 µl of enzyme mix and 10 µl of Q-solution. The concentration 
of the primers varied from 0.5-1.2 µM, and the amount of template varied from 0.5 µg-2 µg. PCR 
conditions were 30 minutes at 50°C, 15 minutes at 95°C, followed by  30 cycles of 1 minute at 
94°C , 1 minute at 60°C and 1,5 minute at 72°C and finally 10 minutes and 72°C. PCR products were 
separated on agarose gel.
RT-PCR on HFKs
Reverse transcriptase PCR was performed as described previously (van den Brule et al., Am J 
Pathol 1991) using primers and annealing temperatures as listed in Supplementary Table 1. PCR 
products were separated on agarose gel. Quantitative RT-PCR for HPV16 E7WT was used to 




RATIONAL DESIGN OF DNA VACCINES 
FOR THE INDUCTION OF HPV16 E6 





Many DNA vaccine candidates have been developed for the treatment of HPV16 induced 
malignancies. Most of these vaccines consist of a fusion of E7 with a “carrier-protein” that 
functions to increase the potency of the vaccine. The nature of these carrier-proteins 
varies widely, and the mechanisms proposed to explain the enhanced immunogenicity of 
such fusions are often linked to the biological function of the carrier-protein. However, 
the potentiating effect of these carrier-proteins might also be explained by more general 
mechanisms such as the provision of CD4+ T cell help, increased antigen stability or 
altered subcellular localization of the antigen. To assess whether these more generic 
mechanisms could suffice to generate highly immunogenic DNA vaccines, we evaluated 
a series of modular HPV E7 DNA vaccines in which the presence of CD4+ T cell help, 
the presence of an endogenous carrier protein and the subcellular localization of the 
antigen could be systematically altered. Using this approach we demonstrate that the 
addition of an element that provides CD4+ T cell help and an element that enforces ER 
localization/retention are both necessary and sufficient to create markedly effective E7 
directed DNA vaccines. Importantly, the resulting design rules also apply to an HPV16 
E6 directed DNA vaccine. The thus developed “HELPER HPV DNA vaccines” encode 
only very limited additional sequences besides the antigen, thereby reducing the risk of 
antigenic competition and/or autoimmunity.
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introduction
The E6 and E7 proteins of high risk HPV strains are ideal tumor associated antigens. First, the 
expression of these proteins is essential for cellular transformation (1), and as a consequence 
every HPV-induced (pre)malignancy expresses these proteins (2). Second, as E6 and E7 are 
foreign proteins, a high avidity T cell repertoire specific for these antigens is likely to be present 
and the activity of these cells should not affect healthy tissue (3). Importantly, the presence of 
E6 and E7 specific T cell responses is correlated with the clearance of HPV induced lesions (4, 
5), and the boosting of this immune reactivity in women with premalignant vulvar lesions by 
peptide vaccination is associated with regression of those lesions (6). 
As HPV type 16 is one of the most common subtypes associated with HPV induced 
malignancies, a substantial interest has grown in the development of therapeutic vaccination 
strategies that aim to enhance HPV16 E6 and E7 specific T cell responses (7, 8). Among these 
strategies DNA vaccination is attractive because of its relative simplicity, excellent safety record, 
and its ability to elicit strong cellular immunity (9, 10). The number of DNA vaccine candidates 
that have been developed for the induction of HPV16 E7 or E6-specific T cell responses is large 
(11). Most of these vaccine candidates consist of a genetic fusion of the E6 or E7 antigen and a 
so-called “carrier protein”. The nature of the carrier proteins used for this purpose varies widely 
and examples include heat shock proteins (HSPs) (12, 13), calreticulin (CRT) (14), E. coli Beta 
glucoronidase (GUS) (15), interferon gamma inducible protein 10 (IP10) (16), Herpes simplex 
viral protein 22 (HSV VP22) (17), and Tetanus toxin fragment C (TTFC) (18) (see also table 1). In 
most cases, the enhanced immunogenicity of these fusion proteins has been postulated to 
be directly related to the specific biological function of the carrier protein. To provide some 
examples: ER chaperones such as calreticulin have been suggested to deliver the antigen 
directly into the antigen presentation pathway thereby increasing the efficiency of antigen 
presentation (14, 19); linkage to HSPs or Flt3 ligand is thought to result in an enhanced uptake 
of the antigen by antigen presenting cells (12, 20); Fusion with HSV VP22 is believed to result in 
enhanced immunogenicity as a consequence of transfer of the coupled antigen to neighboring 
cells, thereby increasing antigen cross presentation (17); Fusion with IP-10 is thought to lead 
to enhanced immunogenicity by promoting the recruitment T cells to the vaccination site 
through its chemo-attractive function (16). 
Noting that such a diverse group of carriers can apparently enhance HPV vaccine 
immunogenicity we considered the possibility that vaccine immunogenicity might primarily 
be determined by more general properties of the vaccine-encoded protein. For instance, 
in those cases in which the carrier is a foreign molecule (e.g. mycobacterial HSP-70, TTFC, 
HSV VP22 and Pseudomonas Aaeruginose exototoxin A), provision of CD4+ T cell help may 
at least partly explain the carrier effect (12, 21-23). Secondly, both HPV16 E6 and E7 proteins 
are known to have a short half life (24, 25) and for several of the carrier proteins that have 
been utilized, fusion has been shown to result in increased steady state levels of the antigen 
(15, 17, 18). As it has previously been demonstrated that the extent of in vivo accumulation of 
DNA vaccine-encoded antigens correlates with the magnitude of the CD8+ T cell response 
(26), such carrier-induced protein stabilization could contribute to vaccine immunogenicity. 
Finally, many of the fusions that have been utilized result in an altered subcellular localization 
of the antigen (14, 16, 20, 27, 28), and antigen localization – rather than the biological function 
of the carrier used – could conceivably alter immunogenicity. In line with this possibility, in 
some reports addition of only protein domains, or even signal sequences was shown to already 




relative importance of these generic mechanisms, we have developed a modular DNA vaccine 
and utilized this to assess which elements are crucial for HPV E7 and also HPV E6 DNA vaccine 
immunogenicity. 
Table 1. Selected examples of carrier proteins known to improve the immunogenicity of HPV16 E7 
or E6 encoding DNA vaccines.
carrier protein antigen Proposed mode of action reference
Mycobacterium tuberculosis HSP-70 E7
Provision of CD4+ T cell help, 
increased antigen uptake by DC
(12)
Heat shock protein 60 E6, E7 Increased antigen uptake by DC (13)
Calreticulin E6, E7
Targeting of antigen into the 
antigen presentation pathway
(14, 27)
Extracellular domain of Flt3-ligand E7
Altered subcellular localization/ 
increased antigen uptake by DC
(20)
HSV VP22 E7
Antigen spreading, improved 
antigen stability
(17)
E. coli β-glucoronidase E7 Enhanced stability/ altered 
subcellular localisation
(15)
Pseudomonas aeruginosa exotoxin A 
(domain II)
E7 Enhanced cross presentation (50)
Invariant chain with PADRE epitope 
insertion
E6 Provision of CD4+ T cell help (45)
IP-10 E7









C57BL/6 mice (6-10 weeks) were obtained from Jax® Mice (The Jackson Laboratory). All 
experiments were approved by the Experimental Animal Committee of The Netherlands Cancer 
Institute and in accordance with institutional and national guidelines. 
DNA vaccines
DNA vaccines based on HPV16 E6 and E7 genes were generated by the introduction of target 
genes or gene fragments into pVAX 1 (Invitrogen). The generation of E7SH, TTFC-E7SH, E6SH 
and TTFC-E6SH has been described previously (18). FM4 consists of 4 moieties of a mutated 
human FK506 binding protein (97% homology to the mouse protein) with the signal peptide of 
hGH fused to the N-terminus (33). FM4-HELP-E7SH (see Fig. 1A for a schematic representation) 
was ordered from GeneArt with codon-optimization for expression in human cells and was 
cloned between the HindIII and XbaI sites of pVAX. FM4-E7SH and HELP-E7SH were generated 
by removal of either the BamHI flanked helper cassette or the SpeI flanked FM4 moiety. Histone 
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2B, endoplasmic reticulum protein 29, keratin 14 and cluster of differentiation antigen 8a (all 
mouse origin), were ordered from GeneArt with codon optimization for expression in human 
cells and flanked by SpeI sites. FM4(minus sig)-HELP-E7SH was generated by PCR using FM4-
HELP-E7SH as a template. sig-HELP-E7SH-KDEL was constructed by replacing the complete 
FM4 sequence with only the signal peptide. The KDEL sequence was fused to E7SH and E6SH 
by PCR. The different E6SH encoding DNA vaccines were constructed by replacing E7SH with 
E6SH or E7SH-KDEL by E6SH-KDEL. Identity of all fusion genes was confirmed by sequence 
analysis. Plasmids were expressed in E. coli DH5a and were purified using an endotoxin free 
DNA purification kit (Qiagen). DNA vaccines for intradermal tattoo application were dissolved 
at a concentration of 2mg/ml in water for injections (Aqua B. Braun). 
Transfection and immunoblotting 
HEK 293 T cells were transfected with 10 µg of a mixture of a GFP encoding plasmid and 
the indicated constructs at a ratio of 3:7 by use of FuGENE 6 (Roche), according to the 
manufacturer’s instructions. Cells were harvested 24 hours after transfection and equal 
transfection efficiency was confirmed by analyzing the percentage of GFP positive cells by flow 
cytometry. Subsequently, the remainder of the samples was lysed on ice in RIPA buffer (Sigma-
Aldrich) supplemented with protease inhibitor cocktail (Roche) and 0.1mM PMSF (Thermo 
Fisher Scientific). Cell lysates were subsequently cleared by centrifugation at 4 oC. Total 
cellular protein was determined using a Bradford assay (Bio-Rad Corporation) and proteins 
were separated at 30ug per lane on 4–12% NuPage Bis-Tris gradient gels (Invitrogen) in MES 
buffer, according to the manufacturer’s instructions. Following immunoblotting, E7 expression 
was detected using a monoclonal mouse anti-HPV16 E7 antibody (Invitrogen, clone 8C9, 
1:100 dilution) and actin expression was detected using a mouse anti-human actin antibody 
(Millipore, clone C4, 1:10000 dilution). In both cases HRP-rabbit anti-mouse antibody (DAKO, 
P 0161) was used as secondary antibody at a 1:7500 dilution and detection was performed by 
enhanced chemiluminescence (Pierce Biotechnology).
Tattoo vaccination
Intradermal DNA tattoo vaccination was performed on day 0, 3 and 6, as described previously 
(18). In brief, on day -1 the hair on the hind leg was removed using depilating cream (Veet®, 
Reckitt Benckiser). On day 0, mice were anesthetized and 10 µl of a 2 mg/ml DNA solution in 
water was applied to the hairless skin of the hind leg. The DNA vaccine was then applied with 
a Permanent Make Up (PMU) tattoo machine (kindly provided by MT Derm), using a sterile 
disposable 9-needle bar with a needle depth of 1 mm and oscillating at a frequency of 100 Hz 
for 30 seconds. Unless indicated otherwise, vaccination was repeated on day 3 and 6. In cases in 
which mice received a single tattoo vaccination, 15µl of the DNA solution was used.
Detection of HPV-specific CD8+ T cells
Peripheral blood cells were obtained by tail bleeding, and erythrocytes were removed by 




, 0.1mM EDTA (pH 7.4)) on ice. 
Cells were subsequently stained in FACS buffer (1× PBS, 0.5% BSA and 0.02% sodium azide) with 
allophycocyanin (APC)-conjugated anti-CD8a mAb (BD Pharmingen) plus phycoerythrin (PE)-
conjugated H-2Db E7
49–57
 or H-2Kb E6
48-57
 tetramers for 15 min at 20 °C. Subsequently, cells were 
washed two times in FACS buffer before analysis. Live cells were selected based on PI exclusion. 




Detection of P30 and PADRE specific CD4+ T cells
Intracellular IFN-g staining was performed using the BD Cytofix/Cytoperm kit (BD Biosciences) 
according to the manufacturer’s protocol. Peripheral blood cells were stimulated for 16 h with 
either the PADRE (AKFVAAWTLKAAA) or P30 (FNNFTVSFWLRVPKVSASHLE) peptide at a 1µg/
ml concentration. Cells were subsequently stained using PE-conjugated anti-INF-g mAb (BD 
Pharmingen), and APC-conjugated anti-CD8a mAb (BD Pharmingen). All samples were analysed 
on a FACScalibur (BD Biosciences), using Flow-Jo® software for data analysis.  
TC-1 tumor challenge 
C57BL/6 mice were injected subcutaneously with 105 TC-1 tumor cells that express both HPV16 
E6 and E7 (32). DNA tattoo vaccination was subsequently performed on either day 4, or on 
day 4, 7 and 10 after tumor challenge, as indicated. Tumor growth was monitored by caliper 
measurements in two dimensions, tumor volume was calculated as (width2 x length)/2. Mice 
were sacrificed when tumor length reached 15 mm or when the tumor volume exceeded 
1000 mm3. 
Statistical analysis
Statistical analysis was performed using the student’s t-test. A p-value <0.05 was considered to 
be significant (two-tailed). For evaluation of survival data a log-rank test was used. 
results
Design of a modular DNA vaccine 
In order to be able to separate the contribution of factors such as antigen localization, 
antigen stabilization and the presence of T-helper cell epitopes on vaccine immunogenicity, 
we designed a modular HPV E7 directed DNA vaccine that contains an endogenous ‘carrier 
protein’ and a separate minimal domain for the provision of CD4+ T cell help (see Fig. 1A). 
The use of this design minimizes the risk of antigenic competition at the level of CD8+ T cell 
response induction as only minimal foreign sequences are incorporated besides the antigen. 
As a first carrier protein we selected an engineered human protein called FM4. This protein 
contains four repeats of a point mutated version of the FK506 binding protein, FKBP12, and is 
targeted to the endoplasmic reticulum (ER) by the inclusion of a signal peptide. As a result of 
these modifications, FM4 forms stable aggregates inside the ER (33). To generate a minimal 
domain that would provide CD4+ T cell epitopes that can be presented by a large series of MHC 
class II alleles we created a ‘helper-cassette’ (Fig. 1B), consisting of the TTFC P30 pan DP epitope 
(34), the PADRE pan DR epitope (35) and the HIV NEF pan DQ epitope (36). Both P30 and PADRE 
are also recognized in the context of mouse MHC class II allowing evaluation of this strategy in 
mice (35, 37). In order to avoid the potential formation of CD8+ T cell epitopes at the junctions 
of these three sequences, all epitopes were linked by GPGPGPG spacers (38). To obtain insight 
in the value of the individual components used, we also generated HPV E7 encoding vaccines 
that only contained the FM4 carrier protein or only the helper-cassette (Fig. 1C). In all cases, 
a gene shuffled version of E7 (E7SH) was used as antigen, in order to avoid the risk of cellular 
transformation at the vaccination site (18, 39). All fusion constructs displayed the expected 
molecular weight when expressed in HEK 293 cells. Furthermore, the expression level of all E7 
fusion vaccines was strongly increased compared to that of a non-fused E7SH vaccine (Fig. 1D).
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The combined inclusion of a carrier protein and helper-cassette results 
in superior vaccine immunogenicity. 
In order to reveal possible differences in immunogenicity between the above-described 
vaccines, C57BL6/J mice (n=5 per group) were immunized by short interval DNA tattooing 
(40) and E7 specific CD8+ T cell responses in peripheral blood samples were analyzed over 
time. As shown in Fig. 2A-B,  a clear pattern in vaccine immunogenicity is noted. First, HPV16 
E7 specific CD8+ T cell responses are not above background in mice that received a vaccine 
that solely encodes E7SH, but clear CD8+ T cell responses are detected in groups that were 
treated with the fusion vaccines, thereby underlying the value of such genetic fusions. Second, 
when comparing the magnitude of the CD8+ T cell responses induced by the different fusion 
vaccines at the peak of the primary response (Fig. 2C) it is apparent that both the addition 
of the FM4 carrier (FM4-E7SH) and in particular the helper cassette (HELP-E7SH) results in a 
substantial improvement in immunogenicity of E7SH, but that the combination of the carrier 
and the helper-cassette (FM4-HELP-E7SH) is clearly superior (mean peak response of 19.05 ± 
5.02% E7
49-57
 specific CD8+ T cells directly ex vivo, p< 0.05 relative to HELP-E7SH the second 
best vaccine) FM4-HELP-E7SH also significantly (p< 0.05) outperformed a vaccine encoding 













































































Figure 1. Design and validation of a modular DNA vaccine construct. A) Schematic representation 
of vaccine design. The carrier and the helper cassette are both placed between identical restriction 
sites to allow their removal. The antigen is placed between two different restriction sites to enable 
replacement. B) Design of the “helper-cassette”. GPGPGPG spacers (see text) are included to avoid 
formation of CD8+ T cell epitopes at the junctions. C) Schematic representation of the constructs 
used for proof of principle experiments and their expected molecular weight. D) Western blot 
analysis of HEK 293 cells transfected with the constructs shown in C. In all cases a dominant band of 




















































































*   P < 0.05
**  P < 0.01
*** P < 0.001























































































































Figure 2. Synergistic effect of an endogenous carrier protein and a helper-cassette on vaccine 
immunogenicity. C57BL/6 mice (n=5 per group) were immunized by DNA tattoo vaccination on day 
0, 3 and 6 with 20 µg the indicated vaccines, and peripheral blood was analyzed for antigen-specific 
CD8+ T cells by MHC tetramer staining. A) Representative dot plots of H-2Db E7
49-57 
MHC tetramer 
stainings at the peak of the response. The number depicts the % of E7 specific CD8+ T cells. B) Plot 
depicting the mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells for the indicated groups 
over time. C) Bar graph depicting the mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells 
for the indicated groups at the peak of the response. D) Bar graph depicting the area under the 
curve (AUC) +/- S.D. for recipients of the indicated vaccines as a measure that describes both T 
cell response magnitude and persistence. E) Bar graph showing the mean percentage +/- S.D. of 
interferon-g positive CD4+ T cells in peripheral blood samples (day 11 post-vaccination), following 16 
h stimulation with the indicated peptides.
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our lab (18). Differences in T cell response magnitude were not only observed at the peak of 
the primary CD8+ T cell response but remained visible over time and were maintained after a 
secondary challenge, as shown in Fig. 2D by area under the curve (AUC) values for each group. 
In order to evaluate whether the inclusion of the helper cassette resulted in the expected 
CD4+ T cell responses towards the encoded epitopes, CD4+ T cell reactivity against P30 and 
PADRE epitopes was evaluated by intracellular IFN-g staining. In mice that received DNA 
vaccines encoding the helper-cassette, P30 and PADRE specific CD4+ T cell responses could 
readily be demonstrated. In mice vaccinated with TTFC-E7SH, which contains the P30 but not 
the PADRE epitope, P30 specific CD4+ T cell responses could also be observed (Fig. 2E). 
Only ER-localized carriers enhance vaccine immunogenicity 
Having demonstrated that the combination of a carrier molecule and the helper-cassette 
results in superior immunogenicity we wished to explore which aspects of the carrier molecule 
determined its effect on vaccine potency. To this purpose we selected 4 endogenous proteins - 
histone 2B (H2B, nuclear localization), endoplasmic reticulum protein 29 (ERP-29, ER localized), 
keratin 14 (KRT 14, cytosolic localization), cluster of differentiation antigen 8a (CD8a, plasma 
membrane localized) - for which there are no prior data that would suggest a specific role in 
antigen presentation. As shown in Fig. 3B, transfection of HEK 293 T cells with the different 
constructs leads to expression of proteins with the expected size (see Fig. 3A). Furthermore, 
while expression levels vary widely, in all cases the expression level of the fusion vaccine is 
strongly enhanced relative to that of unmodified E7SH. 
In order to study possible differences in vaccine immunogenicity, mice were vaccinated 
and immune responses were monitored as described above. Of the 5 fusion vaccines tested, 
both FM4-HELP-E7SH and ERP29-HELP-E7SH were significantly (p<0.05) more immunogenic 
than HELP-E7SH, whereas the immunogenicity of H2B-HELP-E7SH and CD8a-HELP-E7SH was 
comparable to that of HELP-E7SH. Finally, KRT14-HELP-E7SH was significantly (p<0.01 based on 
AUC) less immunogenic than HELP-E7SH. These differences in vaccine immunogenicity did not 
directly correlate with differences in expression levels as displayed in Fig. 3B. For example, the 
expression level of CD8a-HELP-E7SH was extremely high but immunogenicity was mediocre. 
Vice versa, the expression level of FM4-HELP-E7SH was intermediate, but immunogenicity was 
high. Thus, when a series of different endogenous carriers is utilized (for which the the presence 
of CD4 T cell epitopes is therefore not a confounding factor), the enhancement of vaccine 
immunogenicity can only partially be ascribed to increased accumulation of the antigen. An 
interesting observation in this regard is that the two carrier proteins that results in a significant 
enhancement of E7 vaccine immunogenicity are both ER localized.
The carrier effect can be fully explained by ER targeting of the antigen
In order to determine whether the observed correlation between ER localization of the carrier 
and vaccine immunogenicity was due to chance or reflected a true effect of ER localization, 
we generated vaccine variants of FM4-HELP-E7SH in which either the signal peptide of FM4 
was removed (FM4(minus-sig)-HELP-E7SH), or in which only the signal peptide of the FM4 
moiety was retained. In the latter case (sig-HELP-E7SH-KDEL), a C-terminal KDEL sequence 
was included to achieve ER retention. As a control, a variant that encoded the antigen with 
the signal peptide and ER retention signal but that lacked the helper-cassette (sig-E7SH-KDEL) 




Figure 3. Only ER localized self-carriers provide an advantage over the addition of the helper-
cassette alone. A) Schematic representation and molecular weights of DNA vaccines with different 
carrier proteins. B) Western blot analysis of HEK 293 cells transfected with the constructs shown in 
A. In all cases a dominant band of the expected size could be detected, demonstrating the correct 
expression of the DNA vaccine encoded antigens. C) Plot depicting the mean percentage +/- S.D. 
of peripheral blood H-2Db E7
49-57
-specific CD8+ T cells over time in C57BL6/J mice (n=5) DNA tattoo 
vaccinated on day 0, 3 and 6  with 20 µg of the indicated vaccines. D) Bar diagram depicting the mean 
percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells for the indicated groups at the peak of the 
response. E) Bar diagram depicting the total area under the curve (AUC) +/- S.D. for each vaccine as 
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of protein products of the expected size was demonstrated by western blotting (Fig. 4B) as 
described above. 
As shown in Fig. 4 C-E, removal of the signal peptide from FM4 resulted in a strong decrease 
in immunogenicity of FM4-HELP-E7SH. Furthermore, the same detrimental effect of signal 
peptide removal was observed for ERP29, the second ER localized carrier protein (data not 
shown). In stark contrast, the sole inclusion of an ER localization signal (i.e. signal peptide and 
KDEL) sufficed to significantly enhance the immunogenicity of HELP-E7SH (p<0.05). Together 
these results demonstrate that retention in the ER suffices to explain the potentiating effect of 
endogenous carriers on E7 vaccine-specific T cell responses. Consistent with the notion that 
such a ‘minimal carrier’ does not provide CD4+ T cell epitopes, inclusion of the helper-cassette 
was required for maximal immunogenicity as illustrated by the very moderate immunogenicity 
of sig-E7SH-KDEL (Fig. 4F-H). 
Application of design rules to HPV E6SH encoding vaccines
The above data indicate that the combination of a helper-cassette and ER targeting/ retention 
signal suffices to create a highly immunogenic E7 DNA vaccine. In order to further validate this 
minimal “HELPER” design for HPV directed vaccines, we generated a set of HPV16 E6SH DNA 
vaccines (Fig. 5A) in which the value of the helper cassette or the combination of this cassette 
with ER localization were compared. Mice were tattoo vaccinated with these vaccines and E6
 
specific CD8+ T cell responses were monitored directly ex-vivo by MHC tetramer staining. 
Similar to what was observed for E7SH encoding vaccines, the addition of the helper cassette 
by itself strongly improved the immunogenicity of E6SH.  In addition, the joint inclusion of the 
minimal ER localization/retention signal led to a further increase in immunogenicity, although 
the latter difference was not statistically significant (Fig. 5C-E). Importantly, the CD8+ T cell 
responses induced by sig-HELP-E6SH-KDEL significantly outperformed those elicited by a 
previously developed TTFC-E6SH fusion vaccine (18) (p<0.01 based on AUC). Superiority of the 
“HELPER” DNA vaccine design was also apparent when immunogenicity was assessed in HLA-A2 
transgenic mice (41), demonstrating that these design rules also apply in the context of human 
MHC class I  (Suppl. Fig. 1). 
“HELPER” vaccine formats allow for dose reduction and show superior 
anti-tumor effects 
As the CD8+ T cell responses observed after vaccination with sig-HELP-E7SH-KDEL were highly 
potent, we evaluated whether substantial CD8+ T cell responses could still be induced in case 
either the number of vaccinations or the vaccine dose was reduced. As shown in Fig. 6A, 
vaccination with a single dose of the control vaccines HELP-E7SH and TTFC-E7SH led to the 
induction of only very modest CD8+ T cell responses.  In contrast vaccination with a single dose 
of the sig-HELP-E7SH-KDEL vaccine still induced CD8+ T cell responses of around 15% ex vivo 
(Fig. 6A, compare with Fig. 4F,G). Likewise, marked (>20% ex vivo) CD8+ T cell responses were 
still induced by sig-HELP-E7SH-KDEL when mice were vaccinated with a 5-fold reduced DNA 
dose (0.4 mg/ml instead of 2mg/ml) (Fig. 6B). The latter finding is of particular relevance for 
clinical translation as the inability to scale DNA doses used in mice to humans is considered one 
of the main explanations for the lower efficacy of DNA vaccination in humans as compared to 
small animals (42).
In order to evaluate whether the enhanced immunogenicity of the HELPER E6 and E7 
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Figure 4. The ‘carrier effect’ can be solely explained by ER targeting of the antigen. A) 
Schematic representation and molecular weights of constructs used to determine if the carrier 
effect can be explained by ER targeting of the antigen. B) Western blot analysis of HEK 293 cells 
transfected with the constructs shown in A. In all cases a dominant band of the expected size could 
be detected, demonstrating the correct expression of the DNA vaccine encoded antigens. C-E. 
Data demonstrating that the removal of the signal peptide renders the carrier useless. C) Curve 
depicting the mean percentage +/- S.D. of peripheral blood H-2Db E7
49-57
-specific CD8+ T cells over 
time in C57BL6/J mice (n=5) DNA tattoo vaccinated on day 0, 3 and 6 with 20 µg of the indicated 
vaccines. D) Bar diagram depicting the mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T 
cells for the indicated groups at the peak of the primary response. E) Bar diagram depicting the total 
area under the curve (AUC) +/- S.D. for each vaccine as measure for the total vaccine potency. F-H) 
Data demonstrating that the addition of only ER localization and retention signals is sufficient to 
increase the immunogenicity of HELP-E7SH. F) Time curve depicting the mean percentage +/- S.D. 
of peripheral blood H-2Db E7
49-57
-specific CD8+ T cells over time in C57BL6/J mice (n=5) DNA tattoo 
vaccinated on day 0, 3 and 6  with 20 µg of the indicated vaccines. G) Bar diagram depicting the mean 
percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells for the indicated groups at the peak of the 
response. H) Bar diagram depicting the total area under the curve (AUC) +/- S.D. for each vaccine as 
measure for the total vaccine potency.
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Figure 5. The combined addition of the helper-cassette and ,ER entry/retention signal also 
improves the immunogenicity of E6SH. A) Schematic representation and molecular weights of 
E6SH encoding DNA vaccines utilized. B) Representative dot plots at the peak of the response for 
the indicated vaccines. The number depicts the % of E6 specific CD8+ T cells. C) Curve depicting 
the mean percentage +/- S.D. of peripheral blood H-2Kb E6
48-57
-specific CD8+ T cells over time in 
C57BL6/J mice (n=5) DNA tattoo vaccinated on day 0, 3 and 6 with 20 µg of the indicated vaccines. 
D) Bar diagram depicting the mean percentage +/- S.D. of H-2Kb E6
48-57
-specific CD8+ T cells for the 
indicated groups at the peak of the response. E) Bar diagram depicting the total area under the 
curve (AUC) +/- S.D. for each vaccine as measure for the total vaccine potency. 
with HPV E6/E7-expressing TC-1 cells and vaccination was started at day 4. Notably, a single 
vaccination with sig-HELP-E7SH-KDEL induced initial regression of tumors in 10 out of 10 
mice, whereas a single vaccination with TTFC-E7SH only induced regression in 2 out of 10 mice 
(Fig. 6C). This difference also translated into a significant effect on survival (P=0.0019) (Fig. 6D). 
A similar pattern was observed in mice vaccinated with the E6SH encoding variants: sig-HELP-
E6SH-KDEL significantly (p=0.0002) outperformed TTFC-E6SH in terms of tumor control and 
survival. These results show that both E6 and E7 HELPER DNA vaccines are superior with respect 





In this study we aimed to rationally design DNA vaccines that induce immune reactivity against 
the HPV16 E6 and E7 oncoproteins. The resulting vaccine designs, sig-HELP-E6SH-KDEL and 
sig-HELP-E7SH-KDEL contain only minimal additional sequences apart from the antigen of 
interest, and induce extremely potent E6 and E7 specific CD8+ T cell responses. Our results 
underscore the importance of the addition of CD4+ T cell help in DNA vaccination and indicate 
that the enhanced immunogenicity that can be observed after addition of a carrier molecule 
can be achieved by the mere ER localization of the fused antigen. 
The importance of CD4+ T cell help for the generation of effective CD8+ T cell responses is 
well established (43). In the field of DNA vaccination, multiple strategies have been developed 
to provide such CD4+ T cell help, and the most commonly used method is to fuse the antigen 
A B
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Figure 6. The novel design allows for dose sparing and shows superior functionality. A) Curve 
depicting the mean percentage +/- S.D. of peripheral blood H-2Db E7
49-57
-specific CD8+ T cells 
over time in C57BL6/J mice (n=5) after a single DNA tattoo vaccination with 30 µg of the indicated 
constructs. B) Curve depicting the mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells 
over time in C57BL6/J mice (n=5) DNA tattoo vaccinated 3 times with the indicated vaccines, but 
using a 5 times lower DNA concentration (0.4 mg/ml) resulting in a dose of 4 µg DNA/tattoo. C-D) 
Tumor regression and prolonged survival after DNA tattoo vaccination with the sig-HELP-E7SH-
KDEL and sig-HELP-E6SH-KDEL vaccine. C57BL/6 mice (n=10 per group) were injected with 1*105 TC-1 
tumor cells on day 0. Subsequently, mice were immunized by a single DNA tattoo vaccination with 
15µg DNA on day 4 (1x) after tumor challenge or with 20 µg DNA on day 4, 7, 10 (3x), as indicated in 
the legend. C) Plot depicting the mean tumor diameter (mm)  +/- S.D. for the indicated groups over 
time. D) Plot depicting the percentage survival for the indicated groups over time.
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of interest to an exogenous (e.g. bacterial) protein (21, 22). An extensively studied example 
of such as carrier protein is domain 1 of Tetanus Toxin fragment C that contains several CD4+ 
helper epitopes that can be presented by multiple MHC class II alleles (18, 21). A potential 
drawback of the use of foreign proteins as carrier molecules is that such proteins are likely 
to contain competing CD8+ T cell epitopes as well. This could result in skewing of the CD8+ 
T cell response towards the carrier molecule by the principle of immunodominance (44). A 
more elegant strategy is therefore to fuse the antigen of interest to one or multiple minimal 
CD4 T cell epitopes. Following this line of thought, prior work has shown the immunogenicity 
of DNA vaccines in which a modified version of the MHC class II invariant chain was used in 
which the CLIP peptide was replaced by CD4+ T cell epitopes such as P30 or PADRE (21, 45), 
although clinical application of this strategy may potentially be limited by the concern that 
vaccination could result in the induction of autoimmune reactivity towards the invariant chain. 
In the current study we show that robust CD4+ T cell help can simply be provided by fusing a 
set of promiscuous CD4+ helper epitopes that can be presented by a variety of common DP, 
DR and DQ alleles (see Fig. 2 and 5) to HPV E6 and E7 antigens. Because of the broad MHC class 
II coverage of those epitopes there may be little advantage in the inclusion of further CD4+ T 
cell epitopes, but if necessary this set can obviously be expanded. Importantly, as only minimal 
foreign sequences are added to the antigen of interest in this approach, the risk of antigenic 
competition should be small. 
The observation that the immunogenicity of DNA vaccines can also be improved by the 
genetic fusion to carrier molecules that are of self origin indicates that mechanisms other than 
the provision of CD4+ T cell help must also play a role. Examples of endogenous carrier proteins 
that have been shown to improve the immunogenicity of HPV16 E6 and or E7 DNA vaccines 
include calreticulin, HSP 60 and IP-10 (13, 14, 16, 27). As discussed within the introduction, the 
enhanced immunogenicity of these self carriers is often attributed to the specific biological 
function of the carrier molecule (see also Table 1). However, noting that vaccine immunogenicity 
can be enhanced by such a variety of approaches, we speculated that more generic mechanisms 
may be involved, and such mechanisms could for instance involve the effect of fusion on antigen 
accumulation or subcellular localization (26). Comparison of the immunogenicity of E7 DNA 
vaccines utilizing 5 different endogenous carrier molecules indicated that immunogenicity was 
strongly enhanced by fusion to 2 different ER localized carrier proteins for which there is no 
prior data suggesting a specific role in antigen presentation. Direct support for the notion that 
antigen localization is the key parameter in these vaccines was provided by the demonstration 
that the mere addition of ER targeting and ER retention signals is sufficient to enhance 
immunogenicity, and this effect applied to E7SH, HELP-E7SH and HELP-E6SH. In this regard 
it is noteworthy that many of the strategies previously shown to improve the immunogenicity 
of E7 and or E6 also do result in ER localization (14, 20, 27, 28). A conceptual advantage of the 
use of a minimal ER localization/ retention system as developed here is the reduced risk of 
antigenic competition in case a foreign sequence is used, and the reduced risk of induction of 
autoimmune reactivity in case an endogenous protein is utilized. 
At present it is unclear why ER localization of E6 and E7 benefits the induction of CD8+ 
T cell responses. It may be speculated that ER localization could increase the half-life of the 
(likely unfolded) vaccine-encoded antigens and thereby increase the size of the protein pool 
available for cross presentation (26). However, the observation that the correlation between 
the extent of antigen accumulation and immunogenicity is at best partial indicates that this 
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Supplementary figure 1. sig-HELP-
E6SH-KDEL strongly outperforms 
TTFC-E6SH in HLA-A2 transgenic 
mice. HLA-A2 transgenic mouse 
class I knock-out (HHD) mice (n=3 
per group) were immunized by DNA 
tattoo vaccination on day 0, 3 and 6, 
and peripheral blood was analyzed for 
antigen-specific CD8+ T cells by MHC 
tetramer staining. A) Representative 
dot plots of A2-Kb E6
29-38
 MHC 
tetramer stainings at the peak of the 
response for the different vaccines B) 
Plot depicting the mean percentage 
+/- S.D. of A2-Kb E6
29-38
-specific CD8+ 
T cells for the indicated groups over 
time. C) Bar diagram depicting the 
mean percentage +/- S.D. of A2-Kb 
E6
29-38
-specific CD8+ T cells for the 
indicated groups at the peak of the 
response. D) Bar diagram depicting 
the total area under the curve (AUC) 
+/- S.D. for each construct as measure 
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Supplementary figure 2. ER localization of the antigen and not the ER-stress provoked is 
causing the increased immunogenicity. A) Schematic representation and estimated molecular 
weights of the DNA vaccines used to test if ER-stress or ER localization is causing the increase in 
immunogenicity. B) Westernblot analysis of HEK 293 cells transfected with the vaccines shown in A. 
The FM4-2A-HELP-E7SH encoding constructs shows a dominant band of the size of HELP-E7SH and 
only a minor band of the size of FM4-HELP-E7SH demonstrating the functionality of the 2A linker. 
C) Curve depicting the mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells over time in 
C57BL/6J mice (n=5) tattoo vaccinated on day 0,3 and 6 with the indicated vaccines D) Bar diagram 
depicting the mean percentage +/- S.D. of H-2Db E7
49-57
-specific CD8+ T cells for the indicated groups 
at the peak of the response. E) Bar diagram depicting the total area under the curve (AUC) +/- S.D. 




SHIELDING THE CATIONIC CHARGE 
OF NANOPARTICLE-FORMULATED 
DERMAL DNA VACCINES IS ESSENTIAL 





Nanoparticle-formulated DNA vaccines hold promise for the design of in vivo vaccination 
platforms that target defined cell types in human skin. A variety of DNA formulations, 
mainly based on cationic liposomes or polymers, has been investigated to improve 
transfection efficiency in in vitro assays.
Here we demonstrate that formulation of DNA into both liposomal and polymeric cationic 
nanoparticles completely blocks vaccination-induced antigen expression in mice and ex 
vivo human skin. Furthermore, this detrimental effect of cationic nanoparticle formulation 
is associated with an essentially complete block in vaccine immunogenicity. The blocking 
of DNA vaccine activity may be explained by immobilization of the nanoparticles in the 
extracellular matrix, caused by electrostatic interactions of the cationic nanoparticles 
with negatively charged extracellular matrix components. Shielding the surface charge 
of the nanoparticles by PEGylation improves in vivo antigen expression more than 55 fold. 
Furthermore, this shielding of cationic surface charge results in antigen-specific T cell 
responses that are similar as those induced by naked DNA for the two lipo- and polyplex 
DNA carrier systems. These observations suggest that charge shielding forms a generally 
applicable strategy for the development of dermally applied vaccine formulations. 
Furthermore, the nanoparticle formulations developed here form an attractive platform 
for the design of targeted nanoparticle formulations that can be utilized for in vivo 
transfection of defined cell types.
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introduction
Non-viral carrier systems are widely used as transfection reagents to deliver nucleic acids 
for both in vitro and in vivo applications. In these systems, negatively charged DNA is bound 
by electrostatic interaction to an excess of a positively charged carrier. In this complexation 
process, DNA is condensated into positively charged, nanosized particles and protected from 
nuclease degradation, resulting in substantially higher transfection efficiencies compared 
to naked nucleic acids in in vitro assays. The two most frequently used carriers to enhance 
transfection efficiency are cationic lipids and cationic polymers, and the resulting DNA 
nanoparticles are referred to as lipoplexes and polyplexes, respectively (1-4). In addition 
to the beneficial effect on in vitro transfection efficiency, formulation of DNA into cationic 
particles has also been shown to result in a higher transfection efficiency than naked DNA upon 
intramuscular injection (5,6).
While DNA vaccines were first described using intramuscular injection as an administration 
route (7), a growing interest has developed into intradermal DNA vaccine delivery. Specifically, 
because of its natural barrier function, the skin is perceived as a site that is well-equipped for 
the induction of adaptive immune responses and the high density of antigen-presenting cells 
in skin provides indirect support for this notion. Dermal DNA vaccines can be applied by various 
methods, including classical intradermal injection, gene gun and DNA tattoo (8). The latter 
strategy delivers naked plasmid DNA into the skin through thousands of punctures using an 
oscillating multiple needle tattoo device. DNA tattooing leads to the induction of strong and 
rapid antigen-specific cellular immune responses in mice (8). Furthermore, the immunogenicity 
of DNA tattoo is approximately 10-100 fold higher than that of classical intramuscular DNA 
vaccination in non-human primates (9). Importantly, in spite of the high immunogenicity of 
DNA tattoo, the in vivo transfection efficiency of naked DNA with this technique is extremely 
low, with approximately 1 out of 5x106 to 5x109 plasmid copies applied being taken up, 
transcribed and translated (10). Based on the strongly positive effect on transfection that is 
generally observed for DNA encapsulation in cationic lipo- and polyplexes in in vitro assays, we 
aimed to determine whether such formulations could also result in improved transfection and 
subsequent immune response for intradermal vaccines applied by DNA tattooing. Development 
of these nanoparticle-formulated DNA vaccines forms an essential first step towards the further 
development of targeted intradermal DNA vaccines. 
materials and methods
Materials
The pVAX:Luc-NP plasmid (8) encodes the influenza A NP
366-374
 epitope as a genetic fusion with 
firefly luciferase gene, inserted in the EcoRI/NotI site of minimal pVAX1 plasmid backbone 
(Invitrogen, Carlsbad, USA). pVAX:GFP was generated by inserting Green Fluorescence 
Protein (GFP) encoding DNA into the BamHI/NotI site of pVAX1. Plasmids were expressed and 
amplified in E. Coli DH5 and were purified by Endofree™ QIAGEN® Mega-kit (QIAGEN®, Hilden, 
Germany). 1,2-dioleoyl-oxypropyl-3-trimethyl-ammonium chloride (DOTAP) was obtained 
from Avanti Polar lipids (Alabster, AL, USA). Dioleoylphosphatidyl-ethanolamide (DOPE) and 
distearoylphosphatidylethanolamine-polyethyleneglycol 2000 (DSPE-PEG) were a kind gift 
from Lipoïd GmbH (Ludwigshafen, Germany). NonPEGylated and PEGylated poly(amido amine) 




the main chain and hydroxybutyl groups in the side chains (CBA-ABOL), were synthesized by 
Michael addition polymerization of N,N’-cystaminebisacrylamide with the appropriate amine 
according to the procedure described previously (11). The PEGylated analog was prepared using 
11 mol% of MeO-PEG-NH
2  
in  the total amino monomer feed during the PAA synthesis. All other 
chemicals were of analytical grade.
Liposome preparation
NonPEGylated liposomes, composed of DOTAP-DOPE, were prepared in a 1:1 molar ratio. For 
PEGylated liposomes, DOPE was replaced by DSPE-PEG at different concentrations to keep the 
total molarity of lipids constant. Lipid mixtures were dissolved in chloroform/methanol (1:1 
v/v) and mixed in a round-bottomed flask. Organic solvents were evaporated at 40 ºC using 
a vacuum evaporator and the obtained lipid films were purged with nitrogen for 30 min. Lipid 
films were rehydrated in 20 mM HEPES, pH 7.4, 10% sucrose, to give a final lipid concentration 
of 35 mM. The resuspended lipids were extruded 8 times through two stacked polycarbonate 
membranes (Poretics, Livermore, USA, 200 and 100 nm) to obtain small unilamellar vesicles of 
100 nm.  
Lipoplex and polyplex preparation and characterization
Lipo- and polyplexes were prepared by mixing an equal volume of plasmid and cationic 
liposomes or dissolved polymer. All formulations were prepared in 20 mM HEPES pH 7.4, 10% 
sucrose buffer with a high viscosity and a low ionic strength, conditions previously shown to be 
favourable for obtaining small and stable DNA complexes (12). Formulation characterizations 
were performed with the Luc-NP construct.
N/P ratios were defined as the charge ratio between cationic nitrogen residues in DOTAP 
or PAA and anionic phosphate groups in the DNA. Ratios were calculated assuming that 302 
and 532 g/mol correspond with each (protonable) nitrogen containing-repeating unit of PAA 
and PEG-PAA, respectively. For DOTAP 699 g/mol is the mass bearing one cationic nitrogen. 
For plasmid DNA 330 g/mol corresponds with the average mass of a repeating unit bearing one 
negative phosphate group. For polyplexes, weight ratios polymer/DNA are also provided. All 
complexes were formulated with a final DNA concentration of 0.5 mg/mL. Control naked DNA 
was diluted to the same concentration in the same buffer. The size of obtained particles was 
measured in 20 mM HEPES pH 7.4, 10% sucrose, with dynamic laser scattering using an ALV/
GCS-3 (Malvern Instruments, UK). Particle size distribution is described using the polydisperity 
index (PDI), ranging from 0 for a monodisperse to 1 for a heterodisperse preparation. The zeta 
potential of obtained particles was determined in 20 mM HEPES pH 7.4, using a Zetasizer Nano 
Z (Malvern Instruments). Both instruments were calibrated using polystyrene latex beads of 
defined size and electrophoretic mobility. The presence of unbound DNA was visualized by 
electrophoresis at 85 V using a 1% agarose gel containing 0.5 µg/mL etidium bromide. Only 
particle formulations shown not to be aggregated and containing no free DNA were used in 
further experiments. 
Transfection of epidermal cell suspensions
Healthy human abdominal skin from female patients (41-63 years) was obtained from the plastic 
surgery department of the institute according with the guidelines of the Antoni van Leeuwenhoek 
Hospital/ The Netherlands Cancer Institute. Subcutaneous fat was directly removed by blunt 
dissection. Skin was transported on ice and used within 2 hours after surgical removal.  
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To obtain an epidermal cell suspension, skin was incubated for 1 hour in 10 mg/mL dispase 
II (Sigma Aldrich, St. Louis, MO, USA ) in complete keratinocyte serum free medium (SFM) 
containing 1% penicillin/streptomycin and 0.25 µg/mL amphotericin B (all Invitrogen) at 37 ºC, 
upon which the epidermis was mechanically peeled from skin samples. The obtained epidermal 
sheet was digested at 37 ºC in complete keratinocyte medium containing 0.05% trypsin. After 
15 min, the epidermis was disrupted with a glass pipette and 10% FCS was added to the medium, 
after which the cells were filtered through 70 µm nylon gauze to remove debris. 
Per well, 1 x 105 cells of a freshly prepared epidermal cell suspension were seed in 24-well 
tissue culture plates in complete keratinocyte medium. Cells were incubated with 50 µl naked 
pVAX:GFP or the indicated nanoparticle formulation (all at 0.04 mg/mL DNA to obtain a final 
concentration of 1 µg DNA/well) at 2% CO
2
, 37 ºC. After 24 hours, cells were harvested and 
analyzed for GFP expression using a FACSCalibur (Becton Dickinson, Franklin Lakes, USA) and 
data were analyzed using Flowjo software (Three Star, Ashland, USA). Live cells were selected 
based on propidium iodide exclusion.
DNA tattooing of ex vivo human skin
Formulations and naked DNA controls encoding firefly luciferase were administered to intact skin 
by DNA tattooing (8) to allow longitudinal luciferase expression measurements. Alternatively, 
formulations and naked DNA controls encoding GFP were used for flow cytometric analysis of 
transfected cell types. The skin model used in these experiments has been described previously 
for the optimization of tattooing of naked DNA in skin (10). In brief, 10µl of the indicated 
formulation at a final DNA concentration of 0.5 mg/ml was applied to the skin into a custom 
fabricated mould to keep the area of tattooing constant (diameter 8mm, surface 50 mm2). The 
formulation was subsequently administered into the skin using a Permanent Make Up (PMU)® 
tattoo machine (kindly provided by MT Derm GmbH, Berlin, Germany). For all tattoos, 9-needle 
cartridges at an oscillating frequency of 100 Hz were used. The needle depth was adjusted to 1.5 
mm and tattoo duration was 20 seconds. 
After tattooing, skin samples were kept at 5% CO
2
, 37 ºC in complete keratinocyte serum 
free medium (SFM) containing 1% penicillin/streptomycin and 0.25 µg/mL amphotericin B (all 
Invitrogen) to allow longitudinal expression measurements of luciferase. During this incubation, 
skin was cultured at the air-medium interface with the epidermis exposed to the air to mimic 
the natural situation. 
Measurement of antigen expression using intravital imaging of ex vivo 
human skin
The expression of luciferase was measured in intact skin samples at the indicated time points 
after tattooing. The substrate luciferin (Xenogen, Hopkinton, USA) was added to the medium 
in a final concentration of 45 µg/mL. During this procedure extra medium was added to the 
box in which skin was incubated, to cover the complete epidermis of skin samples with fluid to 
guarantee full accessibility of luciferin to the tattooed areas. 30 minutes after the addition of 
the substrate, luminescence produced by active luciferase was acquired during 30 s with an IVIS 
system 100 CCD camera (Xenogen, Hopkinton, USA).  
Signal intensity was quantified as the sum of all detected light within the tattoo area of 
interest. In all measurements, background luminescence was determined for non-treated skin 





Flow cytometric analysis of DNA vaccine induced antigen expression
For flow cytometry experiments, tattooed areas of interest were removed from the intact 
skin with a 6 mm biopsy punch and transferred into 48-well plates. Directly upon tattooing, 
epidermal sheets were removed as described above and incubated overnight at 37 °C. After 
incubation, epidermal sheets were digested and stained with antibodies. The antibodies used 
were mouse anti-human CD1a allophycocyanin (APC) (Immunotech) and mouse anti human 
cytokeratin (equal mixture of clone LP34 and MNF116 (both Dako, Glostrup Denmark)), labelled 
with Alexa Fluor 647 (Invitrogen) according to manufacturer’s protocol. Prior to cytokeratin 
staining, epidermal cell suspensions were permeabilized using the BD Cytofix/Cytoperm kit (BD 
Sciences, Franklin Lakes, NJ, USA) according to the manufacturer’s protocol. In case of anti 
CD1a staining, live cells were selected based on propidium iodide exclusion. 
DNA immunization
C57BL/6J mice (6-8 weeks) were obtained from the experimental animal department of The 
Netherlands Cancer Institute. All animal procedures were performed according to approved 
protocols and in accordance with recommendations for the proper use and care of laboratory 
animals. All animal experiments were approved by the NKI-AVL Animal Research Committee. 
To allow simultaneous measurement of antigen expression and T cell responses, mice were 
immunized by DNA tattooing with formulations containing the pVAX:Luc-NP construct. Before 
intradermal DNA vaccination, the hair at the administration sites was removed with depilatory 
cream (Veet sensitve, Reckitt Benckiser, Hull, UK). During immunization, 15 µl of lipo- or 
polyplex formulation or naked DNA solution at a final concentration of 0.5 mg/ml was applied 
to the skin of the hind leg and administered using a disposable 9-needle cartridge mounted 
on an PMU® tattoo machine. DNA vaccines were tattooed during 30 s at a needle depth of 1.0 
mm, and the needle bar oscillated at 100 Hz. Using this needle depth setting, cells in both the 
epidermis and upper layer of the dermis are transfected (8). Mice were vaccinated on day 0, 3 
and 6. All mice were anesthetized with isoflurane (Abbott Laboratories, Illinois, USA), during 
treatment. At the indicated time points after immunization, approximately 50 µl of peripheral 
blood was collected by tail bleeding for the measurement of T cell responses.
Measurement of antigen expression using intravital imaging
Antigen expression upon DNA vaccination was measured by a light-sensitive camera to allow 
longitudinal in vivo expression of firefly luciferase. Mice were anesthetized with isoflurane. A 
solution of the substrate luciferin in PBS (150 mg/kg, Xenogen) was intraperitoneally injected 
and after 18 min, the luminescence produced by active luciferase was acquired during 30 s in 
an IVIS® system 100 CCD camera (Xenogen). Signal intensity was quantified as the sum of all 
detected light within the region of interest, after subtraction of background luminescence.
Antigen-specific T cell assay
To measure antigen-specific T cell responses, peripheral blood lymphocytes were stained on 
different time points with H-2Db/NP
366–374
-tetramers and APC-conjugated CD8α antibody (BD 
Pharmingen, San Jose, USA) at 20 °C for 15 min in FACS buffer (1× PBS, 0.5% BSA and 0.02% 
sodium azide) as described before (13). Cells were washed three times in FACS buffer and 
analyzed by flow cytometry. Live cells were selected based on propidium iodide exclusion. 
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Statistical Analysis
A two-tailed Mann-Whitney U-test was used for statistical analysis and a value of p < 0.05 was 
considered significant. A Bonferroni adjustment test was applied to correct the significant level 
when multiple groups were compared.
results 
Cationic nanoparticles increase transfection efficiency in epidermal 
cell suspensions but decrease antigen expression in ex vivo human skin 
and in mice
In order to develop nanoparticle formulations for intradermal application of DNA vaccines, DNA 
was complexed with cationic DOTAP-DOPE liposomes or with cationic poly(amidoamine) (PAA) 
polymers, to form lipoplexes and polyplexes, respectively. DOTAP-DOPE was chosen since this 
is the most commonly used composition in liposomal based transfection experiments. PAA was 
chosen as a novel and biodegradable polymeric carrier system. As DNA vaccination is known 
to require high DNA concentrations (14-16), complexes were formulated with a final DNA 
concentration of 0.5 mg/mL, which is relatively high for these systems. The obtained lipoplexes 
and polyplexes were characterized for particles size and surface charge (as reflected by the zeta 
potential). Both types of DNA-nanoparticles had particle sizes below 240 nm, did not contain 
free DNA (as determined by gel electrophoresis) and exhibited a zeta potential above +40 mV. 
To determine the effect of DNA formulation into nanoparticles on in vitro transfection 
efficiency, fresh suspensions of non-transformed human epidermal cells were used. These 
target cells were transfected in vitro with either lipoplex or polyplex nanoparticles that had 
been formulated with a GFP encoding construct, and transfection-induced GFP expression was 
analyzed 24 hrs after addition to the cells, by flow cytometry. For both types of nanoparticles, 
nanoparticle formulation resulted in marked increase in transfection efficiency when compared 
with naked DNA (by a factor of >26 and >900 for polyplexes and lipoplexes respectively, Figure 
1A). These data demonstrate that the superior in vitro transfection properties of formulated 
cationic nanoparticles previously shown for human cell lines also apply to non-transformed 
human skin cells.
To study the performance of cationic DNA-nanoparticles in a clinically more relevant model, 
antigen expression was measured in intact ex vivo human skin upon tattooing of nanoparticles 
formulated with a luciferase encoding construct. Luciferase expression was measured with a light 
sensitive CCD camera. Surprisingly, antigen expression induced by application of both lipoplex 
and polyplex DNA nanoparticles was extremely low (see Figure 1B). In contrast, intradermal 
application of naked DNA resulted in robust levels of antigen expression, as observed previously 
(10). Consistent with the data obtained in human skin, application of lipo- or polyplexes to murine 
skin also yield very low levels of antigen expression (Figure 1C) and corresponding undetectable 
antigen-specific immune responses in vaccinated mice (see below).
These results demonstrate that in vitro transfection data of these positively charged DNA 
vaccine formulations bear little, if any, predictive value for in vivo expression in either murine 
or human skin.  Furthermore, the data provide the more general indication that cationic 




Shielding of the cationic surface charge restores transfection efficiency 
of nanoparticles in ex vivo human skin 
To determine the underlying reason for the discordance between the effectiveness of DNA 
nanoparticles in in vitro and in/ ex vivo assays we focussed on potential differences between 
intact skin and skin cell cultures. First, the presence of the extracellular matrix (ECM) in skin 
tissue conceivably reduces free diffusion of particles in intact skin. As condensation of DNA into 
nanoparticles results in a reduced size compared to free DNA it is unlikely that a sieve function 
of the ECM is responsible for the reduction in effectiveness in vivo. However, several ECM 
components carry a net negative charge and are likely to interact with the positively charged 
nanoparticles, with the result that the nanoparticles become  immobilized in the ECM. Thus, 
while in in vitro cultures the cationic charge of the nanoparticles is positively contributing to 
the transfection process by promoting binding to cell surfaces, this positive effect is most likely 
surpassed in vivo by electrostatic interactions with anionic ECM components and consequent 
immobilization of these nanoparticles in the ECM, preventing the particles to reach their target. 
In order to evaluate whether the positive particle charge is responsible for the absence of 
vaccination-induced antigen expression in intact skin, we introduced poly (ethylene glycol) 
(PEG) moieties to both types of nanoparticles, a strategy that is known to reduce the surface 
charge of lipo-and polyplexes. The presence of increasing concentrations of PEG in both lipo- 




























































































































These results demonstrate that in vitro transfection data of these positively charged 
DNA vaccine formulations bear little, if any, predictive value for in vivo expression in 
either murine or human skin.  Furthermore, the data provide the more general 
indication that cationic nanoparticles are ill-suited for the intradermal application of 
DNA vaccines. 
 
Shielding of the cationi  su face charge restores tra sfection efficiency of 
nano articl s in ex vivo human skin  
Figure 1. Discordant in vitro and in vivo
performance of cationic nanoparticles. 
(A) Transfection of epidermal cell 
suspensions with naked DNA, DOTAP-
DOPE/DNA complexes (‘lipoplex’), and 
PAA/DNA complexes (‘polyplex’). Bars 
represent the mean + SD of three 
independent measurements.  
(B) Luciferase activity upon application of 
naked DNA, lipoplex or polyplex formulation 
to intact ex vivo human skin by DNA tattoo. 
Data shown depict luciferase activity 
measured 5 hours after DNA application. 
The same poor performance of lipoplex and 
polyplex DNA formulations was observed 
after 21 hrs. Bars represent the mean + SD of 
3-5 measurements.  
(C) Luciferase activity upon application of 
naked DNA, lipoplex or polyplex formulation 
to murine skin. Data shown depict the poor 
performance of lipoplex and polyplex DNA 
formulation when compared with naked 
DNA. Expression was measured 8 hours after 
tattooing. Bars represent the mean + SD of 
5-8 mice.  
All formulations were prepared at a charge 
(N/P) ratio of 5 (lipoplexes) or 55 
Figure 1. Discordant in vitro and in vivo performance 
of cationic nanoparticles. (A) Transfection of 
epidermal cell suspensions with naked DNA, DOTAP-
DOPE/DNA complexes (‘lipoplex’), and PAA/DNA 
complexes (‘polypl x’). Bars represent the mean + SD 
of three independe t measurements. (B) Luciferase 
activity upon application of nake  DNA, lipoplex or 
polyplex formulation to intact ex vivo human skin 
by DNA tattoo. Data shown depict luciferase activity 
measured 5 hours after DNA application. The same 
poor performance of lipoplex and polyplex DNA 
formulations was observed after 21 hrs. Bars represent 
the mean + SD of 3-5 measurements. (C) Luciferase 
activity upon application of naked DNA, lipoplex or 
polyplex formulation to murine skin. Data shown 
depict the poor performance of lipoplex and polyplex 
DNA formulation when compared with naked DNA. 
Expression was measured 8 hours after tattooing. Bars 
represent the mean + SD of 5-8 mice. All formulations 
were prepared at a charge (N/P) ratio of 5 (lipoplexes) 
or 55 (polyplexes), to obtain particles with sizes below 
240 nm and a zeta potential above +40 mV.
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+40-60 to close to neutrality for both formulations, together with a modest (2-fold or less) 
reduction in particle size (see supplementary Figures 1-3). 
Subsequently, PEGylated nanoparticles were applied to intact human skin by DNA tattooing 
and vaccination-induced antigen expression was analyzed. In agreement with our hypothesis 
that blocking of the intradermal expression as observed for the cationic nanoparticles is due 
to their positive surface charge, the PEGylated nanoparticles showed a very marked increase 
in antigen expression (~50-fold and ~20-fold for lipo- and polyplexes, respectively, see Figures 
2 and 3). 
For the PEGylated lipoplexes, antigen expression levels reached a plateau value at a 
DSPE-PEG content between 15 and 17.5% (Figure 2A) with an expression level that was 1.6 
± 0.3 fold (mean ± SD, measured in three independent pieces of skin) higher at the peak of 
expression than naked DNA. At a DSPE-PEG content of 10%, no difference in antigen expression 
was observed between N/P ratio 2 and 5 (data not shown).Chapter 6 
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Figure 2: Antigen expression (luciferase) upon tattoo vaccination of PEGylated lipoplexes in ex vivo human 
skin. 
(A) Expression induced by administration of naked DNA (○), or by administration of DOTAP-DOPE/DNA 
complexes as a function of DSPE-PEG content at an N/P ratio of 5 (●). Expression was measured at 5 hrs 
post DNA application. 
(B) Longitudinal expression upon application of naked DNA (○) or application of DOTAP-DOPE/DNA 
lipoplexes (N/P of 5) with (●) or without (▼)17.5 mol % DSPE-PEG. Each point represents the mean + SD of 
3-8 data points, randomized tattooed over one biopsy of skin. All experiments were performed in 
triplicate.  
* Values significantly different from naked DNA control. 
 
The PEGylated polyplexes showed a plateau in antigen expression levels at a 
polymer/DNA w/w ratio between 25:1 and 50:1 (Figure 3B) that was 8.5 ± 4.4 fold 
(mean ± SD, measured in three independent pieces of skin) higher than naked DNA. 
 
Finally, to determine whether the physical incorporation of PEG into nanoparticles is 
essential to restore antigen expression, a control experiment was performed in which 
unbound PEG 2000 was added to the nonPEGylated lipo- and polyplexes in the same 
concentrations as used in the PEGylated particles. Application of these formulations 
to human skin resulted in non-detectable levels of antigen expression levels (data 
not shown). This demonstrates that the observed effects are due to the PEG 
modification of the particles rather than to the presence of PEG itself in the 
formulation solutions. 
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vivo human skin. (A) Expression induced by administration of naked DNA (○), or by administration of 
DOTAP-DOPE/DNA complexes as a function of DSPE-PEG content at an N/P ratio of 5 (●). Expression 
was measured at 5 hrs post DNA application. (B) Longitudinal expression upon application of naked 
DNA (○) or application of DOTAP-DOPE/DNA lipoplexes (N/P of 5) with (●) or without (▼)17.5 mol 
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The PEGylated polyplexes showed a plateau in antigen expression levels at a polymer/DNA 
w/w ratio between 25:1 and 50:1 (Figure 3B) that was 8.5 ± 4.4 fold (mean ± SD, measured in three 
independent pieces of skin) higher than naked DNA.
Finally, to determine whether the physical incorporation of PEG into nanoparticles is 
essential to restore antigen expression, a control experiment was performed in which unbound 
PEG 2000 was added to the nonPEGylated lipo- and polyplexes in the same concentrations 
as used in the PEGylated particles. Application of these formulations to human skin resulted 
in non-detectable levels of antigen expression levels (data not shown). This demonstrates 
that the observed effects are due to the PEG modification of the particles rather than to the 




PEGylated nanoparticles and naked DNA primarily transfect epidermal 
keratinocytes
It has been reported that vaccination by nanoparticles can result in preferential targeting of 
Antigen Presenting Cells (APCs) (17-19). Therefore, it is of interest to evaluate which type of 
cells are transfected upon DNA tattoo vaccination with PEGylated lipo-and polyplexes. To 
this purpose, a GFP encoding plasmid was applied by DNA tattooing to human skin biopsies, 
either as uncomplexed DNA, or encapsulated in PEGylated lipo- or polyplexes. After DNA 
application, the epidermis of the skin was removed and digested to a single cell suspension. 
Cells were subsequently stained with anti-cytokeratin and anti-CD1a antibodies to reveal 
transfection of cytokeratin positive epidermal keratinocytes and CD1a positive Langerhans 
Cells, respectively. Flow cytometric analysis of obtained cell populations demonstrated that, 
as is the case for uncomplexed DNA (10), intradermal application of DNA encapsulated into 
PEGylated lipoplexes or polyplexes resulted in the near-exclusive transfection of keratinocytes, 
with at most a sporadic GFP positive Langerhans Cell (LCs) (Figure 4). These data reveal that ex 
vivo nanoparticle administration by DNA tattooing, does not result in preferential expression 
in epidermal LCs.
Figure 3. Antigen expression upon tattoo 
vaccination of PEGylated polyplexes in ex vivo 
human skin. (A) Expression upon application of naked 
DNA (○), or application of PAA/DNA polyplexes as 
a function of the percentage of PEGylated PAA at a 
w/w ratio polymer/DNA of 50 (●). (B) Expression 
upon application of PEGylated PAA /DNA polyplexes 
at different ratios polymer/DNA. Expression 
was measured at 5hrs post DNA application.  (C) 
Longitudinal expression of luciferase in human skin 
upon application of naked DNA (○), PEGylated PAA/
DNA polyplexes at a w/w ratio polymer/DNA of 50 (●) 
or nonPEGylated PAA/DNA complexes at a w/w ratio 
polymer/DNA of 50 (▼). Each point represents the 
mean + SD of 3-8 data points, randomized tattooed 
over one biopsy of skin. All experiments were 
performed in triplicate. * Values significantly different 
from naked DNA control.
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PEGylated nanoparticles and naked DNA primarily transfect epidermal 
keratinocytes 
It has been reported that vaccination by nanoparticles can result in preferential 
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Figure 3: Antigen expression upon tattoo 
vaccination of PEGylated polyplexes in ex 
vivo human skin. 
(A) Expression upon application of naked 
DNA (○), or application of PAA/DNA 
polyplexes as a function of the percentage 
of PEGylated PAA at a w/w ratio 
polymer/DNA of 50 (●).  
(B) Expression upon application of 
PEGylated PAA /DNA polyplexes at different 
ratios polymer/DNA. Expression was 
measured at 5hrs post DNA application. 
 (C) Longitudinal expression of luciferase in 
human ski  upon application of naked DNA 
(○), PEGylated PAA/DNA olyplexes at a w/w 
ratio polymer/DNA of 50 (●) or 
nonPEGylated PAA/DNA complexes at a w/w 
ratio polymer/DNA of 50 (▼). Each point 
represents the mean + SD of 3-8 data points, 
randomized tattooed over one biopsy of 
skin. All experiments were performed in 
triplicate.  
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Shielding of the cationic surface charge of nanoparticles results in an 
increased transfection efficiency and preserved immunogenicity of 
lipoplexes upon in vivo tattooing
The in vivo antigen expression and immunogenicity of the PEGylated nanoparticles was 
studied in C57/B6 mice. To this purpose, mice were vaccinated with naked DNA or lipo- or 
polyplex (both nonPEGylated and PEGylated) formulations using a standard tattoo vaccination 
protocol, with DNA administrations on day 0, 3 and 6 (8). To allow the simultaneous detection 
of vaccination-induced antigen expression and vaccination-induced antigen-specific T cell 
responses, a pVAX:Luc-NP model DNA vaccine was utilized. Use of this model DNA vaccine 
permits the monitoring of in vivo antigen expression by assessment of luciferase activity, while 




Consistent with the results from the ex vivo human skin model, PEGylation of nanoparticles 
was essential to obtain substantial antigen expression by either lipoplexes or polyplexes 
(with an increase in AUC of 73-fold and 55-fold by PEGylation for lipoplexes and polyplexes, 
respectively). Furthermore, PEGylated lipo- and polyplexes showed a significant increase 
in antigen expression as compared to the naked DNA control (Figure 5), where again the 
PEGylated polyplexes induced higher expression levels as compared to PEGylated lipoplexes. 
When compared to naked DNA, the AUC of antigen expression were 2.1 and 5.4 fold higher for 
lipo- and polyplexes, respectively.
To investigate whether shielding of the surface charge is sufficient to restore the 
immunogenicity of nanoparticle-formulated DNA vaccines, vaccine-induced, antigen-specific 
T cell responses were measured directly ex vivo in peripheral blood by staining with MHC 
tetramers (Figure 6). We focused exclusively on effector T cell immunity in this study since 
we are developing DNA tattooing as a method for therapeutic tumor immunization (20), 
Figure 4. Flow cytometric analysis of epidermal cell suspensions of tattooed skin. Skin was 
tattooed with naked GFP-encoding DNA, DOTAP-DOPE/DNA lipoplexes with 17.5 mol % DSPE-PEG 
(N/P ratio 5), or PEG-PAA/DNA polyplexes (w/w ratio 50). Cell suspensions of tattooed or control 
skin were stained with anti CD1a (top) antibody or with anti-cytokeratin antibody (bottom).
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transfection of cytokeratin positive epidermal keratinocytes and CD1a positive 
Langerhans Cells, respectively. Flow cytometric analysis of obtained cell populations 
demonstrated that, as is the case for uncomplexed DNA (10), intradermal application 
of DNA encapsulated into PEGylated lipoplexes or polyplexes resulted in the near-
exclusive transfection of keratinocytes, with at most a sporadic GFP positive 
Langerhans Cell (LCs) (Figure 4). These data reveal that ex vivo nanoparticle 




Figure 4: Flow cytometric analysis of epidermal cell suspensions of tattooed skin. Skin was tattooed with 
naked GFP-encoding DNA, DOTAP-DOPE/DNA lipoplexes with 17.5 mol % DSPE-PEG (N/P ratio 5), or PEG-
PAA/DNA polyplexes (w/w ratio 50). Cell suspensions of tattooed or control skin were stained with anti 
CD1a (top) antibody or with anti-cytokeratin antibody (bottom). 
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 The in vivo antigen expression and immunogenicity of the PEGylated nanoparticles 
was studied in C57/B6 mice. To this purpose, mice were vaccinated with naked DNA 
or lipo- or polyplex (both nonPEGylated and PEGylated) formulations using a 
standard tattoo vaccination protocol, with DNA administrations on day 0, 3 and 6 (8). 
To allow the simult eous detection of vaccination-induced antigen ex ression and 
vaccination-induced antig n-specifi  T cell responses, a pVAX:Luc-NP model DNA 
vaccine was utilized. Use of this model DNA vaccine permits the monitoring of in vivo 




which aims for high T cell titres (21). As expected, due to the absence of substantial levels 
of antigen expression, no significant T cell responses were detected in animals vaccinated 
with  nonPEGylated nanoparticles. In contrast, vaccination with the matched PEGylated 
nanoparticles resulted in a strong T cell response that peaked between day 15 and 17, similar to 
that observed for the naked DNA control group. The magnitude of the antigen-specific T cell 
response induced by vaccination with naked DNA or with PEGylated lipoplexes or polyplexes 
was similar, with no significant difference (Figure 6). These data establish that the presence 
of the PEG moieties on the DNA nanoparticles is not only sufficient to restore vaccination-
induced antigen expression in human and murine skin but also leads to a full restoration of 
vaccine immunogenicity.
Figure 5. In vivo antigen expression in mice upon tattoo vaccination of: (A) Naked DNA (○) or 
DOTAP-DOPE/ DNA lipoplex with (●) or without (▼) 17.5 mol % DSPE-PEG (both lipoplexes at an 
N/P ratio of 5). (B) Naked DNA (○), PEGylated PAA/DNA polyplexes (●) or nonPEGylated PAA/DNA 
polyplex (▼) (both polyplexes at a w/w ratio polymer/DNA 50). Expression of the vaccine-encoded 
antigen (luciferase) was measured at the indicated time points upon tattooing with a light sensitive 
camera.  * Values significantly different from naked DNA control. Each point represents the mean + 
SD of 8 mice.
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immunogenicity can be determined by monitoring of T cell responses against the 
vaccine-encoded influenza NP366-374 epitope. 
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Figure 5: In vivo antigen expression in mice upon tattoo vaccination of: 
(A) Naked DNA (○) or DOTAP-DOPE/ DNA lipoplex with (●) or without (▼) 17.5 mol % DSPE-PEG (both 
lipoplexes at an N/P ratio of 5). (B) Naked DNA (○), PEGylated PAA/DNA polyplexes (●) or nonPEGylated 
PAA/DNA polyplex (▼) (both polyplexes at a w/w ratio polymer/DNA 50). Expression of the vaccine-
encoded antigen (luciferase) was measured at the indicated time points upon tattooing with a light 
sensitive camera.  * Values significantly different from naked DNA control. Each point represents the mean 
+ SD of 8 mice. 
 
Consistent with the results from the ex vivo human skin model, PEGylation of 
nanoparticles was essential to obtain substantial antigen expression by either 
lipoplexes or polyplexes (with an increase in AUC of 73-fold and 55-fold by 
PEGylation for lipoplexes and polyplexes, respectively). Furthermore, PEGylated lipo- 
and polyplexes showed a significant increase in antigen expression as compared to 
the naked DNA control (Figure 5), where again the PEGylated polyplexes induced 
higher expression levels as compared to PEGylated lipoplexes. When compared to 
naked DNA, the AUC of antigen expression were 2.1 and 5.4 fold higher for lipo- and 
polyplexes, respectively. 
 
To investigate whether shielding of the surface charge is sufficient to restore the 
immunogenicity of nanoparticle-formulated DNA vaccines, vaccine-induced, antigen-
specific T cell responses were measured directly ex vivo in peripheral blood by 
staining with MHC tetramers (Figure 6). We focused exclusively on effector T cell 
immunity in this study since we are developing DNA tattooing as a method for 
therapeutic tumor immunization (20), which aims for high T cell titres (21). As 
expected, due to the absence of substantial levels of antigen expression, no 
significant T cell responses were detected in animals vaccinated with  nonPEGylated 
nanoparticles. In contrast, vaccination with the matched PEGylated nanoparticles 
resulted in a strong T cell response that peaked between day 15 and 17, similar to 
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that observed for the naked DNA control group. The magnitude of the antigen-
specific T cell response induced by vaccination with naked DNA or with PEGylated 
lipoplexes or polyplexes was similar, with no significant difference (Figure 6). These 
data establish that the presence of the PEG moieties on the DNA nanoparticles is not 
only sufficient to restore vaccination-induced antigen expression in human and 
murine skin but also leads to a full restoration of vaccine immunogenicity. 
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Figure 6:  T cell responses upon tattoo vaccination of DNA nanoparticles. NP366-374 specific T cell responses 
upon tattoo vaccination with the Luc-NP construct are shown for: (A) Mice vaccinated with naked DNA (○) 
or DOTAP-DOPE/ DNA lipoplex with (●) or without (▼)17.5 mol % DSPE-PEG (both lipoplexes at an N/P 
ratio of 5).  (B) Mice vaccinated with naked DNA (○), PEGylated PAA/DNA polyplexes (●) or nonPEGylated 
PAA/DNA polyplexes  (▼)(both polyplexes at a w/w ratio polymer/DNA of 50). NP366-specific T cell 
responses were measured by direct ex vivo MHC tetramer staining of peripheral blood lymphocytes. Each 
point represents the mean + SD of 8 mice. 
 
Discussion 
Incorporation of DNA in nanoparticles may offer the possibility to enhance cellular 
uptake and may offer the opportunity to develop intradermal DNA vaccines that are 
amenable to target specific cell types. A first requirement in this research is the 
development of particles that can be active in vivo. This study shows that cationic 
lipo- and polyplexes that are highly active in in vitro assays (22) (Figure 1A) yield only 
marginal vaccination-induced antigen expression in either murine or human intact 
skin. We demonstrate that the poor performance of cationic nanoparticles in the 
latter cases can be significantly improved by shielding the  positive surface charge of 
the nanoparticles by PEGylation to generate near-neutrally charged nanoparticles 
that yield robust vaccination-induced antigen expression in both murine and human 
skin.  
A possible explanation for the marked discordance between the effectiveness of 
cationic nanoparticles in cell culture and intact skin is the presence of ECM in intact 
Figure 6.  T cell responses upon tattoo vaccination of DNA nanoparticles. NP
366-374
 specific T cell 
responses upon tattoo vaccination with the Luc-NP construct are shown for: (A) Mice vaccinated 
with naked DNA (○) or DOTAP-DOPE/ DNA lipoplex with (●) or without (▼)17.5 mol % DSPE-PEG 
(both lipoplexes at an N/P ratio of 5).  (B) Mice vaccinated with naked DNA (○), EGylated PAA/DNA 
polyplexes (●) or nonPEGylated PAA/DNA polypl xes  (▼)(both polyplexes at a w/w ra io polymer/
DNA of 50). NP
366
-specific T cell responses were measured by direct ex vivo MHC tetramer staining 
of peripheral blood lymphocytes. Each point represents the mean + SD of 8 mice.
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discussion
Incorporation of DNA in nanoparticles may offer the possibility to enhance cellular uptake and 
may offer the opportunity to develop intradermal DNA vaccines that are amenable to target 
specific cell types. A first requirement in this research is the development of particles that can 
be active in vivo. This study shows that cationic lipo- and polyplexes that are highly active in 
in vitro assays (22) (Figure 1A) yield only marginal vaccination-induced antigen expression in 
either murine or human intact skin. We demonstrate that the poor performance of cationic 
nanoparticles in the latter cases can be significantly improved by shielding the  positive surface 
charge of the nanoparticles by PEGylation to generate near-neutrally charged nanoparticles 
that yield robust vaccination-induced antigen expression in both murine and human skin. 
A possible explanation for the marked discordance between the effectiveness of cationic 
nanoparticles in cell culture and intact skin is the presence of ECM in intact skin. It is known that 
major ECM components in the skin (like proteoglycans and hyaluronic acid) have a negative 
charge at physiological pH (23). These negatively charged components may be responsible for 
electrostatic binding and immobilisation of the positively charged nanoparticles in the matrix after 
intradermal administration. Indirect support for this hypothese is also provided by the reported 
observation that inclusion of ECM components in the transfection medium can inhibit cellular 
uptake of lipo-and polyplexes in in vitro assays (24-26). Although PEGylated particles induce low 
levels of in vitro transfection their performance upon in vivo tattooing was markedly improved 
compared to the unPEGylated particles and naked DNA. It is known that PEGylation of particles 
affects in vitro transfection both at the level of cellular uptake and intracellular trafficking. The 
transfection efficiency of PEGylated particles is generally 2-fold lower compared to nonPEGylated 
particles due to a decrease in cell binding and uptake (27,28). In contrast, the mobility of PEGylated 
particles through the cytosol upon in vitro microinjection is 2-fold faster than nonPEGylated 
particles (29). During intracellular trafficking, both PEGylated and nonPEGylated complexes are 
thought to be unpacked similar in the cytosol before the DNA can enter the nucleus (28). In our 
view, these in vitro data do not explain the marked difference in transfection properties observed 
between PEGylated and nonPEGylated particles upon in vivo tattooing but do indeed suggest that 
nonPEGylated particles do not reach the skin cells upon tattooing.
The current data demonstrate that PEGylation of the nanoparticles to a level that allows a 
near complete shielding of the surface charge suffices to restore and even enhance antigen 
expression in intact skin. These PEGylated nanoparticles give higher antigen expression than 
naked DNA controls in the ex vivo and in vivo experiments. It seems plausible that further 
optimization of nanoparticle properties and dosing may yield shielded formulations that give a 
further increase in in vivo antigen expression and immunogenicity. 
In addition to the optimization of the properties of shielded nanoparticle formulations 
to enhance vaccination-induced antigen expression, a second key step is the introduction of 
defined ligands within these formulations (30-32). The current shielded nanoparticles form a 
highly suited platform for such introduction, as ligands can readily be attached to the terminal 
ends of the PEG chains, using standard protocols. Two specific goals may be achieved by 
introduction of such ligands. First, introduction of ligands for defined cell surface receptor may 
enhance cellular uptake or may be used to target defined epidermal cell types (for example 
epidermal LCs). Second, the introduction of Toll-like receptor ligands or ligands for other 
pathogen-associated molecular pattern receptors on the surface of the nanoparticles is an 
attractive option to further enhance the immunogenicity of shielded nanoparticle vaccines, by 
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Supplementary Figure 1:. Lipoplex characteristics: 
effect of increasing DSPE-PEG content on size (A), 
Polydispersity Index (PDI) (B) and ζ potential (C)
of DOTAP-DOPE/DNA lipoplexes. Complexes were 
prepared at a charge (N/P) ratio of 2 (black bars or 
●) and 5 (grey bars or ▼) at 0.5 mg/mL DNA in 20 
mM HEPES pH 7.4, 10% sucrose.  
Bars or symbols represent the mean + SD of three 
independent measurements.  
Aggregated lipoplexes are indicated by bars that 
reach the upper axis.  
 
Supplementary Figure 2: Condensation of 
plasmid DNA with DOTAP-DOPE liposomes 
containing increasing concentration of DSPE-PEG 
at a charge (N/P) ratio of 2 (A) or 5 (B). Each lane 
was loaded with 2 µl formulation, corresponding 
to 1 µg DNA, and samples  were analyzed by gel 
electrophoresis. Lane M; l/Hind III DNA molecular-
weight markers; lane N, naked DNA control; lane 
0 to 25,  DOTAP-DOPE/ DNA lipoplexes prepared 
with an increasing mol percentage of DSPE-PEG. 
Data demonstrate that up to a DSPE-PEG 
percentage of 10% (for N/P 2) or 17.5% (for N/P 5) 
all DNA is complexed as no free DNA is detected. 
Supplementary Figure 1. Lipoplex characte-
ristics: effect of increasing DSPE-PEG content 
on size (A), Polydispersity Index (PDI) (B) and ζ 
potential (C) of DOTAP-DOPE/DNA lipoplexes. 
Complexes were prepared at a charge (N/P) ratio 
of 2 (black bars or ●) and 5 (grey bars or ▼) at 0.5 
mg/mL DNA in 20 mM HEPES pH 7.4, 10% sucrose. 
Bars or symbols represent the mean + SD of three 
independent measurements. Aggregated lipoplexes 
are indicated by bars that reach the upper axis.
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DNA with DOTAP-DOPE liposomes containing 
increasing concentration of DSPE-PEG at a charge 
(N/P) ratio of 2 (A) or 5 (B). Each lane was loaded 
with 2 µl formulation, corresponding to 1 µg DNA, 
and samples  were analyzed by gel electrophoresis. 
Lane M; l/Hind III DNA molecular-weight markers; 
lane N, naked DNA control; lane 0 to 25,  DOTAP-
DOPE/ DNA lipoplexes prepared with an increasing 
mol percentage of DSPE-PEG. Data demonstrate 
that up to a DSPE-PEG percentage of 10% (for N/P 2) 
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Supplementary Figure 3: 
Polyplex characteristics:
effect of PEGylation on 
particle size (bars) and 
Polydispersity Index (PDI) 
(lines) of polymer/DNA 
polyplexes. Polyplexes were 
prepared at the indicated 
polymer/DNA ratios, either 
with nonPEGylated PAA 
polymer (A) or with 
PEGylated PAA polymer (B). 
(C) PEGylated and 
nonPEGylated PAA polymer 
was mixed at the indicated 
ratios (always in a 50/1 w/w 
ratio polymer/DNA) to 
obtain particles with a range 
of ζ potentials. Bars or 
symbols represent the mean 
+ SD of three independent 
measurements. All 
complexes were prepared at 
0.5 mg/mL DNA in 20 mM 
HEPES pH 7.4, 10% sucrose. 
Aggregated polyplexes are 
indicated by bars that reach 
the upper axis. Gel 
electrophoresis showed no 
free DNA in all polyplexes 
formulated at the tested 
Supplementary Figure 3: Polyplex characteristics: effect of PEGylation on particle size (bars) 
and Polydispersity Index (PDI) (lines) of polymer/DNA polyplexes. Polyplexes were prepared 
at the indicated polymer/DNA ratios, either with nonPEGylated PAA polymer (A) or with PEGylated 
PAA polymer (B). (C) PEGylated and nonPEGylated PAA polymer was mixed at the indicated ratios 
(always in a 50/1 w/w ratio polymer/DNA) to obtain particles with a range of ζ potentials. Bars or 
symbols represent the mean + SD of three independent measurements. All complexes were prepared 
at 0.5 mg/mL DNA in 20 mM HEPES pH 7.4, 10% sucrose. Aggregated polyplexes are indicated by bars 
that reach the upper axis. Gel electrophoresis showed no free DNA in all polyplexes formulated at 









As outlined in the introduction there is a strong rationale for the development of therapeutic 
HPV vaccines. In this thesis we focused on the preclinical development of DNA vaccine 
candidates targeting HPV16 E6 and E7. In short, we show that the immunogenicity of E6 and E7 
encoding DNA vaccines can be strongly influenced by the design of the DNA vaccine. Beside 
this, we show that DNA vaccines encoding gene-shuffled versions of E6 and E7 no longer posses 
the transforming potential that is associated with the wild-type versions of these genes. Below 
we provide a summary of the chapters with a focus on open questions that remain. 
Despite the high expectations in the 1990s, to date no DNA vaccines have been approved 
for human use. In chapter 2 we provide a review that discusses the possibilities to improve the 
immunogenicity of DNA vaccines, with a focus on a delivery method called DNA tattooing that 
was developed in our lab (1). We think that DNA tattooing has great potential to overcome the 
so called ‘simian-barrier’: the observation that DNA vaccines although highly immunogenic 
in mice are only weakly immunogenic in non-human primates (2). This optimism is based on 
the 10- to 100-fold increase in the magnitude of vaccine specific T cell responses in peripheral 
blood from DNA tattooed rhesus macaques, as compared to T cell responses in animals 
immunized via intramuscular (IM) route (3). Advantages of DNA tattooing compared to 
other DNA delivery methods are: targeting of the skin being the ultimate organ for immune 
surveillance, provision danger signals by the thousands of inflictions made during tattooing, 
delivery without requirement of expensive instruments (such as the gene gun), and the relative 
ease to scale doses used in mice to equivalent doses in humans by increasing the surface of the 
tattooed area. The review also summarizes our knowledge on the mechanism of T cell priming 
upon DNA (tattoo) vaccination, providing clues for the improvement of DNA vaccines. We 
are optimistic that advances in the design and delivery of DNA vaccines will result in clinical 
application of DNA vaccines in the near future. The recent licensing of three different DNA 
vaccines in the field of veterinary medicine (4) and a recent clinical trial showing DNA vaccine 
mediated protection from influenza challenge (5) fuels this optimism. 
In chapter 3 we show that fusion with Tetanus Toxin Fragment C (TTFC) considerably 
increased the immunogenicity of both wild-type E7 as gene-shuffled versions of E6 and E7. 
These data form a nice illustration of the enormous impact of antigen design on DNA vaccine 
immunogenicity. TTFC was selected as carrier-molecule as it had been shown to improve the 
immunogenicity of C-terminally fused minimal T cell epitopes (6, 7). We thus extent this finding 
to full-length proteins. The function of TTFC is most likely to provide CD4+ T cell help and 
improve the stability/half-life of the antigen. Previous more fundamental studies in our lab 
already pointed towards an important role of these two factors in DNA vaccine immunogenicity 
(8, 9). We observed in this study that the effect for E7 is much more pronounced than for E6. 
This might be explained by distinct intrinsic properties of the antigens, such as the stability. 
On the other hand the lower impact of TTFC fusion on the immunogenicity of E6 can be 
explained by immunogenic competition (10). As TTFC is a large foreign protein it likely contains 
competing CD8+ T cell epitopes, possibly resulting in immunodominant immune responses 
against TTFC. This effect would be expected to be largely dependent on the HLA make up 
of the target species. Therefore, it is very well possible that the hierarchy that we observe in 
inbred mice is not predictive for the human situation. An experimental finding that supports 
this hypothesis is that in HLA-A2 transgenic mice we could show TTFC-E6SH responses after in 
vitro re-stimulation, but not against TTFC-E7SH (unpublished observation). However, it is also 
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possible that the inability to raise E7 directed responses in these mice reflect a short-coming 
of the HLA-A2 transgenic mice as a model (11). The use of detoxified versions of E6 and E7 is 
considered necessary to prevent the risk of cellular transformation at the vaccination side (see 
also chapter 4). Most often this is achieved by point mutations that affect the binding of E6 and 
E7 to their known cellular targets, respectively p53 and pRb. As gene-shuffling can be expected 
to result in much more drastic conformational changes it has the conceptual advantage of also 
preventing the binding to other cellular targets apart from p53 and pRb. This is of particular 
relevance as also the binding to such targets is believed to play a role in the transformation 
process (12-14). Therefore we think that TTFC-E7SH and TTFC-E6SH have a better safety profile 
than most other candidate DNA vaccines that rely on point mutations for detoxification. 
Despite perceived good safety profile of TTFC-E6SH and TTFC-E7SH we wished to 
provide experimental proof for the absence of oncogenic potential, before moving to clinical 
application. chapter 4 reports on the detailed safety evaluation that we performed in order 
to demonstrate the absence of oncogenic potential of these candidate vaccines. To this end, 
two different cell-types were used namely murine NIH 3T3 cells and primary human foreskin 
keratinocytes (HFKs). In both assay systems we could show that TTFC-E6SH and TTFC-E7SH 
alone and in combination have lost the oncogenic potential that is associated with the wild-type 
proteins. Although HFKs are a common system to study the transforming potential of high-risk 
HPV types (15, 16), their use for the evaluation of the safety of E6 and E7 directed vaccines has 
not been reported before. We show that it is feasible to use these primary human cells for this 
purpose. We consider HFKs as a more relevant system compared to NIH 3T3 cells as HFKs are of 
human origin and because keratinocytes are the natural target cells of HPV infections and are 
also targeted by most DNA vaccination strategies. In this study TTFC-E6SH and TTFC-E7SH were 
compared with their wild-type counterparts. It would however be interesting to compare the 
various detoxification methods (i.e. gene-shuffling and the introduction of point-mutations) 
with each other, using HFKs, in a future study. 
As we hypothesized that a large foreign carrier molecule carries the risk of inducing 
immunodominant immune responses directed against the carrier molecule, we aimed to 
further optimize our DNA vaccine design. In chapter 5 we report on the development of 
rationally designed modular DNA vaccines encoding HPV16 E6SH and E7SH. We hypothesized 
that it would be possible to split the anticipated effect on antigen stability and the addition 
of CD4+ T cell help. To this end we used a self carrier protein and a so called helper-cassette 
consisting of 3 promiscuous minimal CD4 helper epitopes (PADRE, P30 and NEF). Using this 
modular design, we could show that addition of both elements was necessary for optimal 
DNA vaccine immunogenicity. When comparing a set of 5 self carrier molecules with different 
subcellular localization we found that only ER localized carriers improved the immunogenicity. 
Subsequently we demonstrated that the carrier effect could be entirely explained by ER targeting 
of the antigen. Thereby, suggesting an important role for ER localization for the improvement of 
DNA vaccine immunogenicity. Importantly, the resulting minimal ER-HELP design also resulted 
in optimal T cell responses against E6SH. Interestingly, many carrier-proteins used to improve 
the immunogenicity of HPV16 E7 encoding DNA vaccines are also ER localized (17-20). Based on 
our data we hypothesize that in those cases not so much the biological function of the carrier-
protein explains the enhanced immunogenicity of the fusion product, but rather the effect on 
antigen localization. In light of this, it is interesting to note that the addition of ER localization 
and retention signals to an adenoviral vector encoded E7 improved its immunogenicity to the 




mechanism that we defined in the context of DNA vaccination might also hold true for other 
vaccine vectors. It will therefore be interesting to test if our design rules apply in the context 
of for example adenovirus-based vaccines or Semliki Forest virus based vaccines. Experiments 
with the latter vector system are ongoing. 
An interesting open question is whether the design rules defined in this chapter are also 
applicable to other antigens. To this end we selected 3 clinically relevant antigens namely 
Hepatitis B virus (HBV) core protein, human gp100 and Plasmodium Berghei circumsporozoite 
protein (Pb CSP) and compared the immunogenicity of the antigen alone (Ag), TTFC-Ag, 
HELP-Ag and sig-HELP-Ag-KDEL. Surprisingly, the design rules that resulted in highly 
immunogenic E6 and E7 directed DNA vaccines did not hold true for these 3 new antigens 
(unpublished observation). Only in the case of HBV core protein we could show improved 
immunogenicity after fusion with the helper-cassette albeit this effect was not significant 
(unpublished observation). In case of PbCSP there was no difference in immunogenicity between 
the antigen alone and the modified versions, and in case of human gp100 all modifications 
resulted in a loss of immunogenicity compared to the antigen alone. Possible explanation for 
this failure is that our modifications negatively impacted on other antigen properties that are 
important for DNA vaccine immunogenicity, for example antigen stability or the ability to 
form a particulate structure as has been reported for HBV core protein (22). An interesting 
experiment would be to gene shuffle these new antigens, to destroy any special property of the 
antigen, and see if our design rules would subsequently apply. Another possibility would be to 
select different (model) antigens that resemble E6SH and E7SH more closely, namely instable 
cytosolic antigens, and see if our design rules would apply to such a more specific category of 
antigens. Nonetheless these results make clear that optimization of antigens in the context 
of DNA vaccination requires detailed knowledge of the antigens and is not simply a generic 
process. 
Besides optimization of the antigen design or the physical delivery method it is believed 
that DNA vaccine immunogenicity can be enhanced by improving the formulation for example 
by encapsulating DNA in so called nanoparticles. This assumption is based on the inefficient 
cellular uptake of naked/non formulated DNA upon vaccination, estimated to be extremely 
low in the order of 1 out of 1x106 to 5x 109 plasmids applied for DNA tattooing (23). These 
nanoparticles generally consist of a complex between the negatively charged DNA and with 
cationic polymers or lipids. It is thought that nanoparticle formulated DNA is better protected 
from degradation and by its condensed nature can more easily pass the cell membrane (24). In 
chapter 6 we show that, though efficient in vitro, these nanoparticles completely block DNA 
tattoo mediated gene expression and immunogenicity. Interestingly, the gene-expression 
could be completely restored by shielding positive charge of these nanoparticles by addition 
of polyethylene glycol (PEG) chains. Despite the fact that gene-expression in mice in vivo was 
up to 5 times higher than that of an equivalent dose of naked DNA, the immunogenicity was not 
significantly improved, suggesting that stronger improvement of the gene expression levels is 
necessary to have an impact on immunogenicity. On the other hand, other factors might play 
a role such as a reduced immune stimulatory capacity of the formulation compared to naked-
DNA. Importantly, the current shielded nanoparticles form a highly suited platform for the 
introduction of targeting ligands (to improve cellular up-take or affect cell-type specificity) or 
the addition of immunostimulatory molecules such as TLR agonists. It will be very interesting to 
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future outlook
Will the DNA vaccines candidates described in this thesis be the cure for HPV induced 
malignancies in the near future? To be able to provide a meaningful answer to this question, 
first of all, the outcome of clinical trials has to be awaited. Such clinical trials should show robust 
induction of E6 and E7 specific T cell immunity and ultimately objective and relevant clinical 
responses against HPV induced (pre-)malignancies. Important considerations regarding the 
planning of such clinical studies are discussed below. 
Patient selection
The most important consideration will be the type of patient to select for clinical evaluation of 
the developed DNA vaccines. It is well documented that high-risk HPV types have evolved to 
escape the host immune response (25, 26). Mechanisms that are thought to play a role are: the 
ability of the virus to maintain a very low profile (e.g. low expression levels of the viral proteins, 
absence of a blood-borne phase etc.), modulation of antigen presentation (e.g. by loss of MHC 
class I expression (27)) and local immune suppression (e.g. by suppression of IFN transcription 
(28, 29)). Thus, even in case vaccination would yield powerful systemic E6 and E7 specific T 
cell responses, such mechanisms can result in immune escape of the HPV induced lesions. 
Treatment of early stage patients, that are generally thought to be less immune suppressed, is 
likely to result in a more favorable outcome than treatment of late stage patients (30). This is 
clearly demonstrated by the high response rates (47% complete regression) in VIN 3 patients 
with a vaccine that consist of multiple E6 and E7 derived overlapping synthetic long-peptides 
(SLP) (31). Notably the spontaneous regression rate for these types of lesions is below 1.5% 
(32). The same vaccine did induce vaccine specific immune responses and lesion regression in 
end-stage cervical cancer patients, but only 1 out of 35 patients (not tested for HPV16 positivity) 
experienced complete regression (33). Thus in order to demonstrate clinical efficacy it seems 
highly important to treat early-stage patients. Nevertheless, for ethical reasons safety will have 
to be established first in end-stage patients. 
Combining vaccination with (local) immune modulation
Another important consideration, related to the ability of high-risk HPV to escape the host 
immune response, will be to combine systemic vaccination with local or systemic immune 
modulation. This is even more crucial in the treatment of patients with late-stage lesions as 
they are oftentimes severely immunosuppressed, as mentioned above.
As systemic immune modulation can induce considerable side effects  (34-36), local immune 
modulation would be my first choice (37). A compound that has the ability to non-specifically 
activate the immune system is Toll-like receptor 7/8 agonist imiquimod (38). Imiquimod 
can be administered locally as a 5% cream (Aldara®) and is registered for the treatment of 
genital warts. Interestingly, imiquimod has also been shown to result in complete histological 
regression in 35% of treated VIN stage 2/3 patients after 16 weeks of treatment (39). The clinical 
benefit of this treatment is associated with normalization of immune cell counts at the site of 
the lesion, suggesting that HPV specific adaptive immunity played a (direct or indirect) role in 
the success of the treatment (40). The promise of combining local immune modulation with 
systemic vaccination is demonstrated by a recent clinical study. In this study a protein-based 
vaccine TA-CIN (HPV16 L2/E6/E7 fusion protein) was applied to VIN 2/3 patients after 8 weeks 




of the patients and a significant increase in both systemic and local vaccine specific cellular 
responses was observed in the clinical responders (41). The same vaccine was shown to result 
in detectable E6 and E7 specific T cell immunity when combined with a viral boost (see below) 
in a previous study, albeit without clinically relevant responses (42). Other toll-like receptors 
agonists like MPL-A (TLR-4) and CpG (TLR-9) should in principle be able to exert similar effects. 
Although these molecules are available in the clinic as vaccine adjuvants, their usefulness for the 
local treatment of HPV induced malignancies has not been explored so far (43). Interestingly 
also more conventional treatments such as chemotherapy and irradiation are also believed to 
impact on the local tumor environment by inducing (immunogenic) tumor cell death (44, 45). 
And indeed, the combination of radiation or chemotherapy (Cisplatin as well as DMXAA) and 
HPV specific vaccination, improved the anti tumor effect compared to vaccination alone in the 
TC-1 model in mice (46-48). Importantly clinical evaluation of such conventional therapies in 
combination with vaccination seems rather straightforward. 
Nowadays a wide array of therapeutics is available to systemically impact on T cell regulation. 
Most of these therapeutics are antibodies that impact on co-inhibitory or co-stimulatory 
signaling, thereby lowering the threshold for T cell activation. Well known examples of 
antibodies that inhibit co-inhibitory signaling are CTLA4 blocking antibodies (49, 50) anti-PD-1 
antibodies (51) and anti-GITR antibodies (49). Examples of antibodies that aim to induce co-
stimulatory signaling are agonistic anti-CD40 antibodies (36) and agonistic anti-4-1BB ligand 
antibodies (52). Monotherapy with these type of agents has been shown to induce tumor 
regression in both preclinical models as well as in clinical trials (53, 54). Interestingly, for both 
for anti-4-1BB antibodies and anti-GITR antibodies the combination of E7 specific vaccination 
has been shown to be much more effective in the eradication of established TC-1 tumors in 
mice than vaccination alone (52, 55). However the latter examples still need validation in human 
subjects and, as mentioned above, the fact that this class of therapeutics has considerable side 
effects may limit their application as ‘vaccine adjuvants’. 
Prime-boost regimens
If DNA vaccines might turn out to be not powerful enough as a stand alone method for T cell 
induction in humans, they could still be highly useful as part of heterologous prime-boost 
regimens (56). For this purpose viral vaccines are attractive as they are generally considered 
more powerful than DNA vaccines for the induction of T cell immunity, but have the drawback 
that they cannot be administered repeatedly. This is explained by the induction of vector 
specific immunity, most often neutralizing antibodies against viral (capsid) components (57, 
58). As DNA vaccination only results in expression of the transgene and no other foreign 
proteins are present, DNA vaccines do not induce vector specific immune responses and can 
thus be administered repeatedly (59). Many reports, including clinical studies, have shown that 
DNA priming followed by viral boosting can induce highest responses when compared with 
homologous prime-boost regimens (60). Therefore we consider it worthwhile to evaluate our 
vaccine candidates in the context of prime-boost regimens. For this purpose Modified Vaccinia 
Ankara (MVA) based vectors, poxvirus vectors or replication deficient adenoviral vectors are 
the most obvious candidates, as clinical trials or non-human primate studies have already 
shown the beneficial effect of DNA priming followed boosting with these vaccine platforms 
(60-63). Nevertheless it would also be valuable to validate the effect of prime boosting for 
other vaccine systems such as the Semliki Forest virus (SFV). HPV16 E6 and E7 encoding SFV 
based vaccines have shown promising anti tumor effects in pre-clinical models (64). Before 
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testing such prime boost regimens it would be interesting to evaluate if our E6 and E7 specific 
antigen designs, as developed in the context of DNA vaccines, are also superior in the context 
of the above-mentioned viral vectors. Evidence that this could be the case comes from the 
finding that optimizations that have been shown to improve the immunogenicity of antigens 
in the form of naked DNA also improved their immunogenicity in the context of an adenoviral 
vectors (65-67). Another argument to test our designs in other vectors is that we found it to be 
essential to boost with the very same antigen for optimal induction of memory T cell responses 
in the context of DNA vaccination (non published observation). As mentioned before, validation 
of our DNA vaccine design rules in the context of SFV is currently ongoing. Finally, also the 
combination of DNA vaccination with non viral vaccine modalities such as peptide or protein 
based vaccines holds promise. Many preclinical studies have for example shown improved 
(Th1 type) immunogenicity and efficacy of DNA prime protein boost strategies compared to 
homologous prime boosting with either vectors (68-70). An obvious vaccine candidate to test 
in combination with our DNA vaccines would be the E6 and E7 derived overlapping SLP vaccine 
that has proven clinical efficacy ((31) and see above). 
Further optimization of the current candidate vaccines
The results obtained in this thesis show the enormous potential of modifications of the antigen 
as such. To the best of our knowledge the E6 and E7 specific DNA vaccines tested so far in 
clinical trials were only moderately immunogenic in mice compared to our optimal DNA vaccine 
candidates: sig-HELP-E6SH-KDEL and sig-HELP-E7SH-KDEL. Therefore we are optimistic that 
our vaccines will result in stronger E6 and E7 specific T cell responses in human subjects. It is 
however not unlikely that further improvements of the antigen design are possible, for example 
inclusion of more diverse set of CD4+ helper epitopes to further improve CD4+ T cell help. An 
obvious set of epitopes to test are those included in the so called N19 polytope, a string of 19 
universal CD4+ T cell epitopes that has extensively been tested as a carrier protein in conjugate 
vaccines (71, 72). Also other possibilities exist to further improve the immunogenicity our 
candidate vaccines such as the inclusion (via bisistronic expression) or co-delivery of molecular 
adjuvants such as GM-CSF (73), IL-12 (74), IL-15 (75) and HGMB1 (76). Such strategies have 
shown promise in pre clinical models in conjunction with a wide variety of antigens (see for 
more examples (77), and can easily be tested in combination with our vaccine candidates in the 
available pre-clinical models. Finally optimization of DNA delivery is a very active field (see also 
chapter 2). The recent improvements particularly in the field of electroporation mediated DNA 
delivery in preclinical models (78, 79) and the recent demonstration of significant increase in 
humoral immunity by combining intramuscular delivery and electroporation in human subjects 
reveal the great potential of this delivery method (80). It is however difficult to judge whether 
results of such preclinical studies should be awaited before initiating clinical trials with the 
current candidate vaccines. 
conclusion
Taken together we have developed highly effective and safe DNA vaccines targeting HPV16 E6 
and E7 in preclinical models, warranting their clinical evaluation. Might these vaccines turn out 
to be not powerful enough as stand alone treatment, many adjuvant strategies are available 
to improve clinical outcome. Of the adjuvant strategies discussed, the combination with local 




SLP vaccines are the most obvious options. The promising clinical responses in recent human 
vaccination trials fuel the optimism that the treatment of HPV induced (pre-)malignancies via 
induction of E6 and E7 specific T cell responses is a realistic scenario. 
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Dit proefschrift beschrijft de ontwikkeling van DNA vaccins voor de behandeling van humaan 
papillomavirus (HPV) geïnduceerde vormen van kanker. HPV virussen zijn wijdverspreid en 
veroorzaken onder andere (genitale) wratten. Voor bepaalde seksueel overdraagbare hoog-
risico subtypes, voornamelijk subtype 16 en 18, is overduidelijk aangetoond dat ze kanker 
kunnen veroorzaken. Dit betreft voornamelijk baarmoederhalskanker (met ongeveer 300.000 
doden per jaar wereldwijd), maar ook andere anogenitale vormen van kanker zoals vulvakanker, 
anuskanker en peniskanker en ook bepaalde vormen van kanker in de mond- en keelholte. 
De huidige behandeling van baarmoederhalskanker is gericht op vroegtijdig opsporen van 
afwijkingen (door middel van het zogenaamde uitstrijkje) en chirurgische verwijdering van 
het verdachte weefsel. Deze behandeling is ingrijpend en het is niet altijd mogelijk al het 
geïnfecteerde weefsel weg te halen. Omdat HPV geïnduceerde tumoren een duidelijke virale 
oorsprong hebben, betekent dit dat er in de tumor lichaamsvreemde antigenen tot expressie 
komen. In theorie kunnen tegen deze lichaamsvreemde eiwitten krachtige immuunresponsen 
opgewekt worden. Hierdoor zou het mogelijk moeten zijn heel gericht de tumor cellen op te 
ruimen met behulp van het immuunsysteem, zonder gezond weefsel aan te tasten. Dit is zo 
ongeveer de heilige graal op het gebied van de oncologie. Voor tumoren waarin een virale 
component ontbreekt is dat veel moeilijker omdat het immuunsysteem is gebaseerd op 
herkenning van “niet-eigen” eiwitten. 
Profylactische vaccins
Tegenwoordig zijn er twee vaccins beschikbaar (Gardasil® en Cervarix ®) die infectie met een 
aantal subtypes van het HPV verhinderen. Deze vaccins bestaan uit de structurele eiwitten 
(L1) die de mantel van het virus vormen. Deze eiwitten vormen op het virus lijkende deeltjes 
waarop het immuunsysteem reageert met een krachtige B-cel respons. Een B-cel respons leidt 
tot de productie van antistoffen die het virus kunnen herkennen en vervolgens onschadelijk 
maken. Deze antistoffen hebben dus een profylactische werking, in andere woorden ze 
beschermen tegen een infectie met HPV. Uit grootschalig onderzoek in de mens is gebleken 
dat dit type vaccin bijna 100% bescherming biedt tegen de ontwikkeling van door deze HPV 
subtypes geïnduceerde tumoren in gevaccineerde individuen. Daarbij is het belangrijk dat het 
vaccin wordt toegediend voordat de HPV infectie optreedt. De praktische consequentie is 
dat dit vaccin al op jonge leeftijd moeten worden toegediend, namelijk voordat het individu 
sexueel actief wordt. Het is echter nog niet bekend hoe lang de bescherming aanhoudt. Het 
belangrijkste nadeel van dit type vaccin is, dat voor een optimale bescherming, de hele bevolking 
gevaccineerd dient te worden terwijl de incidentie van bijvoorbeeld baarmoederhalskanker in 
de westerse wereld maar 7 per 100.000 inwoners bedraagt. Dit betekent dat er veel individuen 
in feite onnodig zullen worden gevaccineerd, wat ongunstig is voor de kosteneffectiviteit. 
Gebaseerd op de incidentie en de kosten per vaccinatie (360 dollar) kost het voorkomen van 
1 geval van baarmoederhalskanker maar liefst 5 miljoen dollar! Hierbij moet wel opgemerkt 
worden dat de profylactische vaccins ook de voorstadia van kanker kunnen vóórkomen 
waarvan de incidentie aanmerkelijk hoger ligt. Voor het behandelen van dergelijke laesies is 




Noodzaak voor ontwikkeling van therapeutische vaccins
Een waarschijnlijk veel goedkoper alternatief is het ontwikkelen van een therapeutisch 
vaccin. Met andere woorden, een vaccin dat kan worden gegeven op het moment er een 
HPV geïnduceerde tumor, of een voorstadium daarvan, wordt geconstateerd. Hierdoor is het 
niet nodig de gehele bevolking op voorhand te vaccineren, maar alleen diegenen met een 
voorstadium van een HPV geïnduceerde tumor. Toepassing van een dergelijk vaccin is daarom 
waarschijnlijk ook haalbaar in ontwikkelingslanden. De profylactische vaccins zijn hiervoor 
momenteel nog te duur, terwijl daar notabene 80% van de HPV gerelateerde slachtoffers 
vallen. Een dergelijk therapeutisch vaccin moet tegen andere antigenen van het virus gericht 
worden omdat de structurele eiwitten in dit stadium niet meer tot expressie komen. De virale 
eiwitten die hiervoor bij uitstek in aanmerking komen zijn E6 en E7. Deze eiwitten spelen 
een grote rol bij het ontstaan van kanker als gevolg van HPV infectie. E6 en E7 zijn namelijk 
in staat te binden aan bepaalde tumorsurpressoreiwitten (respectievelijk p53 en pRb) en deze 
uit te schakelen, waardoor de controle over de celdeling wegvalt. Expressie van E6 en E7 is 
noodzakelijk voor de HPV geïnfecteerde cel om zich te ontwikkelen tot tumorcel, bovendien 
kunnen de eenmaal gevormde tumorcellen niet overleven zonder de expressie van E6 en E7. 
Ook is een ander type immuunrespons nodig, namelijk een T-cel respons in plaats van een 
B-cel/antilichaam respons. T-cellen kunnen virus geïnfecteerde cellen van buitenaf herkennen 
via presentatie van kleine eiwitfragmenten afkomstig van het virus op het oppervlakte van de 
cel. Na herkenning kan een T-cel een geïnfecteerde cel doden zonder verdere schade aan te 
richten. Er zijn vele mogelijke manieren om E6 en E7 specifieke T-cel immuniteit op te wekken, 
zoals eiwit/peptide vaccinatie, vaccinatie met behulp van virale vectoren en DNA vaccinatie. 
DNA vaccinatie heeft een aantal voordelen ten opzichte van de andere methoden. Zo wordt 
DNA vaccinatie als veiliger beschouwd dan virale methoden en effectiever voor het opwekken 
van T-cel immuniteit dan de andere non-virale methoden zoals peptide en eiwit vaccinatie. 
Ook is de productie van DNA vaccins relatief eenvoudig. Hoewel enkele studies in mensen al 
hebben laten zien dat het opwekken van E6 en E7 specifieke T-cel responsen gunstige effecten 
heeft in patiënten met een voorstadium van baarmoederhalskanker, zijn er met DNA vaccins 
tot nu toe nog geen duidelijke successen geboekt. In dit proefschrift hebben we geprobeerd 
nieuwe DNA vaccin kandidaten te ontwikkelen die veel krachtigere T-cel responsen opwekken 
dan de bestaande vaccin kandidaten. Hierbij hebben we bestaande inzichten gecombineerd en 
zijn we ook tot nieuwe inzichten gekomen over hoe DNA vaccins te optimaliseren. 
Inhoud van de verschillende hoofdstukken
In hoofdstuk 1 wordt het verband tussen HPV infectie en baarmoederhalskanker en de keuze 
voor DNA vaccinatie, zoals hierboven uitgelegd, besproken. 
hoofdstuk 2 is een overzichtsartikel over DNA-tatoeage vaccinatie. Deze techniek is in 
het NKI-AVL ontwikkeld om de immunogeniciteit van DNA vaccins te verbeteren. De methode 
bestaat uit het aanbrengen van een DNA oplossing op de huid, die vervolgens met behulp 
van een tatoeage-apparaat in de opperhuid/epidermis wordt geïnjecteerd. De gedachte 
is dat de huid het ideale orgaan is om een immuunrespons in op te wekken omdat de huid 
de natuurlijke barrière met de buitenwereld vormt en erg rijk is aan immuuncellen. Ook de 
huidschade die ontstaat als het gevolg van het tatoeëren is waarschijnlijk van groot belang 
omdat het immuunsysteem hierdoor wordt gealarmeerd. Aan de orde komen onder andere: 
de voordelen van DNA vaccinatie ten opzichte van meer conventionele vaccinatie methoden 




mechanismen waarop DNA tatoeage leidt tot T-cel immuniteit, de voordelen van de DNA-
tatoeage ten opzichte van andere toedieningsmethoden zoals gene-gun (techniek waarbij 
het DNA gekoppeld aan goudbolletjes in de huid wordt geschoten) en electroporatie (een 
techniek die gebruikt maakt van stroomstootjes om het DNA de cel in te krijgen). 
In hoofdstuk 3 wordt de ontwikkeling van twee kandidaatvaccins voor de behandeling 
van HPV geïnduceerde vormen van kanker. Omdat E6 en E7 kankerverwekkende/
transformerende eigenschappen hebben, hebben we gekozen voor het gebruik van ‘door 
elkaar gehusselde’ (in het Engels: ‘shuffled’) en daardoor niet functionele versies van E6 en 
E7, E6SH en E7SH genoemd. Dit om het risico uit te sluiten dat er kanker kan ontstaan op 
de plaats van de vaccinatie. Het bleek echter dat deze ‘shuffled’ versies veel lagere T-cel 
responsen induceerden dan de ongemodificeerde/wild-type varianten. Om dit verlies van 
immunogeniciteit te herstellen hebben we genetische fusies gemaakt van E6SH en E7SH met 
een deel van tetanus toxine fragment C (TTFC). De resulterende fusie vaccins TTFC-E7SH en 
TTFC-E6SH hebben een sterk verbeterde immunogeniciteit ten opzichte van E7SH en E6SH. 
In een muismodel voor HPV geïnduceerde kanker resulteert dit ook in zeer sterk verbeterde 
antitumorreacties na vaccinatie met TTFC-E7SH in vergelijking met E7SH. Een belangrijke 
verklaring voor de verbeterde immunogeniciteit is dat TTFC universele ‘helper T-celepitopen’ 
bevat. De gedachte is dat hierdoor een zogenaamde ‘helper T-cel’ reactie wordt opgewekt 
waardoor de cytotoxische/celdodende T-cel respons, die nodig is om geïnfecteerde cellen 
te doden, verbetert. Een andere verklaring is dat de stabiliteit van het antigeen toeneemt en 
daardoor ook de hoeveelheid antigeen die door het immunsysteem kan worden opgemerkt. 
In hoofdstuk 4 worden de veiligheidsstudies beschreven die we hebben uitgevoerd om 
aan te tonen dat TTFC-E6SH en TTFC-E7SH inderdaad geen kankerverwekkende/
transformerende eigenschappen meer hebben. Hiervoor hebben we 2 verschillende 
uitleessystemen gebruikt namelijk een uit muizen afkomstige cellijn (NIH 3T3 cellen) en 
primaire humane huidcellen afkomstig uit de voorhuid van donoren. Het inbrengen van onze 
kandidaatvaccins in beide typen cellen leidt niet tot transformatie, terwijl het inbrengen van 
de wild-type varianten wél tot transformatie leidt. Ook laten we in de primaire humane cellen 
zien dat de geshufflede varianten niet meer kunnen binden aan hun belangrijkste targets, 
de tumorsuppressoreiwitten p53 en pRb. Op grond van deze data beschouwen wij het gebruik 
van onze kandidaatvaccins in de mens veilig. 
In hoofdstuk 5 wordt de ontwikkeling van nog een tweetal E6 en E7 coderende 
kandidaatvaccins beschreven. Deze nieuwe vaccins bevatten in plaats van het complete 
drager-eiwit Tetanus Toxine Fragment C (TTFC), een set van 3 gedefinieerde universele 
helper T-celepitopen. De gedachte is dat hierdoor het risico op eventuele ongewenste 
cytotoxische T-cel responsen tegen TTFC vrijwel is uitgesloten. Het vaccin wordt hierdoor 
als het ware doelgerichter. Daarnaast zijn deze vaccins naar het endoplasmatisch reticulum 
(ER, een afgegrensd organel binnen de cel) gestuurd met behulp van uitsluitend (korte) 
signaalsequenties. Veel E6 en E7 gerichte DNA vaccins die in de literatuur beschreven staan, 
bestaan uit een fusie met een compleet in het ER gelokaliseerd drager-eiwit. Het voordeel van 
het gebruik van alleen signaalsequenties is het verminderde risico op het induceren van auto-
immuniteit. Belangrijk voordeel van de nieuwe vaccins, sigHELPE6SHKDEL en sigHELPE7SHKDEL 
genoemd, is dat deze vele malen immunogener zijn dan de in hoofdstuk 3 ontwikkelde vaccin 
kandidaten TTFC-E6 en TTFC-E7. Het is dan ook de bedoeling om deze vaccins te gaan testen 




In hoofdstuk 6 is een methode ontwikkeld om de opname van naakt-DNA (DNA zonder 
toevoegingen zoals gebruikt in hoofdstuk 3 en 5) vaccins te verbeteren. Het is algemeen 
bekend dat de opname van naakt DNA door cellen een uiterst inefficiënt proces is. Wij hebben 
berekend dat na DNA tatoeage slechts 1 op de miljoen tot slechts 1 op de 5 miljard DNA 
moleculen wordt opgenomen. Dit wordt waarschijnlijk veroorzaakt door snelle afbraak van het 
DNA in de huid en het feit dat het DNA de celmembraan moeilijk kan passeren. Een mogelijke 
oplossing is het DNA te verpakken in zogenaamde nanobolletjes. Deze nanobolletjes bestaan 
uit een complex van het negatief geladen DNA en een positief geladen polymeer. Hierdoor 
wordt het DNA beschermd tegen afbraak en zou het de celwand makkelijker kunnen passeren 
doordat deze bolletjes compacter zijn dan naakt DNA. Onze studie laat zien dat voor twee 
gangbare typen nanobolletjes de opname van het DNA sterk wordt verbeterd in gekweekte 
cellen (in vitro), maar dat de opname in intacte huid (ex vivo) of in muizen (in vivo) compleet 
wordt geremd. Dit duidt op verschillen in het opname mechanisme in in vitro condities versus 
in vivo condities. Door de lading van de nanobolletjes af te schermen kon de opname van het 
DNA sterk worden verbeterd met als gevolg een 5x hogere expressie van een model vaccin in 
vergelijking met naakt DNA. De verhoogde expressie leidde echter niet tot een significante 
toename in immunogeniciteit. Dit suggereert dat er een sterkere verbetering nodig is of dat 
andere factoren dan alleen de hoogte van de expressie een rol spelen bij de immunogeniciteit 
van in nanobolletjes verpakte DNA vaccins. 
hoofdstuk 7 bevat een samenvattende discussie van het proefschrift en bespreekt een 
aantal factoren die het succes van DNA vaccinatie tegen HPV geïnduceerde tumoren kunnen 
verbeteren. Een belangrijke factor is de selectie van patiënten. Uit verschillende onderzoeken 
blijkt dat het behandelen van patiënten in een vroeg stadium de kans op succes verbeterd. 
Daarnaast kan de uitkomst van de behandeling verbeterd worden door vaccinatie te combineren 
met locale immuunactivatie op de plaats van de tumor. Een hiervoor bij uitstek geschikt middel 
is het geregistreerde Imiquimod (Aldara®). Deze stof wordt al toegepast bij de behandeling van 
genitale wratten en voorstadia van vulvakanker en ook is er al een studie gepubliceerd die een 
gunstig effect laat zien van de combinatie van vaccinatie en Imiquimod. Ook kan het gunstig 
zijn verschillende vormen van vaccinatie (zoals virale vaccinatie en DNA vaccinatie) met elkaar 
te combineren in een zogenaamd heteroloog prime-boost protocol. Hierdoor worden de 
sterke punten van de verschillende systemen als het ware gecombineerd. Verschillende studies 
hebben al laten zien dat dergelijke prime-boost protocollen de efficiënte van vaccinatie sterk 
kunnen verbeteren. Tenslotte is het niet onwaarschijnlijk dat onze kandidaat DNA vaccins nog 
verder kunnen worden verbeterd, bijvoorbeeld door het toevoegen van bepaalde immuun-
activerende genen zoals GM-CSF, IL-12 en IL-15. Onze verwachting is dat de behandeling van 
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